Prudential (NYSE: PUK) profit surges as it targets $7B+ shareholder returns
Prudential plc reports strong 2025 results, higher dividends and larger capital returns. Profit after tax rose to $4,119m from $2,415m, helped by growth in insurance and asset management and a gain on the partial IPO of ICICI Prudential Asset Management.
Basic EPS increased to 154.2 cents, while the total 2025 dividend was raised 15% to 26.60 cents per share. Eastspring’s funds under management grew to $277.7bn. The group expects to return more than $7bn to shareholders over 2024–2027 through dividends and buybacks and ended 2025 with a shareholder capital surplus of $17.1bn and a 262% cover ratio above its prescribed capital requirement.
Positive
- Profit and earnings surge: Profit after tax rose to $4,119m from $2,415m, with basic EPS increasing to 154.2 cents, reflecting strong operational performance and gains from the ICICI Prudential Asset Management IPO.
- Shareholder returns and capital strength: Total 2025 dividend increased 15% to 26.60 cents per share, a completed $2bn buyback and plans to return more than $7bn to shareholders over 2024–2027, supported by a $17.1bn capital surplus and 262% cover ratio.
Negative
- None.
Insights
Strong profit growth, rising dividends and sizeable capital returns signal robust financial health.
Prudential plc delivered a sharp rise in profit after tax to $4,119m, driven by expanding insurance and asset management earnings and the gain from partially selling its stake in ICICI Prudential Asset Management. Basic EPS nearly doubled to 154.2 cents.
The balance sheet remains strong, with an estimated shareholder surplus of $17.1bn and a 262% cover ratio above the Group Prescribed Capital Requirement. The contractual service margin increased to $25.0bn, supporting visibility of future earnings from in-force business.
Capital deployment is notably shareholder-friendly. The company completed a $2bn buyback, issued SGD 600m subordinated debt at a 3.8% coupon, raised $1.4bn net from the IPAMC IPO and now targets more than $7bn of capital returns over 2024–2027. Execution against double‑digit growth guidance in 2025 and reiterated 2026 objectives underpins management’s confidence in the 2027 financial targets.
REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
OR | |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
For the fiscal year ended | |
OR | |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
OR | |
SHELL COMPANY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | |
Title of Each Class | Trading Symbol(s) | Name of Each Exchange on Which Registered |
American Depositary Shares, each representing 2 Ordinary Shares, 5 pence par value each | ||
Forward-looking statements | 8 |
Sources | 10 |
Summary of our business | 11 |
Our business at a glance | 11 |
Our clear and simple strategy | 14 |
Market review | 16 |
Company address and agent | 18 |
Dividend data | 18 |
Competition | 19 |
Strategic and operating review | 20 |
Our business model | 27 |
Financial review | 29 |
Overview | 29 |
Summary consolidated results and basis of preparation of analysis | 31 |
Explanation of performance and other financial measures | 32 |
Investments | 37 |
Additional information on liquidity and capital resources | 38 |
TEV basis, new business profit, free surplus generation and Group adjusted operating profit | 39 |
Determining adjusted operating profit of operating segments | 40 |
Segment discussion | 41 |
Definitions of performance metrics | 51 |
Risk review | 53 |
Introduction | 53 |
Risk governance | 53 |
The Group's principal risks | 55 |
Risk factors | 65 |
Supervision and regulation of Prudential | 77 |
Global regulatory and geopolitical developments and trends | 77 |
Prudential in Asia | 78 |
Prudential in Africa | 82 |
Disclosure obligations under Section 219 of the Iran Threat Reduction and Syria Human Rights Act of 2012 | 82 |
Governance | 83 |
Governance at a glance | 83 |
Our leadership | 84 |
How we operate | 93 |
Committee reports | 104 |
Audit committee financial expert | 121 |
Differences between Prudential’s governance practice and the NYSE corporate governance rules | 121 |
Memorandum and Articles of Association | 123 |
Code of ethics | 126 |
Insider trading policies | 126 |
Compensation and employees | 127 |
Remuneration at a glance | 127 |
Annual report on remuneration | 130 |
Additional remuneration disclosures | 156 |
Share ownership | 157 |
Employees | 157 |
Additional information | 158 |
Significant subsidiaries | 158 |
Major shareholders | 158 |
Intellectual property | 159 |
Legal proceedings | 159 |
Material contracts | 159 |
Exchange controls | 159 |
Taxation | 159 |
Documents on display | 162 |
Controls and procedures | 162 |
Listing information | 163 |
Description of securities other than equity securities | 163 |
Purchases of equity securities by Prudential plc and affiliated purchasers | 164 |
Principal accountant fees and services | 164 |
Limitations on enforcement of US Laws against Prudential, its Directors, management and others | 164 |
Financial Statements | 165 |
Consolidated financial statements | 165 |
Condensed financial information of Registrant | 253 |
Additional unaudited financial information | 260 |
Exhibits | 268 |
Item | 20-F Form Requirements | Section in this Annual Report on Form 20-F | Page |
Item 1 | Identity of Directors, Senior Management and Advisers | n/a | |
Item 2 | Offer Statistics and Expected Timetable | n/a | |
Item 3 | Key Information | ||
Capitalisation and indebtedness | n/a | ||
Reasons for the offer and use of proceeds | n/a | ||
Risk factors | Risk factors | 65 | |
Item 4 | Information on the Company | ||
History and development of the company | –Our business at a glance | 11 | |
–Company address and agent | 18 | ||
–Documents on display | 162 | ||
–Strategic and operating review | 20 | ||
Business overview | –Our clear and simple strategy | 14 | |
–Our business model | 27 | ||
–Strategic and operating review | 20 | ||
–Segment discussion | 41 | ||
–Definitions of performance metrics | 51 | ||
–Competition | 19 | ||
–Supervision and regulation of Prudential | 77 | ||
–Investments | 37 | ||
–TEV basis, new business profit, free surplus generation and Group adjusted operating profit | 39 | ||
–Sources | 10 | ||
Organisational structure | –Our business model | 27 | |
–Significant subsidiaries | 158 | ||
Property, plants and equipment | Note C10 to the consolidated financial statements | 239 | |
Item 4A | Unresolved Staff Comments | n/a | |
Item 5 | Operating and Financial Review and Prospects | ||
Operating results | –Strategic and operating review | 20 | |
–Financial review | 29 | ||
–Summary consolidated results and basis of preparation analysis | 31 | ||
–Determining adjusted operating profit of operating segments | 40 | ||
–Explanation of performance and other financial measures | 32 | ||
Liquidity and capital resources | –Explanation of performance and other financial measures | 32 | |
–Additional information on liquidity and capital resources | 38 | ||
–Note D5 to the consolidated financial statements | 241 | ||
Research and development, patents and licenses, etc | n/a | ||
Trend information | –Strategic and operating review | 20 | |
–Explanation of performance and other financial measures | 32 | ||
Critical Accounting Estimates | –Note A3 to the consolidated financial statements | 176 |
Item | 20-F Form Requirements | Section in this Annual Report on Form 20-F | Page |
Item 6 | Directors, Senior Management and Employees | ||
Directors and senior management | Board of Directors | 84 | |
Compensation | Compensation and employees: | 127 | |
–Remuneration at a glance | 127 | ||
–Annual report on remuneration | 130 | ||
–Summary of current Directors' remuneration policy | 128 | ||
–Additional remuneration disclosure | 156 | ||
Board practices | –How we operate | 93 | |
–Committee reports | 104 | ||
Employees | Employees | 157 | |
Share ownership | Share ownership | 157 | |
Disclosure of a registrant's action to recover erroneously awarded compensation | n/a | ||
Item 7 | Major Shareholders and Related Party Transactions | ||
Major shareholders | Major shareholders | 158 | |
Related party transactions | Note D4 to the consolidated financial statements | 240 | |
Interests of Experts and Counsel | n/a | ||
Item 8 | Financial Information | ||
Consolidated statements and other financial information | Financial statements | 165 | |
Legal proceedings | 159 | ||
Significant changes | n/a | ||
Item 9 | The Offer and Listing | ||
Offer and listing details | Listing information | 163 | |
Markets | Listing information | 163 | |
Item 10 | Additional Information | ||
Share capital | n/a | ||
Memorandum and Articles of Association | Memorandum and Articles of Association | 123 | |
Material contracts | Material contracts | 159 | |
Exchange controls | Exchange controls | 159 | |
Taxation | Taxation | 159 | |
Dividends and paying agents | n/a | ||
Statement by experts | n/a | ||
Documents on display | Documents on display | 162 | |
Subsidiary information | Note D6 to the consolidated financial statements | 241 | |
Annual report to security holders | Submitted separately |
Item | 20-F Form Requirements | Section in this Annual Report on Form 20-F | Page |
Item 11 | Quantitative and Qualitative Disclosures about Market Risk | –Risk review | 53 |
–Note C6 to the consolidated financial statements | 231 | ||
Item 12 | Description of Securities Other than Equity Securities | ||
American depositary shares | Description of securities other than equity securities | 163 | |
Item 13 | Defaults, Dividend Arrearages and Delinquencies | n/a | |
Item 14 | Material Modifications to the Rights of Security Holders and Use of Proceeds | n/a | |
Item 15 | Controls and Procedures | Controls and procedures | 162 |
Item 16A | Audit Committee Financial Expert | Audit committee financial expert | 121 |
Item 16B | Code of Ethics | Code of ethics | 126 |
Item 16C | Principal Accountant Fees and Services | Principal accountant fees and services | 164 |
Item 16D | Exemptions from the Listing Standards for Audit Committees | n/a | |
Item 16E | Purchases of Equity Securities by Prudential plc and Affiliated Purchasers | Purchases of equity securities by Prudential plc and affiliated purchasers | 164 |
Item 16F | Change in Registrant’s Certifying Accountant | n/a | |
Item 16G | Corporate Governance | Differences between Prudential’s governance practice and the NYSE corporate governance rules | 121 |
Item 16H | Mine Safety Disclosure | n/a | |
Item 16I | Disclosure Regarding Foreign Jurisdictions that Prevent Inspections | n/a | |
Item 16J | Insider trading policies | Insider trading policies | 126 |
Item 16K | Cybersecurity | –Risk review | 53 |
–Risk factors | 65 | ||
Item 17 | Financial Statements | n/a | |
Item 18 | Financial Statements | Financial statements | 165 |
Item 19 | Exhibits | Exhibits | 268 |

n | Our markets |
n | Life insurance – offering a range of products including health and protection |
n | Asset management |

Our markets | Life business market ranking1 | APE sales | Top 10 asset manager2 | Eastspring funds under management or advice3 | |
Hong Kong and Macau | Top 5 | $2,221m | $7.7bn | ||
Indonesia | Top 3 | $258m | $4.0bn | ||
Mainland China | Top 5 | $621m | $14.0bn | ||
Malaysia | Top 3 | $436m | $16.8bn | ||
Singapore | Top 3 | $938m | $148.0bn | ||
Other Markets: | |||||
Africa | Top 5 in 3 markets | $148m | |||
Cambodia | Top 3 | $14m | |||
India | Top 5 | $259m | $43.9bn | ||
Japan | $6.8bn | ||||
Laos | Top 3 | <$1m | |||
Myanmar | Top 5 | $12m | |||
Philippines | Top 3 | $151m | |||
Taiwan | Top 3 | $1,184m | $11.2bn | ||
Thailand | Top 5 | $360m | $14.1bn | ||
Vietnam | Top 10 | $57m | $7.0bn |

Scale franchise in Asia and Africa: |
Well positioned to access growth opportunities in our markets |
1. | 2. | 3. | 4. | |||||||||||||
Leading positions across high growth markets in Asia and Africa | Trusted household brand with nearly 180- year heritage | Balanced and scaled distribution channels | Integration of life insurance and asset management capabilities | |||||||||||||
Top three positions in nine life markets | ![]() | Second largest number of MDRT agents globally The #1 independent life insurer in Asia bancassurance | Total $277.7bn funds under management by Eastspring |
Driving Value creation through focus on execution: |
Agency | Bancassurance | Health | Customer | |||
Improving technology capabilities and operational effectiveness |
Delivering high quality, consistent growth and driving shareholder returns: | ||||||||
Growth | Capital | Consistency | Confidence | |||||
Delivered >10% growth across our key metrics1 | Implementing additional $1.2bn buyback in 2026. Expected $1.3bn capital return in 20272. >$7bn Capital returns to shareholders in 2024– 273 | 2026 guidance of double-digit growth across our key metrics1 | On track to deliver 2027 objectives | |||||

Organisational model replicating successes at pace and scale |
Multi-market growth engines |
Read more about our markets in the 'Market Review' and 'Segment discussion' sections |
Greater China | ASEAN | India | Africa |
Technology- powered distribution | Transforming health business model | Enhancing customer experiences |
Group-wide enablers |
Open-architecture technology platform | Engaged people & high-performance culture | Wealth and investment capabilities |
Value creation for all stakeholders |
Customers | Employees | Shareholders | Communities |
Managing our risks |
Thoughtful risk management through advocating the interests of our people, customers, regulators and shareholders |
Underpinned by the three pillars of our sustainability strategy |
Simple and accessible health and financial protection • Responsible investment • Sustainable business |

Low life insurance penetration | Large health protection gap | High growth markets | ||||||
Penetration of GDP1 (%) | Asia Health Protection Gap2 | Prudential's life markets forecast3 | ||||||
c. $300 billion premium equivalent | ||||||||







g | Asia |
g | World |
How Prudential is responding: | ||||||||
Focused on being a trusted partner to our customers. Targeted investment in structural growth markets in Asia and Africa. Operational execution across our strategic pillars. Financial delivery for shareholders through our revised capital allocation framework. | ||||||||

US cents per share | 2025 | 2024 | 2023 | 2022 | 2021 |
First Interim Ordinary Dividend | 7.71 | 6.84 | 6.26 | 5.74 | 5.37 |
Second Interim Ordinary Dividend | 18.89 | 16.29 | 14.21 | 13.04 | 11.86 |

![]() | See more on our strategic pillars of technology powered distribution, transforming the health business model and enhancing customer experiences in the Strategic and operating review section |
We exist to help people achieve financial security and peace of mind by providing life insurance, health protection, and asset management solutions across Asia and Africa. Our goal is to deliver sustainable long-term value for customers, shareholders, and communities. |
Underpinned by our commitment to sustainability Focusing on our rigorous risk management |

Writing new business |
Managing the monies and policies of our existing customers |
Allocating capital |
Value we create for stakeholders | |||
Customers | |||
We aim to deliver superior customer experiences. Our mission is ‘to be the most trusted partner and protector for this generation and generations to come, by providing simple and accessible financial and health solutions’. How we are delivering for our customers will be assessed against our ambition to achieve top quartile relationship NPS by 2027 and our customer retention rate. | |||
Employees | |||
We provide an inclusive working environment where we develop talent, reward performance, protect our people and value our differences. We measure success for our employees through engagement scores from annual surveys. | |||
Shareholders | |||
We can accelerate value creation for our shareholders and other stakeholders by exercising operational and financial discipline as we execute our strategy. | |||
Communities | |||
Our purpose reflects our commitment to the wider communities in which we operate, through meeting the underserved needs of our markets and supporting a more sustainable future. Our commitment to sustainability is underpinned by our ambition to achieve net zero by 2050 and a 55% reduction in weighted average carbon intensity (WACI) by 2030 against our 2019 baseline. | |||
2025 $m | 2024 $m | 2023 $m | |
Insurance revenue | 11,080 | 10,358 | 9,371 |
Insurance service expense: | |||
Claims incurred | (3,331) | (3,147) | (2,913) |
Directly attributable expenses incurred | (1,455) | (1,328) | (1,258) |
Amortisation of insurance acquisition cash flows | (3,435) | (3,157) | (2,745) |
Other insurance service expenses | (23) | (131) | (197) |
(8,244) | (7,763) | (7,113) | |
Net expense from reinsurance contracts held | (212) | (302) | (171) |
Insurance service result | 2,624 | 2,293 | 2,087 |
Investment return: | |||
Interest revenue calculated using the effective interest method | 413 | 477 | 340 |
Other investment return on financial investments | 15,851 | 5,442 | 9,423 |
16,264 | 5,919 | 9,763 | |
Fair value movements on investment contract liabilities | (72) | (95) | (24) |
Net insurance and reinsurance finance income (expense): | |||
Net finance expense from insurance contracts | (14,612) | (4,154) | (8,839) |
Net finance (expense) income from reinsurance contracts held | (159) | (338) | 191 |
(14,771) | (4,492) | (8,648) | |
Net investment result | 1,421 | 1,332 | 1,091 |
Other revenue | 411 | 382 | 369 |
Non-insurance expenditure | (1,031) | (1,003) | (990) |
Finance costs: interest on core structural borrowings of shareholder-financed businesses | (183) | (171) | (172) |
Gain (loss) attaching to corporate transactions | 1,515 | (71) | (22) |
Share of profit (loss) from joint ventures and associates, net of related tax | 364 | 477 | (91) |
Profit before tax (being tax attributable to shareholders’ and policyholders’ returns) note | 5,121 | 3,239 | 2,272 |
Tax charge attributable to policyholders' returns | (180) | (286) | (175) |
Profit before tax attributable to shareholders' returns | 4,941 | 2,953 | 2,097 |
Total tax charge attributable to shareholders' and policyholders' returns | (1,002) | (824) | (560) |
Remove tax charge attributable to policyholders' returns | 180 | 286 | 175 |
Tax charge attributable to shareholders' returns | (822) | (538) | (385) |
Profit for the year | 4,119 | 2,415 | 1,712 |
Attributable to: | |||
Equity holders of the Company | 3,978 | 2,285 | 1,701 |
Non-controlling interests | 141 | 130 | 11 |
Profit for the year | 4,119 | 2,415 | 1,712 |
Earnings per share (in cents) | 2025 | 2024 | 2023 |
Based on profit attributable to equity holders of the Company: | |||
Basic | 154.2¢ | 84.1¢ | 62.1¢ |
Diluted | 153.5¢ | 84.0¢ | 61.9¢ |
2025 $m | 2024 $m | |
Net opening balance at 1 January | 21,960 | 21,012 |
Changes that relate to future service | ||
Changes in estimates that adjust the CSM | 1,811 | 724 |
New contracts in the year | 2,835 | 2,596 |
4,646 | 3,320 | |
Changes that relate to current service | ||
Release of CSM to profit or loss | (2,554) | (2,352) |
Net finance expense (income) from insurance contracts | ||
Accretion of interest on GMM contracts | 348 | 321 |
Other net finance expense (income) | (43) | 15 |
305 | 336 | |
Effect of movements in exchange rates | 648 | (356) |
Net closing balance at 31 December | 25,005 | 21,960 |
Actual exchange rate | |||
2025 $m | 2024 $m | 2023 $m | |
Net investment return and other items | (41) | 21 | (21) |
Interest payable on core structural borrowings | (184) | (171) | (172) |
Corporate expenditure | (237) | (237) | (230) |
(462) | (387) | (423) | |
Restructuring and IFRS 17 implementation costs* | (171) | (207) | (201) |
Central costs unallocated to a segment | (633) | (594) | (624) |
Group IFRS shareholders' equity | ||
2025 $m | 2024 $m | |
Profit for the year | 4,119 | 2,415 |
Less non-controlling interest | (141) | (130) |
Profit after tax for the year attributable to shareholders | 3,978 | 2,285 |
Exchange movements, net of related tax | 443 | (309) |
External cash dividends | (594) | (552) |
Share repurchases/buybacks | (1,234) | (878) |
Adjustment to non-controlling interest | – | (857) |
Other movements | 32 | (20) |
Net increase (decrease) in shareholders’ equity | 2,625 | (331) |
IFRS shareholders’ equity at beginning of the year | 17,492 | 17,823 |
IFRS shareholders’ equity at end of the year | 20,117 | 17,492 |
IFRS shareholders' equity per share3 | 790¢ | 658¢ |
31 Dec 2025 | 31 Dec 2024 | ||||||
Shareholder | Policyholder* | Total† | Shareholder | Policyholder* | Total† | ||
Group capital resources ($bn) | 27.6 | 19.3 | 46.9 | 24.8 | 16.3 | 41.1 | |
of which: Tier 1 capital resources ($bn) | 19.9 | 1.5 | 21.4 | 17.6 | 1.3 | 18.9 | |
Group Minimum Capital Requirement ($bn) | 6.0 | 0.8 | 6.8 | 5.1 | 0.7 | 5.8 | |
Group Prescribed Capital Requirement ($bn) | 10.5 | 13.3 | 23.8 | 8.9 | 11.3 | 20.2 | |
GWS capital surplus over GPCR ($bn) | 17.1 | 6.0 | 23.1 | 15.9 | 5.0 | 20.9 | |
GWS coverage ratio over GPCR (%) | 262% | 197% | 280% | 203% | |||
GWS Tier 1 surplus over GMCR ($bn) | 14.6 | 13.1 | |||||
GWS Tier 1 coverage ratio over GMCR (%) | 316% | 325% | |||||
31 Dec 2025 $m | 31 Dec 2024 $m | |
Core borrowings of shareholder-financed businesses | 4,459 | 3,925 |
Less: holding company cash and short-term investments | (4,282) | (2,916) |
Net core structural borrowings of shareholder-financed businesses | 177 | 1,009 |
Group leverage ratio (Moody's total leverage basis) | 13% | 13% |
Actual exchange rate | |||
2025 $m | 2024 $m | Change % | |
Net cash remitted by business units | 2,137 | 1,383 | 55 |
Net interest (paid) received | (55) | 17 | n/a |
Corporate expenditure | (308) | (253) | (22) |
Centrally funded recurring bancassurance fees | (223) | (198) | (13) |
Total central outflows | (586) | (434) | (35) |
Holding company cash flow before dividends and other movements | 1,551 | 949 | 63 |
Dividends paid, net of scrip dividends | (594) | (552) | (8) |
Operating holding company cash flow after dividends but before other movements | 957 | 397 | 141 |
Other movements | |||
Issuance of debt, net of costs | 462 | – | n/a |
Share repurchases/buybacks (including costs) | (1,252) | (860) | n/a |
Other corporate activities | 1,117 | (109) | n/a |
Total other movements | 327 | (969) | n/a |
Net movement in holding company cash | 1,284 | (572) | n/a |
Cash and short-term investments at the beginning of the year | 2,916 | 3,516 | |
Foreign exchange movements | 82 | (28) | |
Cash and short-term investments at the end of the year | 4,282 | 2,916 | |
Actual exchange rate | Constant exchange rate | Actual exchange rate | ||||||
2025 $m | 2024 $m | Change | 2024 $m | Change | 2023 $m | |||
APE sales | 2,221 | 2,063 | 8% | 2,065 | 8% | 1,966 | ||
Profit before shareholder tax | 1,414 | 949 | 49% | 949 | 49% | 1,047 | ||
Profit after tax | 1,333 | 851 | 57% | 851 | 57% | 976 | ||
Adjusted operating profit | 1,219 | 1,069 | 14% | 1,070 | 14% | 1,013 | ||
Actual exchange rate | Constant exchange rate | Actual exchange rate | ||||||
2025 $m | 2024 $m | Change | 2024 $m | Change | 2023 $m | |||
APE sales | 258 | 262 | (2)% | 252 | 2% | 277 | ||
Profit before shareholder tax | 271 | 221 | 23% | 213 | 27% | 199 | ||
Profit after tax | 224 | 181 | 24% | 174 | 29% | 156 | ||
Adjusted operating profit | 250 | 268 | (7)% | 258 | (3)% | 221 | ||
Actual exchange rate | Constant exchange rate | Actual exchange rate | ||||||
2025 $m | 2024 $m | Change | 2024 $m | Change | 2023 $m | |||
APE sales | 621 | 464 | 34% | 464 | 34% | 534 | ||
(Loss) profit | (24) | 159 | n/a | 159 | n/a | (577) | ||
Adjusted operating profit | 411 | 363 | 13% | 363 | 13% | 368 | ||
Actual exchange rate | Constant exchange rate | Actual exchange rate | ||||||
2025 $m | 2024 $m | Change | 2024 $m | Change | 2023 $m | |||
APE sales | 436 | 406 | 7% | 434 | –% | 384 | ||
Profit before shareholder tax | 416 | 380 | 9% | 405 | 3% | 320 | ||
Profit after tax | 325 | 296 | 10% | 316 | 3% | 257 | ||
Adjusted operating profit | 410 | 338 | 21% | 361 | 14% | 305 | ||
Actual exchange rate | Constant exchange rate | Actual exchange rate | ||||||
2025 $m | 2024 $m | Change | 2024 $m | Change | 2023 $m | |||
APE sales | 938 | 870 | 8% | 890 | 5% | 787 | ||
Profit before shareholder tax | 1,137 | 659 | 73% | 674 | 69% | 607 | ||
Profit after tax | 966 | 566 | 71% | 579 | 67% | 512 | ||
Adjusted operating profit | 706 | 693 | 2% | 709 | –% | 584 | ||
Actual exchange rate | Constant exchange rate | Actual exchange rate | ||||||
2025 $m | 2024 $m | Change | 2024 $m | Change | 2023 $m | |||
APE sales | 2,187 | 2,137 | 2% | 2,184 | —% | 1,928 | ||
Profit before shareholder tax | 640 | 655 | (2)% | 660 | (3)% | 875 | ||
Profit after tax | 535 | 503 | 6% | 504 | 6% | 775 | ||
Adjusted operating profit | 614 | 688 | (11)% | 689 | (11)% | 746 | ||
Actual exchange rate | Constant exchange rate | Average exchange rate | ||||||
2025 | 2024 | Change | 2024 | Change | 2023 | |||
Total funds under management ($bn) | 277.7 | 258.0 | 8% | 266.4 | 4% | 237.1 | ||
Fee margin based on operating income (bps) | 30 | 30 | –bps | 30 | –bps | 31 | ||
Cost/income ratio (%) | 52 | 52 | –ppts | 52 | –ppts | 53 | ||
Profit before shareholder tax ($m) | 1,889 | 293 | 545% | 290 | 551% | 280 | ||
Profit after tax ($m) | 1,633 | 264 | 519% | 260 | 528% | 254 | ||
Profit after tax excluding corporate transactions ($m) | 305 | 275 | 11% | 272 | 12% | (26) | ||
Adjusted operating profit ($m) | 329 | 304 | 8% | 301 | 9% | 280 | ||
Actual exchange rate | Constant exchange rate | Actual exchange rate | ||||||
2025 | 2024 | Change | 2024 | Change | 2023 | |||
$m* | $m* | % | $m* | % | $m* | |||
External funds under management ($bn) | 103.2 | 109.4 | (6) | 109.4 | (6) | 96.1 | ||
Internal funds under management ($bn) | 127.5 | 115.4 | 10 | 123.8 | 3 | 110.0 | ||
Internal funds under advice ($bn) | 47.0 | 33.2 | 42 | 33.2 | 42 | 31.0 | ||
Total internal funds under management or advice ($bn) | 174.5 | 148.6 | 17 | 157.0 | 11 | 141.0 | ||
Total funds under management or advice ($bn) | 277.7 | 258.0 | 8 | 266.4 | 4 | 237.1 | ||
Total external net flows | 5,573 | 5,824 | (4) | 5,637 | (1) | 4,054 | ||
Analysis of adjusted operating profit | ||||||||
Retail operating income | 470 | 414 | 14 | 412 | 14 | 353 | ||
Institutional operating income | 339 | 333 | 2 | 335 | 1 | 347 | ||
Operating income before performance-related fees | 809 | 747 | 8 | 747 | 8 | 700 | ||
Performance-related fees | 5 | – | n/a | – | n/a | (2) | ||
Operating income (net of commission) | 814 | 747 | 9 | 747 | 9 | 698 | ||
Operating expense | (418) | (385) | (9) | (390) | (7) | (372) | ||
Group's share of tax on joint ventures' adjusted operating profit | (67) | (58) | (16) | (56) | (20) | (46) | ||
Adjusted operating profit | 329 | 304 | 8 | 301 | 9 | 280 | ||
Adjusted operating profit after tax | 305 | 275 | 11 | 272 | 12 | 254 | ||
Average funds managed by Eastspring ($bn) | 271.7 | 249.3 | 9 | 251.6 | 8 | 225.9 | ||
Fee margin based on operating income | 30bps | 30bps | –bps | 30bps | –bps | 31bps | ||
Cost/income ratio | 52% | 52% | –ppts | 52% | –ppts | 53% | ||
Market | Operation | Key regulator | AML Reporting Agency |
Cambodia | Prudential (Cambodia) Life Assurance PLC | Insurance Regulator of Cambodia (under the Non-Banking Financial Service Authority) | Cambodian Financial Intelligence Unit |
India | ICICI Prudential Life Insurance Company Limited | Insurance Regulatory and Development Authority of India (IRDAI) | Financial Intelligence Unit - India (under the Ministry of Finance) |
Laos | Prudential Life Assurance (Lao) Company Limited | Ministry of Finance and its regulatory unit, Department of Government Investment Enterprise and Insurance Management Authority (DSI) | Anti-Money Laundering Intelligence Office (AMLIO) |
Myanmar | Prudential Myanmar Life Insurance Company Limited | Financial Regulatory Department (under the Ministry of Planning and Finance (MoPF)) | Myanmar Financial Intelligence Unit |
The Philippines | Pru Life Insurance Corporation of UK | Insurance Commission (IC) | Anti-Money Laundering Council (AMLC) |
Taiwan | PCA Life Assurance Company Limited | Financial Supervisory Commission (FSC) | Financial Intelligence Unit, Taiwan |
Market | Operation | Key regulator |
Hong Kong | Eastspring Investments (Hong Kong) Limited | Securities and Futures Commission (SFC) |
Indonesia | PT Eastspring Investments Indonesia | Otoritas Jasa Keuangan (OJK) |
Japan | Eastspring Investments Limited | Japan Financial Services Agency (JFSA) |
Luxembourg | Eastspring Investments (Luxembourg) S.A. | Commission de Surveillance du Secteur Financier (CSSF) |
Taiwan | Eastspring Securities Investment Trust Co. Ltd. | Financial Supervisory Commission Republic of China (Taiwan) (FSC) Securities Investment Trust & Consulting Association (SITCA) |
United States | Eastspring Investments Inc. | Securities Exchange Commission (US SEC) Financial Industry Regulatory Authority (FINRA) |
Vietnam | Eastspring Investments Fund Management Company | State Securities Commission of Vietnam (SSC) |

![]() | Audit | ![]() | Nomination & Governance | ![]() | Remuneration | ![]() | Risk | ![]() | Sustainability | ![]() | Committee Chair |



























Shareholders | ||
Board of Directors | ||
The Board establishes the purpose, values and strategy of the Group and promotes its long-term success for the benefit of our shareholders and other stakeholders. The Board delegates to the following principal committees: | ||
Audit Committee | Risk Committee | Remuneration Committee | Nomination & Governance Committee | Sustainability Committee | |||||
Responsible for oversight and review of financial reporting. It oversees the effectiveness of the internal control and risk management framework, including the effectiveness of financial and non- financial reporting controls, and for making the relevant disclosures in the Annual Report. It also considers the effectiveness and objectivity of the internal and external auditors. | Responsible for oversight and review of the Group’s risk appetite, tolerance and strategy. It monitors current and potential future risk exposures, the effectiveness of the Group’s risk management framework and adherence to applicable risk policies and regulatory obligations. | Responsible for recommending remuneration policy and overseeing the implementation and operation of that policy, including approving remuneration for the Chair, the CEO and other members of the Group Executive Committee. | Responsible for oversight of Board and executive succession plans (unless considered by the Board), nominating candidates for appointment to the Board, oversight of Board performance and corporate governance matters. | Responsible for providing leadership, direction and oversight of the Group’s sustainability strategy, including environmental matters, responsible investment, social sustainability, and people. The Committee leads on workforce engagement. | |||||
Chief Executive Officer (CEO) | |||||||||
Responsible for the day-to-day management of the business. | |||||||||
Group Executive Committee | |||||||||
The Group Executive Committee (GEC) is responsible for executing the strategy approved by the Board and supporting the CEO. | |||||||||
Chief Financial Officer The Chief Financial Officer (CFO) is responsible for managing the Finance function, including all aspects of financial reporting and planning, and investor engagement. | Chief Risk and Compliance Officer The Chief Risk and Compliance Officer (CRCO) is responsible for leadership of risk management and compliance activities of the Group, including setting the Group Risk Framework and related policies, supporting strategic planning to ensure risks are managed within appetite, and leading engagement with regulators and policymakers across markets. | Company Secretary The Company Secretary advises the Board and management on governance-related matters and supports the Chair in ensuring the effective functioning of the Board and its committees. The Company Secretary is available to all Directors to provide advice and support and facilitates Directors’ induction and ongoing professional development. | |||
The CFO and the CRCO are standing attendees at, and receive all papers for, meetings of the Board (except private meetings of Non-executive Directors). They also attend meetings of the Audit and Risk committees and the CFO attends meetings of the Sustainability Committee. | |||||
The CFO and CRCO are members of the GEC, but the Board approves their appointment and removal. Their performance reviews consider feedback from the Chairs of the Audit and Risk committees respectively, and their remuneration is determined by the Remuneration Committee. | |||||

Role and responsibilities | Board member | Board meetings1 | AGM attendance 2025 | |||
Chair The Chair is responsible for the leadership of the Board in its role to promote the long-term sustainable success of the Company and in holding management to account. She shapes the culture in the boardroom, is responsible for ensuring the Board’s effectiveness and leads on Director- level succession. Working with the CEO, the Chair sets the Board’s agenda, with a focus on strategy, performance and value creation, and ensures effective communication with shareholders and other stakeholders. Together with the CEO, she also represents the Group externally. | Shriti Vadera | 7/7 | Y | |||
CEO The CEO is accountable to, and reports to, the Board. He is responsible for the day-to-day management of the Group, including developing and recommending the Group’s long-term strategic objectives and business plans to the Board. He is also responsible for executing the approved strategy and business plans, and embedding the Group’s values and culture. The CEO plays a key role in communicating with shareholders and other stakeholders, and in establishing the Group’s internal control framework. | Anil Wadhwani | 7/7 | Y | |||
Senior Independent Director The SID acts as a sounding board for the Chair and supports her in the delivery of her objectives. The SID is also an intermediary for other Directors and shareholders as needed and leads the annual performance evaluation of the Chair. | Jeremy Anderson | 7/7 | Y | |||
Non-executive Directors Non-executive Directors offer constructive challenge to management and hold them to account against agreed performance objectives. They also provide strategic guidance, offer specialist advice and serve on at least one of the Board’s principal committees. | ||||||
Arijit Basu | 7/7 | Y | ||||
Chua Sock Koong | 7/7 | Y | ||||
Guido Fürer (from July 2025) | 3/3 | n/a | ||||
Ming Lu | 7/7 | Y | ||||
George Sartorel | 7/7 | Y | ||||
Mark Saunders | 7/7 | Y | ||||
Claudia Suessmuth Dyckerhoff | 7/7 | Y | ||||
Jeanette Wong | 7/7 | Y | ||||
Amy Yip (until 31 October 2025) | 5/6 | Y | ||||
Committee chairs Committee chairs are responsible for the leadership and governance of their respective Committees. They set the agenda for committee meetings and report to the Board on committee activities. | ||||||
Jeanette Wong (Audit Committee) | ||||||
Jeremy Anderson (Risk Committee) | ||||||
Chua Sock Koong (Remuneration Committee) | ||||||
Shriti Vadera (Nomination & Governance Committee) | ||||||
George Sartorel (Sustainability Committee) | ||||||

Q1 | Q2 | |||
February | May | |||
–Discussed macro-economic context and key areas of focus for the year. These included the three key strategic priorities of agency, health and operations, and particular markets; –Considered potential IPO of ICICI Prudential Asset Management Company; –Discussed action plan to address key findings from the investor perception survey carried out in 2024; and –Received feedback from the Group-wide Supervisor on key observations and actions expected of the Group following the Regulatory College in November 2024 and approved the Group’s response. | –Considered updates to the Group’s capital allocation framework; –Approved in principle the IPO of ICICI Prudential Asset Management Company; –Discussed aspects of Group strategy, in particular regarding agency, the Hong Kong business, and the framework for developing the Group’s longer-term strategy; –Approved the establishment of an entity in Bermuda as part of an initiative to enhance capital optimisation and internal reinsurance capabilities; –Approved updates to the Group risk appetite and the 2025 Group Own Risk and Solvency Assessment Report for submission to the Hong Kong Insurance Authority; and –Attended the AGM. | |||
March | June | |||
–Discussed macroeconomic and geopolitical trends affecting the Group’s key markets, supported by the Group Chief Economist; –Considered the Group’s capital allocation framework; –Approved the 2024 second interim dividend; –Reviewed the Group’s Operations strategy, a key component for enabling delivery of strategic goals and enhancing customer experience; –Reviewed options for enhancing the Group’s asset management capabilities in particular asset classes; –Discussed priority areas of focus in the agency channel; –Approved the final 2025-2027 Group Business Plan (on TEV basis and with re-based economics); –Discussed the investor communications strategy to address key findings from the 2024 independent investor survey, building on the action plan discussed in February; –Reviewed and approved documents and statements related to year-end reporting, following review and recommendation by the Audit Committee; –Reviewed and confirmed effectiveness of risk management and internal control system; –Discussed findings of the 2024 internal Board performance review and agreed action plan; –Received feedback from the Chair and Remuneration Committee Chair on their annual shareholder engagement programmes; and –Approved key items for the AGM. | –On the recommendation of the Nomination & Governance Committee, approved the appointment of Guido Fürer to the Board. | |||






![]() | Scheduled meeting: Virtual | ![]() | Scheduled meeting: In- person | ![]() | Virtual meeting to consider financial reporting | ||
![]() | AGM | ![]() | Site Visit | ![]() | Strategy Workshop | ![]() | Board committee meeting - virtual |
Q3 | Q4 | |||
July | October | |||
–Reviewed progress of delivery of strategic objectives, focusing particularly on agency, health, technology and operations; –Considered the framework for the development of the Group’s long-term strategy beyond 2027; –Progress review of the execution of the Group’s Health strategy; –Further discussion of the Group’s capital allocation framework and approval of updates announced as part of the Half Year Results; –Considered initiatives to enhance the Group’s asset management capabilities in particular asset classes; –As part of the Board visit to Indonesia, received update on the Indonesia business (see below for further details); –Approved funding for the newly established Bermuda entity; and –Approved the settlement of litigation in Malaysia (announced on 31 July 2025). | –Annual offsite strategy sessions, which included deep dives into key pillars of the Group’s strategy, including AI, Wealth and the Group's strategic approach in China, as well as scenario analysis to underpin the Group’s long-term strategic planning; –Discussed the approach to the Group’s 2026-2028 business plan; –CITIC Pru Life Business and Strategy update, joined by Chair of CITIC Pru Life; –Update on initiative to enhance the Group’s asset management capabilities in certain asset classes; –Discussed development and succession planning for the CEO and other GEC roles; and –Received an update on the IPO of ICICI Prudential Asset Management Company and approved pre-IPO placements. | |||
August | December | |||
–Reviewed and approved documents and statements related to half-year reporting, following review and recommendation by the Audit Committee; and –Approved the first interim dividend for 2025. | –Approved the 2026-2028 business and capital plan and 2026 strategic priorities; –Considered the framework for the development of the Group’s long-term strategy beyond 2027; –Discussed the performance, challenges and strategic transformation of the agency channel; –Deep dive into the Eastspring asset management business; –Considered the Group’s strategic approach in India; –Final approval for IPO of ICICI Prudential Asset Management Company; –Received an update on Government Relations strategy; –Received updates on progress made in the Group’s people and culture initiatives and focus areas for 2026; –Approved the establishment of a Bermuda business unit to support Wealth strategy; and –Reflected on lessons learnt and insights gained over the year. | |||






![]() | Scheduled meeting: Virtual | ![]() | Scheduled meeting: In- person | ![]() | Virtual meeting to consider financial reporting | ||
![]() | AGM | ![]() | Site Visit | ![]() | Strategy Workshop | ![]() | Board committee meeting - virtual |
January | Global sustainability trends impacting the insurance industry (externally-facilitated) (Sustainability Committee) |
February | Impact of global sustainability trends on Prudential (Sustainability Committee) |
March | Geopolitical and macro-economic update Deep dive into key drivers of Group valuation Deep dive into management of participating products (Risk Committee) |
April | Update on US tariffs Deep dive into Hong Kong products and associated investment risk UK Corporate Governance Code – Provision 29 (Audit Committee) |
May | Deep dive into product portfolio (Risk Committee) Overview of global remuneration trends and practices (Remuneration Committee) Hong Kong business update and market overview Board workshop on asset and liability management, led by the Group Chief Investment Officer Update on US tariffs Externally-led Board workshop on AI adoption in practice |
July | Indonesia business update and market overview Externally-led session on Indonesia’s macro-economic and political landscape Deep dive into foreign ownership rules across markets (Risk Committee) Update on GIECA internal model review (Risk Committee) |
October | Global macro-economic and geopolitical trends, led by the Group Chief Economist External view of Prudential from a top 20 investor CITIC Pru Life business update and market overview Update on evolving regulatory capital standards (Risk Committee) Deep dive into investment strategy and governance, led by the Group Chief Investment Officer Asset management business update and market overview |
December | Deep dive into alternatives investment process (Risk Committee) |

Year 1 | ||
External Review | ||
interview-based review, facilitated externally | ||
Year 2 | ||
Internal Review | ||
interview and/or questionnaire-based review, led by the Chair and the Company Secretary | ||
Year 3 | ||
Internal Review | ||
interview and/or questionnaire-based review, led by the Chair and the Company Secretary |

Internal board performance review process for 2025 | |
Scoping | |
–Company Secretary discussed proposed approach with Chair. –Chair and Company Secretary updated Nomination & Governance Committee. | |
Questionnaire | |
–Company Secretary facilitated the performance review of the Board through a questionnaire for the Board and each principal Committee which covered: Board composition and dynamics; meeting management and support; the Board’s oversight of different areas; risk management and internal control; succession planning; the work of the Committees; and priorities for change. | |
Feedback | |
–Company Secretary analysed responses to the questionnaire and discussed themes with Chair. –Chair assessed individual performance of each Director and fed back observations. –SID consulted with Board members on performance of Chair and fed back observations. | |
Outcomes | |
–Outcomes of individual Director reviews were discussed by the Nomination & Governance Committee. –Outcomes of Board performance review were discussed by the Nomination & Governance Committee/Board to exchange ideas, agree priorities and actions. –Each principal Committee discussed the relevant Committee themes. |
Theme | Outcome of 2025 review |
Board training | –Board and Committee training programme to focus on fast-evolving areas such as technology and AI, alongside refresher sessions on key products. |
Operation of the Board | –Noting progress in 2025 in increasing time focused on strategic topics, continue to streamline Board agendas to ensure maximum time is allocated to the development of the Group’s future strategy. –Continue to streamline papers to help support the Board’s focus on key strategic matters. –Deepening Board oversight of senior management development and succession planning. |
Operation of the Committees | –Deepening oversight of talent development and succession planning across the Group (including to ensure a diverse talent pipeline) (Sustainability and Nomination & Governance Committees). –Continue to focus on AI, technology, data and cyber risks and controls (Audit and Risk Committees). –Further refining agendas in order to allocate more time to the most significant topics (Audit, Risk and Sustainability Committees). |
Theme | Outcomes of 2024 review | Progress in 2025 |
Operation of the Board | –Review Board forward agenda to increase time on strategic matters during meetings in person relative to operating and financial performance. –Noting progress in 2024, continue to streamline Board papers and hone key messages. –Refine the suite of metrics to support the Board’s monitoring of performance and progress against execution of strategic and financial objectives. | –Good progress was made in this regard, with significant time spent on strategic matters during 2025. –Board papers continued to evolve, with further focus in this area in 2026 to ensure continuous improvement. –Metrics were updated to keep pace with the development of strategic and financial objectives. Further enhancements are expected in 2026 to capture any new reporting metrics. |
Induction and education | –Identify opportunities for Board education sessions in anticipation of key topics coming to the Board or Committees for discussion. –Bring more external perspectives into the Boardroom. | –Board and Committee education sessions were held on various topics. Further sessions are being arranged in 2026. –External perspectives on a range of topics were shared with the Board, which included speakers on AI, macro- economic and geopolitical trends, and other key external trends impacting the industry, as well as from a long- standing investor. |
Committee members | Member since | 2025 meetings1 | |
Jeanette Wong, Chair | May 2021 (Chair since March 2024) | 15/15 | |
Jeremy Anderson | January 2020 | 15/15 | |
Arijit Basu | September 2022 | 15/15 | |
Guido Fürer | July 2025 | 8/8 | |
Mark Saunders | April 2024 | 15/15 | |
Amy Yip2 | March 2021 | 11/13 |
–Chair of the Board –Chief Executive Officer –Chief Financial Officer –Chief Risk and Compliance Officer | –Company Secretary –Chief of Financial & Capital Reporting –Chief Internal Auditor –External Audit Partners |
Key committee activities in 2025 | |||
March –Full-year reporting; –Annual review of risk management and internal controls; –Internal audit effectiveness; –Consideration of auditor re-appointment; and –Oversight of non-financial reporting (jointly with the Sustainability Committee). April –Q1 Business performance update; and –Externally-facilitated education session: Provision 29 of the UK Corporate Governance Code. May –Projects: transformation of the Finance function and preparation for Provision 29; –Bi-annual actuarial update; –External auditor: effectiveness review and audit engagement terms; –Annual report on Speak-Out programme; and –Technology risk management (jointly with the Risk Committee). July –Half-year reporting; and –Preparation for material controls reporting under Provision 29. August –Half-year reporting. October –Transformation of the Finance function; –Auditor independence policy annual review; –Technology risk management (jointly with the Risk Committee); and –Control environment enhancement project (jointly with the Risk Committee). November –Q3 Business performance update. December –Full-year reporting; –Bi-annual actuarial update; –2026 Internal audit plan; –Review of risk management and internal controls; and –Non-financial reporting controls for full-year 2025 reporting (jointly with the Sustainability Committee). | |||
Committee members | Member since | 2025 meetings1 | |
Jeremy Anderson, Chair | January 2020 (Chair since May 2020) | 8/8 | |
Guido Fürer | July 2025 | 5/5 | |
George Sartorel | May 2022 | 8/8 | |
Mark Saunders | April 2024 | 8/8 | |
Claudia Suessmuth Dyckerhoff2 | January 2023 | 6/8 | |
Jeanette Wong | May 2021 | 8/8 |
–Chair of the Board –Chief Executive Officer –Chief Risk and Compliance Officer –Chief Financial Officer –Company Secretary –Chief Internal Auditor | Members of the Risk, Compliance and Security leadership team are invited to attend each meeting as appropriate. |
Key committee activities in 2025 | |||
March –Approval of top risks; –Business focus – Hong Kong, China and Eastspring; –Emerging risks – medical claims cost, investment risk/ALM, competitive market dynamics; –Management of participating products; and –Annual update on Anti-Bribery & Corruption and on Anti-Money Laundering, Counter Terrorist Financing & Sanctions. May –Annual approval of documents for submission to the Hong Kong IA; –Business focus – Hong Kong and Vietnam; –Annual product portfolio review; –Material Group outsourcing arrangements; and –Technology risk management (jointly with the Audit Committee). July –GIECA methodology – risk implications connected with the transition from EEV to TEV; –Business focus – Indonesia; –Foreign ownership rules; and –Risk considerations regarding the incentive design for the CEO and other members of the GEC. October –Business focus – Hong Kong and Vietnam; –Annual Group risk framework review; –Model risk management; –Evolving regulatory capital standards; –Technology risk management, including cyber security (jointly with the Audit Committee); and –Control environment (jointly with the Audit Committee). December –Business focus – Hong Kong; –Risk modelling assumptions – annual review; –Risk appetite and limits – annual review; –Annual review of the Risk and Compliance function effectiveness and approval of the 2026 Risk and Compliance plan; –Joint venture oversight; and –Alternative assets investment process. | |||
Committee’s purpose The Committee is responsible for the oversight of Board and executive succession (unless considered by the Board), nominating candidates for appointment to the Board, oversight of Board performance and corporate governance matters. It assists the Board in retaining an appropriate balance of skills to support the strategic objectives of the Group, ensuring a formal, rigorous and transparent approach to the appointment of Directors, and maintaining an effective framework for succession planning. It also supports and advises the Board on governance arrangements. |
Committee members | Member since | 2025 meetings | |
Shriti Vadera | May 2020 (Chair since January 2021) | 3/3 | |
Jeremy Anderson | November 2022 | 3/3 | |
Chua Sock Koong | May 2022 | 3/3 | |
Sir Douglas Flint | March 2026 | n/a | |
Ming Lu | May 2021 | 3/3 | |
George Sartorel | May 2022 | 3/3 |
–Chief Executive Officer –Chief Human Resources Officer –Company Secretary |
Key Committee activities in 2025 | |||
March | |||
–Non-executive Director succession planning and Committee membership review; –Year-end consideration of matters relating to Board composition and directors’ performance, underpinning the Committee’s recommendation for the re-election of Directors at the 2025 AGM; –Governance Report for the 2024 Annual Report; –Board and Committee performance review – discussion of output; and –Corporate Governance developments. | |||
November | |||
–Chair succession planning. | |||
December | |||
–Chair succession planning; –Board evaluation – approach; –Director induction; and –Corporate Governance developments. | |||
Approximate time commitment | ||||||||
Board | ||||||||
7 meetings | 30 days | |||||||
Audit Committee | ||||||||
5 meetings | 15 days | |||||||
Risk Committee | ||||||||
5 meetings | 8.5 days | |||||||
Remuneration Committee | ||||||||
4 meetings | 6 days | |||||||
Sustainability Committee | ||||||||
3 meetings | 5.5 days | |||||||
Nomination & Governance Committee | ||||||||
3 meetings | 5 days | |||||||
Committee members | Member since | 2025 meetings1 | |
George Sartorel, Chair | September 2024 | 6/6 | |
Arijit Basu | September 2024 | 6/6 | |
Claudia Suessmuth Dyckerhoff | September 2024 | 6/6 | |
Jeanette Wong | September 2024 | 6/6 |
–Chair of the Board –Chief Executive Officer –Chief Financial Officer –Chief Human Resources Officer | –Chief Sustainability Officer –Company Secretary |
Key committee activities in 2025 | ||||||
January –Externally-facilitated workshop covering the global sustainability and climate change landscape, key trends and challenges, examining headwinds, risks and opportunities, investor perspectives, regulatory outlook and reporting trends. February –Internal workshop considering potential impact of the above on the key pillars of Prudential’s sustainability strategy. The Committee also considered regulatory developments, including evolving sustainability reporting requirements, and agreed its 2025 priorities; –Review of FY24 Sustainability Report; –Annual review of Group Code of Conduct, recommended to the Board for approval; –Update on sustainability-related geopolitical landscape; –Update on FTT investments; –Review of people-related matters, including diversity and employee survey results, considering themes from the employee survey and management’s response to them, including deep dives into 'hotspots'; and –Update on on regulatory developments, including the adoption of ISSB standards across the Group’s markets. March Jointly with the Audit Committee –Oversight of non-financial reporting and approval of FY24 Sustainability Report. April –Review and approval of 2025 Modern Slavery Statement. | June –Update on sustainability-related geopolitical landscape; –Considered approach to Climate Transition Plan; –Considered potential changes to sustainability measures included in long-term incentive plans; –Considered the transition to ISSB-aligned reporting in the FY25 Sustainability Report; –Review of workforce policies and practices, including to ensure alignment with the Group’s purpose, values and strategy; and –Update on Prudence Foundation. October –Approach to FY25 Sustainability Report, including alignment between TCFD and ISSB standards to meet reporting requirements for both Hong Kong and the UK; –Considered position paper on nature and climate adaptation, to supplement our FTT framework; –Inclusive insurance update; and –Diversity, inclusion, equity and belonging strategy. Jointly with the Remuneration Committee –Agreed changes to sustainability measures for long- term incentive plans (ahead of shareholder consultation). December –Publication of FTT addendum white paper to define nature and climate adaptation investment opportunities. Jointly with the Audit Committee –Non-financial reporting controls for FY 2025 disclosures; and –Update on sustainability reporting standards across our markets, including compliance with ISSB. | |||||

Current structure | Proposed structure |
Proportionality –No incentives are paid for performance below threshold. Financial targets are set against the Board-approved plan. –Under the PLTIP, 20 per cent of each portion of the award will vest for achieving threshold performance. –The Committee approves termination arrangements of Executive Directors to ensure that there is no reward for failure. Simplicity –The structure comprises fixed remuneration, annual and long-term incentives only. –There is a demonstrable link between performance and reward outcomes. Alignment to culture –Chief Executive Officer's pension benefit of 13 per cent of salary is aligned with that of the wider workforce. –Advice from the Risk Committee is taken to ensure that risk management, culture and conduct are appropriately reflected in the operation of Executive Directors’ remuneration. –The vesting period attached to the PLTIP reflects the time horizon of the business plan. –The additional post-vesting holding period and share ownership guidelines align Executive Director interests with those of other stakeholders. | Predictability –This report details the connection between the performance of the business and the remuneration outcomes for the Chief Executive Officer under the applicable incentive schemes. Clarity –The Committee consults regularly with the Company’s largest shareholders on executive pay proposals before they are implemented. –Details of Executive Director pay proposals are clearly set out in the Annual report on remuneration. Risk –The Risk Committee advises the Committee on risk management considerations to inform remuneration decisions. –The Committee has flexibility to adjust incentive outcomes and to apply malus and clawback to awards and incentive payments. –The holding period on PLTIP awards extends the award time horizon to five years. –In-employment share ownership guidelines provide a strong connection to the sustained success of the Company. Post-employment requirements continue the alignment with Company success and stakeholder interests. |

Key elements of remuneration | 2026 | 2027 | 2028 | 2029 | 2030 | Key features of operation of the policy | ||||
Fixed pay | Salary and benefits | –Salaries reviewed annually with increases generally no greater than those of the workforce unless there is a change in role or responsibility. Benefits reflect individual circumstances and are competitive in the local market. –Pension contributions and/or a cash supplement up to 13% of salary. –Executive Directors based in Hong Kong receive this in addition to contributions into the Hong Kong Mandatory Provident Fund. | ||||||||
Pension | ||||||||||
Short- term variable pay | Cash bonus | –The maximum opportunity is up to 200 per cent of salary. –40 per cent of bonus is deferred for three years. Deferral will be in cash where share ownership guidelines have been met, or otherwise in shares. –Awards are subject to the achievement of financial and personal objectives, with a Pillar I capital underpin aligned with the Hong Kong Insurance Authority capital framework. –Award is subject to malus and clawback provisions. | ||||||||
Deferred bonus | ||||||||||
Long-term variable pay Three-year performance assessment | Prudential Long Term Incentive Plan (PLTIP) | Performance period | Holding period | –Maximum award under the PLTIP is 550 per cent of salary although regular awards are below this level. –Awards are subject to a three-year vesting period from date of grant and a further two-year holding period from the end of the vesting period. –Awards are subject to relative TSR and financial performance measures, as well as a business integrity scorecard. –Awards are subject to malus and clawback provisions. | ||||||
Share ownership guidelines | –Chief Executive Officer guidelines are 400 per cent of salary. –Executives generally have five years to build this level of ownership. –Executives leaving the Board are required to hold the lower of their actual shareholding at the date they leave the Board or their in- employment share ownership guideline for a period of two years. | |||||||||
Remuneration element | Proposed changes | Rationale | ||
Fixed pay | –Scope to increase the annual salary for Executive Directors above the increases for other employees if the Committee believes it appropriate, based on factors considered during the salary review. | –This allows the Committee to apply its judgement to ensure the overall package remains competitive. Should the Committee consider using this power, this would usually be discussed with major investors before a decision was made. | ||
Short-term variable pay | –The maximum opportunity is 250 per cent of salary for Executive Directors. Annual awards are disclosed in the relevant Annual report on remuneration. | –This change is part of rebalancing the usual total maximum incentive opportunity between long- term incentive and annual bonus. | ||
–AIP awards are to be paid in cash if an Executive Director meets their share ownership guideline at the end of the financial year for which the bonus is paid. If not, they will normally be required to defer in shares the lower of 40 per cent of their bonus, or the portion of bonus sufficient to meet the share ownership guideline. | –This change, together with the other recommended changes, is designed to ensure the overall remuneration package is competitive. Our peers generally deliver a greater proportion of total remuneration in cash and over a much shorter timeframe. | |||
Long-term variable pay | –The statement that 'Annual awards are usually significantly below the maximum 550 per cent of salary' has been removed from the proposed Policy. The Committee would seek to consult with major shareholders before making any increase to current award levels. | –The PLTIP maximum is unchanged, with the proposed 2026 award reduced by 50 per cent of salary to 375 per cent. –The annual PLTIP award level will continue to be disclosed in the Annual report on remuneration. | ||
Measure | Weighting | Outturn | % achieved |

Group new business profit | 36% | 21.3% | |
Group adjusted operating profit | 16% | 16.0% | |
Group net operating free surplus generated | 16% | 16.0% | |
Group cash flow | 12% | 9.6% | |
Total Group financial measures | 80% | 62.9% | |
Personal objectives | 20% | 19.0% | |
Total bonus | 100% | 81.9% |
Measure | Weighting | Outturn | % achieved |
Three-year relative TSR | 35% | –% | |
Return on embedded value | 40% | 33.0% | |
Business integrity scorecard | 25% | 22.1% | |
Total PLTIP | 100% | 55.1% |

Membership and 2025 meeting attendance | ||
Committee members | Member since | 2025 meetings1 |
Chua Sock Koong (Chair) | May 2021 (Chair since May 2022) | 7/7 |
Ming Lu | May 2022 | 7/7 |
George Sartorel | May 2023 | 7/7 |
Shriti Vadera2 | May 2024 | 6/7 |
Regular attendees –Chief Executive Officer –Company Secretary –Chief Human Resources Officer (CHRO) –Director, Group Reward and CHRO, UK –Remuneration Committee Adviser | ||
(1)The Committee held four scheduled meetings. In addition, the Committee held one additional short meeting to consider year-end matters and two short meetings to consider ad hoc business. The Committee also held a working session in May to discuss an early outline of potential changes to the Directors' Remuneration Policy. (2)Shriti Vadera was unable to attend one additional meeting due to travel commitments. | ||
$000s | salary | taxable benefits* | total bonus† | PLTIP releases‡ | pension benefits§ | other remuneration1 | Total fixed remuneration~ | Total variable remuneration~ | Total remuneration the ‘single figure’^ |
Anil Wadhwani (2025) | 1,575 | 635 | 2,580 | 3,581 | 207 | – | 2,417 | 6,161 | 8,578 |
Anil Wadhwani (2024) | 1,574 | 503 | 2,801 | – | 207 | 1,439 | 2,284 | 4,240 | 6,524 |
Executive Director | 2025 salary (local currency) from 1 January 2025 | 2025 salary (USD) from 1 January 20251 |
Anil Wadhwani | HKD 12,281,000 | $1,575,000 |
Executive Director | 2025 pension benefit | Life assurance provision |
Anil Wadhwani | Pension supplement in lieu of pension of 13 per cent of salary and a HKD18,000 employer payment to the Hong Kong Mandatory Provident Fund. | Eight times salary. |
Executive Director | Weighting of measures (% of total bonus opportunity) | Performance against measures (% of max for each component) | 2025 AIP outcome (% of max opportunity) | |||||||
Group financial measures | Personal objectives | Group financial measures | Personal objectives | Maximum 2025 AIP (% of salary) | Actual 2025 AIP (% of salary) | 2025 salary | 2025 AIP award2 | |||
Anil Wadhwani1 | 80% | 20% | 78.6% | 95% | 81.88% | 200% | 163.77% | 1,575,295 | 2,579,793 | |
2025 AIP measure | Weighting | Threshold ($m) | Target ($m) | Stretch target ($m) | Achievement ($m) |
Group TEV new business profit | 45% | 2,571 | 2,856 | 2,999 | 2,782 |
Group adjusted operating profit | 20% | 2,836 | 3,151 | 3,309 | 3,306 |
Group net operating free surplus generated | 20% | 1,358 | 1,509 | 1,585 | 1,675 |
Group cash flow | 15% | 1,600 | 1,829 | 2,058 | 1,829 |
2025 personal objectives | Key achievements | Weighting | Performance outcome |
People and Culture | –Strengthened the Group Executive Committee through senior appointments, effective onboarding and clear portfolio accountability. –Advanced succession planning and leadership pipeline development for key Group Leadership Team roles. –Further embedded a performance led, values driven culture, strengthening alignment between delivery, behaviours and reward outcomes. | 20% | 19% |
Transformation | –Delivered the Group’s financial and operational commitments under the current strategy with double digit growth in our key metrics1, including consistent double digit growth across all quarters in new business profit, reflecting disciplined execution and sustained operational focus –Continued execution of the Transformation Agenda across Agency, Health and Operations, supported by sustained investment in capabilities, systems and technology. –Improved operational efficiency and performance, including reductions in operating variances and enhancement of PruServices (our digital servicing portal now live for customers in nine business units). –Worked with joint venture partners, for example CITIC in China saw new business profit growth of 27 per cent. | 35% | 32% |
Strategy | –Maintained a clear focus on capital allocation and capital management, demonstrating the Group’s ability to fund growth and deliver shareholder returns. –Reached an inflection point in the Group’s operating free surplus generation. Completed the $2bn share buyback and launched a further $1.2bn buyback programme in early 2026. –Delivered key strategic initiatives and transactions (eg the IPO of IPAMC in India), generating cash returns and supporting the Group’s capital position. | 25% | 24% |
Stakeholder relations | –Strengthened shareholder engagement through clear, consistent communication. –Improved rNPs in eight out of ten business units, contributing to an increase in customer retention to 88 per cent. –Engaged with regulators across key markets, securing regulatory approvals and expanding market access. | 20% | 20% |
Recognising Mr Wadhwani’s performance against his personal objectives, the Committee judged that an assessment of 95% of the portion of the bonus attributable to personal objectives (20% weighting) was appropriate. | |||
Weighting | Threshold (20 per cent of award vests) | Stretch (100 per cent of award vests) | Performance achieved | Vesting outcome | |
Relative TSR1 | 35% | Median | Upper quartile | Below median | – |
Return on embedded value (RoEV)2 | 40% | 9.35% | 12.65% | 11.3% | 82.5% |
Reduction in WACI3 | 5% | 25.0% | 35.0% | 53.0% | 100.0% |
GWS operating capital generation4 | 5% | $3,698 million | $5,004 million | Above target but below the cumulative stretch target | 81.2% |
GIECA5 | 5% | $7,853 million | $10,625 million | Above target but below the cumulative stretch target | 82.6% |
Diversity6 | 5% | 35.0% | 40.0% | 38% | 78% |
Conduct7 | 5% | Partial achievement | Stretch achievement | No conduct, culture or governance issues that resulted in significant capital add-ons or material fines | 100.0% |
Total | 100% | 55.09% |
Executive Director | Role | Number of shares subject to award | Face value of award | Percentage of awards released for achieving threshold targets | End of performance period | |
% of salary | (USD)* | |||||
Anil Wadhwani | Chief Executive Officer | 635,353 | 425% | 6,695,004 | 20% | 31 December 2027 |
Threshold1 | Maximum | ||
Measure | Weighting | 20% vesting | 100% vesting |
Relative TSR2 | 45% | Median | Upper quartile |
NBP3,5 | 15% | $8,575m | $11,601m |
Gross OFSG4,5 | 15% | $9,288m | $12,567m |
Business integrity scorecard | 25% | see below | |
Measure | Weighting | Threshold performance1 (20% vesting) | Stretch performance1 (100% vesting) |
Reduction in WACI2 | 5% | 50% reduction | 55% reduction |
GWS capital measure3,5 | 5% | Threshold | Stretch |
GIECA measure4,5 | 5% | Threshold | Stretch |
Diversity6 | 5% | 38% female | 42% female |
Conduct7 | 5% | Partial achievement of Group expectations | Achieving Group expectations |
Replacement award1 | No. of notional shares under option outstanding at 1 January 2025 | Exercise price (HKD) | No. of notional shares exercised in 2025 | No. of notional shares lapsed in 2025 | No. of notional shares under option outstanding at 31 December 2025 | End of performance period (if applicable) | Exercise period | Market price at date of vesting (HKD) |
Performance shares | ||||||||
20222, 3 | 163,004 | 0.48 | 127,686 | 35,318 | – | 31 Dec 2024 | 1 May–8 May 2025 | 84.00 |
Restricted shares | ||||||||
2022 | 60,738 | 0.48 | 60,738 | – | – | n/a | 1–30 March 2025 | 79.40 |
Stock options | ||||||||
2020 | 11,552 | 0.48 | 11,552 | – | – | n/a | 5 March–3 April 2025 | 79.40 |
235,294 | 199,976 | 35,318 | – | |||||

n | Prudential | n | FTSE 100 | n | Peer group |
$0001 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2022 | 2023 | 2023 | 2024 | 2025 |
Chief Executive Officer2,3 | MW | MW | MW | MW | MW | MW | MW | MFP | MFP | AW | AW | AW |
Salary, pension and benefits | 3,029 | 2,415 | 2,423 | 2,122 | 2,126 | 2,249 | 663 | 1,476 | 447 | 1,986 | 2,284 | 2,417 |
Annual bonus payment | 2,904 | 2,673 | 2,848 | 2,804 | 1,355 | 3,057 | 693 | 2,161 | 441 | 2,638 | 2,801 | 2,580 |
(As % of maximum) | (99.5)% | (94.0)% | (95.0)% | (96.0)% | (46.0)% | (96.7)% | (96.0)% | (98.0)% | (97.4)% | (99.0)% | (89.0)% | (81.9)% |
LTIP vesting | 4,016 | 5,955 | 4,837 | 2,746 | 4,286 | 1,052 | 2,108 | 1,255 | 307 | – | – | 3,581 |
(As % of maximum) | (70.8)% | (95.8)% | (62.5)% | (62.5)% | (68.8)% | (17.8)% | (45.5)% | (45.5)% | (27.6)% | – | – | (55.1)% |
Other payment4 | – | – | – | – | – | – | – | – | – | 7,081 | 1,439 | – |
Chief Executive Officer ‘single figure’ of total remuneration5 | 9,950 | 11,042 | 10,109 | 7,671 | 7,768 | 6,358 | 3,464 | 4,892 | 1,195 | 11,705 | 6,524 | 8,578 |
2024 | 2025 | Percentage change | |
All employee pay ($m)1 | 1,210 | 9% | |
Dividends and share buyback programme ($m)2 | 1,360 | 1,834 | 35% |
Salary (% change) | Benefits10 (% change) | Bonus9 (% change) | |||||||||||||||
2024- 25 | 2023- 24 | 2022- 23 | 2021- 22 | 2020- 21 | 2024- 25 | 2023-24 | 2022- 23 | 2021- 22 | 2020- 21 | 2024- 25 | 2023-2 4 | 2022- 23 | 2021- 22 | 2020- 21 | |||
Executive Director | |||||||||||||||||
Anil Wadhwani1 | – | 19% | – | – | – | 26% | 3% | – | – | – | (8)% | 6% | – | – | – | ||
Chair and Non- executive Directors3 | |||||||||||||||||
Shriti Vadera2 | 2% | (1)% | 1% | 2% | 907% | 10% | (18)% | 10% | 35% | – | – | – | – | – | – | ||
Jeremy Anderson | 1% | 5% | 12% | 3% | 13% | 25% | 300% | – | – | – | – | – | – | – | – | ||
Arijit Basu4 | 2% | 1% | 198% | – | – | 33% | 200% | – | – | – | – | – | – | – | – | ||
Guido Fürer5 | – | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||
Ming Lu6 | 2% | 0% | 0% | 58% | – | – | – | – | – | – | – | – | – | – | – | ||
George Sartorel4 | 3% | 7% | 34% | – | – | (40)% | 400% | – | – | – | – | – | – | – | – | ||
Mark Saunders7 | 36% | – | – | – | – | – | – | – | – | – | – | – | – | – | – | ||
Claudia Suessmuth Dyckerhoff8 | 2% | 1% | – | – | – | 50% | 100% | – | – | – | – | – | – | – | – | ||
Chua Sock Koong6 | 1% | (1)% | 5% | 70% | – | 0% | 100% | – | – | – | – | – | – | – | – | ||
Jeanette Wong6 | 6% | 19% | 0% | 74% | – | (33)% | – | – | – | – | – | – | – | – | – | ||
Amy Yip8 | (15)% | 0% | 0% | 1% | 0% | – | – | – | – | – | – | – | – | – | – | ||
UK-based employees | 4.0% | 4.6% | 6.0% | 6.7% | 3.1% | 46.1% | (14.5)% | 45.1% | (7.3)% | 0.7% | (9.9)% | (13.6)% | 143% | 7.9% | 5.8% | ||
Annual fees2 | From 1 July 2024 ($) | From 1 July 2025 ($) |
Basic fee | 125,000 | 129,000 |
Additional fees: | ||
Audit Committee Chair | 92,000 | 92,000 |
Audit Committee member | 39,000 | 39,000 |
Remuneration Committee Chair | 80,000 | 80,000 |
Remuneration Committee member | 39,000 | 39,000 |
Risk Committee Chair | 92,000 | 92,000 |
Risk Committee member | 39,000 | 39,000 |
Nomination & Governance Committee Chair1 | – | – |
Nomination & Governance Committee member | 19,000 | 19,000 |
Sustainability Committee Chair | 60,000 | 60,000 |
Sustainability Committee member | 30,000 | 30,000 |
Senior Independent Director | 61,000 | 61,000 |
2025 fees ($000) | 2024 fees ($000) | 2025 taxable benefits* ($000) | 2024 taxable benefits* ($000) | Total 2025 remuneration: the ‘single figure’ ($000)†‡ | Total 2024 remuneration: the ‘single figure’ ($000)†‡ | |
Chair | ||||||
Shriti Vadera | 986 | 966 | 123 | 112 | 1,109 | 1,078 |
Non-executive Directors | ||||||
Jeremy Anderson | 338 | 335 | 5 | 4 | 343 | 339 |
Arijit Basu | 196 | 192 | 4 | 3 | 200 | 195 |
Guido Fürer1 | 104 | – | – | – | 104 | – |
Ming Lu2 | 185 | 182 | – | – | 185 | 182 |
George Sartorel | 284 | 277 | 3 | 5 | 287 | 282 |
Mark Saunders | 205 | 151 | – | – | 205 | 151 |
Claudia Suessmuth Dyckerhoff | 196 | 192 | 3 | 2 | 199 | 194 |
Chua Sock Koong | 226 | 223 | 2 | 2 | 228 | 225 |
Jeanette Wong | 288 | 271 | 2 | 3 | 290 | 274 |
Amy Yip3 | 138 | 163 | – | – | 138 | 163 |
Total | 3,146 | 2,952 | 142 | 131 | 3,288 | 3,083 |
1 January 2025 (or on date of appointment) | 31 December 2025 (or on date of stepping down) | Share ownership guidelines | |||||||||
Total beneficial interest (number of shares) | Number of shares acquired during the year | Number of shares disposed of during the year | Total beneficial interest* (number of shares) | Number of shares subject to performance conditions† | Total interest in shares | Share ownership guidelines‡ (% of salary/fee) | Beneficial interest as a percentage of basic salary/ basic fees§ | ||||
Chair | |||||||||||
Shriti Vadera | 117,500 | – | – | 117,500 | – | 117,500 | 100% | 159% | |||
Executive Director | |||||||||||
Anil Wadhwani1 | 329,573 | 137,035 | – | 466,608 | 1,770,768 | 2,237,376 | 400% | 403% | |||
Non-executive Directors | |||||||||||
Jeremy Anderson | 19,157 | – | – | 19,157 | – | 19,157 | 100% | 202% | |||
Arijit Basu | 9,691 | 4,000 | – | 13,691 | – | 13,691 | 100% | 144% | |||
Guido Fürer | – | 13,000 | – | 13,000 | – | 13,000 | 100% | 137% | |||
Ming Lu | 12,600 | 5,000 | – | 17,600 | – | 17,600 | 100% | 186% | |||
George Sartorel | 13,000 | 1,000 | – | 14,000 | – | 14,000 | 100% | 148% | |||
Mark Saunders | 13,750 | – | – | 13,750 | – | 13,750 | 100% | 145% | |||
Claudia Suessmuth Dyckerhoff | 4,800 | – | – | 4,800 | – | 4,800 | 100% | 51% | |||
Chua Sock Koong | 15,000 | – | – | 15,000 | – | 15,000 | 100% | 158% | |||
Jeanette Wong | 14,600 | – | – | 14,600 | – | 14,600 | 100% | 154% | |||
Amy Yip | 14,013 | – | – | 14,013 | – | 14,013 | 100% | 148% | |||
Date of contract | Notice period to the Company | Notice period from the Company | |
Executive Director | |||
Anil Wadhwani | 25 February 2023 | 12 months | 12 months |
Chair/Non-executive Director | Appointment by the Board | Notice period | Time on the Board at 2026 AGM |
Chair | |||
Shriti Vadera (Chair from 1 January 2021) | 1 May 2020 | 12 months | 6 years |
Non-executive Directors | |||
Amy Yip1 | 2 September 2019 | 6 months | n/a |
Jeremy Anderson | 1 January 2020 | 6 months | 6 years 4 months |
Ming Lu | 12 May 2021 | 6 months | 5 years |
Chua Sock Koong | 12 May 2021 | 6 months | 5 years |
Jeanette Wong | 12 May 2021 | 6 months | 5 years |
George Sartorel | 14 January 2022 | 6 months | 4 years 4 months |
Arijit Basu | 1 September 2022 | 6 months | 3 years 8 months |
Claudia Suessmuth Dyckerhoff | 1 January 2023 | 6 months | 3 years 4 months |
Mark Saunders | 1 April 2024 | 6 months | 2 years 1 month |
Guido Fürer | 1 July 2025 | 6 months | 10 months |
Resolution | Votes for | % of votes cast | Votes against | % of votes cast | Total votes cast | Votes withheld |
To approve the Directors’ remuneration policy (2023 AGM) | 2,176,820,906 | 95.71 | 97,529,901 | 4.29 | 2,274,350,807 | 12,342,304 |
To approve the Directors’ remuneration report (2025 AGM) | 1,967,863,835 | 92.40 | 161,804,212 | 7.60 | 2,129,668,047 | 1,720,482 |
Measure | Weighting | Threshold performance1 (20% vesting) | Stretch performance (100% vesting) |
Relative TSR2 | 40% | Median | Upper quartile |
NBP3 | 15% | $9,630m | $13,029m |
Gross OFSG4 | 15% | $10,841m | $14,668m |
RoEV5 | 15% | 14.3% | 19.3% |
Business integrity scorecard | 15% | see below | |
Measure | Weighting (% of total LTIP) | Threshold performance (20% vesting) | Stretch performance (100% vesting) |
Financing the Transition1 | 5% | $3.783bn | $4.017bn |
GWS capital measure2, 4 | 5% | Threshold | Stretch |
GIECA measure3, 4 | 5% | Threshold | Stretch |
Policy element(s) | 2023 Policy | Recommended 2026 Policy | Commentary |
Base salary – value | –Annual salary increases for Executive Directors will normally be in line with the increases for other employees unless there is a change in role or responsibility. | –Annual salary increases for Executive Directors will normally be in line with the increases for other employees. The Committee can determine to increase the annual salary for Executive Directors above the increases for other employees if it believes that this is appropriate based on factors considered during the salary review. | –Our long-standing practice has been for annual salary increases for Executive Directors to be below the increases for other employees. Notwithstanding that it is anticipated that this will continue to be the case, this change allows the Committee to apply their judgement to ensure the overall remuneration package remains competitive. –Should the Committee consider using this power, this would usually be discussed with major investors before a decision was made and its reasons for making the decision would be disclosed in the relevant Annual report on remuneration. |
Policy element(s) | 2023 Policy | Recommended 2026 Policy | Commentary |
Benefits | –Executive Directors and Non- executive Directors (NEDs) can receive reimbursement for business expenses (including any tax liability) incurred when travelling overseas in performance of duties. –If as a consequence of the Company’s corporate structure, Non-executive Directors are required to prepare personal tax returns in Hong Kong and/or the UK, in addition to preparing their personal tax return for the jurisdiction which is their place of residence, the Company will reimburse the costs of personal tax return preparation for whichever locations are not their place of residence (including payment of any tax cost associated with the provision of the benefit). | –Business expense reimbursement is also applicable to Executive Directors. The description of reimbursed business expenses has been expanded to include banking fees and any other reasonable fees for professional services incurred when travelling overseas in performance of duties or due to the Company’s corporate structure. –Modest gifts or awards to Executive Directors on customary occasions of the same value as offered to the wider workforce in the same location, for example long service awards. | –Reflects the administrative obligations created for the Executive Directors and NEDs in discharging their services. –Supports alignment with the wider workforce. |
Bonus – opportunity | –The maximum AIP opportunity is up to 200 per cent of salary for Executive Directors. Annual awards are disclosed in the relevant Annual report on remuneration. | –The maximum AIP opportunity is up to 250 per cent of salary for Executive Directors. Annual awards are disclosed in the relevant Annual report on remuneration. | –This change is part of rebalancing the usual total maximum incentive opportunity between long-term incentive and bonus, i.e. reducing the 2026 PLTIP award by 50 per cent of salary and increasing the 2026 AIP award by 50 per cent of salary. |
Bonus – form and timing of payment | –40 per cent of an Executive Director’s bonus will be deferred in cash for three years provided that their share ownership guideline is met. Deferred awards will be made in shares if the Executive Director’s share ownership guideline has not yet been achieved. The Committee retains discretion to vary the proportion of the bonus to be deferred and the length of the deferral period. –The release of deferred bonus awards is not subject to any further performance conditions. Deferred bonus awards in shares carry the right to accumulate an amount to reflect the dividends payable in respect of the shares that vest during the deferral period. These dividend equivalents will normally be settled in shares, but there is the flexibility to deliver them in cash. The amount of the dividend equivalent payment may assume the re-investment of the relevant dividends in shares. | –Up to 40% of an Executive Director’s bonus will be deferred into shares, for three years, while they are building their share ownership and until their share ownership guideline has been met, otherwise a bonus is paid immediately in cash. Achievement of the share ownership guideline will be assessed as at the end of the financial year for which the bonus is paid. –For the avoidance of doubt, an Executive Director will need to continue to meet the share ownership guideline (even during the share ownership guideline build up period) for AIP awards to be paid in cash. If the share ownership guideline is not met at the end of a financial year, the necessary portion of the AIP paid in respect of that year will be delivered in shares. | –This change, together with the other recommended changes, is designed to ensure the overall remuneration package is competitive. Our peers generally deliver a greater proportion of total remuneration in cash and over a much shorter timeframe. |
Fees for the Chair and Non-executive directors | –The Chair receives an annual fee for the performance of their role. –All Non-executive Directors receive a basic fee for their duties as a Board member. Additional fees are paid for added responsibilities. | –The Chair receives an annual fee for the performance of their role. –All Non-executive Directors receive a basic fee for their duties as a Board member. Additional fees are paid for added responsibilities. –A portion of fees may be delivered in the form of shares without performance conditions, based on the market value of the shares, if the Board/ Committee deems that this is appropriate. | –We intend to continue to pay fees in cash in 2026. A provision allowing a portion of fees to be delivered in shares provides the Board/ Committee flexibility in light of relevant circumstances, including changes in market practice, during the life of the Policy. |
Component and purpose | Operation | Opportunity |
Base salary Paying salaries at a competitive level enables the Company to recruit and retain key Executive Directors. | Offer Executive Directors market competitive base salaries. The Committee usually reviews salaries annually with changes normally effective from 1 January. In determining base salary for each Executive Director, the Committee considers factors such as: –Salary increases for other employees across the Group; –The performance and experience of each Executive Director; –The size and scope of the role; –Group financial performance; –Internal relativities; and –External factors such as economic conditions and market data, taking into account the geographies and markets in which the Company operates and competes for talent. | Annual salary increases for Executive Directors will normally be in line with the increases for other employees unless the Committee determines otherwise based on the factors considered during the salary review. |
Benefits Provided to Executive Directors to support their health and wellbeing, and to assist them in carrying out their duties effectively. Relocation and location-specific benefits allow Prudential to attract high calibre Executive Directors in the international talent market and to deploy them appropriately. | The Committee has the discretion to offer Executive Directors benefits which reflect their individual circumstances and are competitive within their local market, including but not limited to: –Health and wellness benefits; –Protection and security benefits; –Transport benefits; –Family and education benefits; –All employee share plans and savings plans; –Relocation and location-specific benefits; –Reimbursed business expenses (including any relevant tax liability, banking fees and any other reasonable fees for professional services such as legal, tax, property and financial advice) incurred when travelling overseas in performance of duties or due to the Company’s corporate structure; and –Modest gifts or awards on customary occasions of the same value as offered to the wider workforce in the same location, such as long service awards. | The maximum paid will be the cost to the Company of providing these benefits. The cost of these benefits may vary from year to year but the Committee is mindful of achieving the best value from providers. |
Provision for an income in retirement Pension benefits provide Executive Directors with opportunities to save for an income in retirement. | Executive Directors are offered pension benefits that are competitive and appropriate in the context of pension benefits for the wider workforce. Executive Directors have the option to: –Receive payments into a defined contribution scheme or similar arrangement; and/or –Take a cash supplement in lieu of contributions. In addition, Executive Directors may receive statutory contributions to mandatory pension arrangements in the country in which they are based, in line with local requirements. | Executive Directors will be entitled to receive pension contributions or a cash supplement (or a combination of the two) in line with the workforce rate. In 2026, this is considered to be 13 per cent of base salary. In addition, statutory contributions will be made to mandatory pension arrangements in the country in which the Executive Directors are based, in line with local requirements. |
Annual bonus Policy for Executive Directors | |
Purpose | The purpose of the Annual Incentive Plan (AIP) is to provide a competitive package in the markets in which we compete for talent. Payments under the AIP reward the delivery of stretching financial, functional and/or personal objectives which are drawn from the annual business plan measured over a period not exceeding one financial year. |
Opportunity | The maximum annual AIP opportunity is up to 250 per cent of salary for Executive Directors. Annual awards are disclosed in the relevant Annual report on remuneration. |
Operation | Currently Executive Directors participate in the AIP with payments based on the achievement of financial, functional and/or personal objectives generally assessed over one financial year. Payments under the AIP will normally be made in cash following the end of the performance year unless an Executive Director is yet to meet their share ownership guideline as assessed at the end of the financial year, in which case they will normally be required to defer 40 per cent of their bonus in the form of shares for three years. If a deferral in shares of less than 40 per cent would mean that the Executive Director has met their share ownership guideline, this lower portion would be deferred in shares and the balance would be paid immediately in cash. The Committee retains discretion to vary the proportion of the bonus to be deferred and/or the length of the deferral period. The release of deferred bonus awards is not subject to any further performance conditions. Deferred bonus awards in shares carry the right to accumulate a 'dividend equivalent' amount to reflect the dividends payable on those shares. The amount of the dividend equivalent may assume the re-investment of the relevant dividends in shares. |
Determining annual bonus awards | The Committee determines the AIP award for each Executive Director with reference to the performance achieved against approved performance ranges. In making this assessment, the Committee will take into account the personal performance of the Executive Director and the Group’s risk management framework and appetite, as well as other relevant factors. To assist them in their assessment, the Committee considers advice from the Risk Committee on whether results were achieved within the Group’s and businesses’ risk management framework and appetite and to relevant conduct standards. The Committee may adjust the formulaic outcome based on the performance targets to reflect the underlying performance of the Company by applying discretion within the limits of the Policy. The Committee will disclose in the relevant Annual report on remuneration where discretion is used. |
Performance measures | The Committee determines the performance conditions and sets annual targets with reference to the business plans approved by the Board. No bonus is payable under the AIP for performance at or below the threshold level, increasing to 100 per cent for achieving or exceeding the maximum level. The weightings of the performance measures for 2026 for the Chief Executive Officer are 80 per cent Group financial measures and 20 per cent personal measures. The Committee retains the discretion to adjust performance conditions and/or targets if events occur (such as a material acquisition and/or divestment of a Group business or the requirements of the Company’s regulators, or a change in prevailing market conditions) which cause the Committee to determine that the measures and/or targets are no longer appropriate and that amendment is required so that they achieve their original purpose. |
Long-term incentive Policy for Executive Directors | |
Purpose | The purpose of the Prudential Long Term Incentive Plan (PLTIP) is to provide a competitive package in the markets in which we compete for talent and to reinforce the community of interest between the Executive Directors and other stakeholders. Specifically, the PLTIP is designed to incentivise the delivery of longer- term business plans; the creation of sustainable long-term returns for shareholders; and the achievement of Group strategic priorities, such as disciplined risk and capital management. |
Opportunity | The value of shares awarded under the PLTIP (in respect of any given financial year) may not exceed 550 per cent of the Executive Director’s annual basic salary. On recruitment, any buy out awards will not count towards this limit provided that they replace foregone awards on a like for like basis. Annual awards are disclosed in the relevant Annual report on remuneration. The Committee would seek to consult with major shareholders before making any increase to current award levels. |
Long-term incentive Policy for Executive Directors | |
Operation | Currently, Executive Directors receive PLTIP awards with full vesting only achieved if the Company meets stretching performance targets normally measured over three years. Subject to the Committee’s discretion mentioned below, the extent that performance conditions are not achieved at the end of the three-year performance period, the unvested portion of any award lapses and performance cannot be retested. Wherever possible, the targets attached to PLTIP awards will be disclosed prospectively at the time of the award. Where PLTIP targets are commercially sensitive, they will be published in the Annual Report of the final year of the performance period. The Committee retains the discretion to adjust (including by reducing to nil) the formulaic outcome under the PLTIP if it considers that: (1)the extent to which any performance condition has been met does not reflect the underlying financial or non-financial performance of the participant or any member of the Group over the performance period; or (2)there exists any other reason why an adjustment is appropriate, taking into account such factors as the Committee considers relevant, including the context of circumstances that were unexpected or unforeseen at the date of grant. The Committee will disclose in the relevant Annual report on remuneration where discretion is used. Vested awards are normally also subject to a holding period which usually ends on the fifth anniversary of the award (unless the Committee determines otherwise, in exceptional circumstances, such as an Executive Director passing away). If the Committee so determines, the Company may sell such number of shares under a PLTIP award as is required to satisfy any income tax liability that in respect of a PLTIP award and the 'net of tax' balance of shares will be subject to the holding period. PLTIP awards carry the right to accumulate a 'dividend equivalent' amount to reflect the dividends payable on those shares. The amount of the dividend equivalent may assume the re-investment of the relevant dividends in shares. |
Performance measures | The performance conditions applicable to PLTIP awards may be set by reference to financial, non-financial and strategic objectives, and the majority of a PLTIP award will be subject to quantitative targets. The Committee sets targets with reference to the business plans approved by the Board. The achievement of performance at the threshold level results in vesting of 20 per cent of the award, increasing to 100 per cent for achieving the maximum level. The Committee may decide to attach different performance conditions and/or change the conditions’ weighting for future PLTIP awards. Where relevant, the performance conditions attached to each award will be based on the business plans and priorities of the Group and disclosed in the relevant Annual report on remuneration. The Committee considers advice from the Risk Committee on whether results were achieved within the Group’s and businesses’ risk management framework and appetite and to relevant conduct standards. The Committee retains the discretion to adjust performance conditions and/or targets if events occur (such as a material acquisition and/or or the requirements of the Company’s regulators or a change in prevailing market conditions) which cause the Committee to determine that the measures and/or targets are no longer appropriate and that amendment is required so that they achieve their original purpose. |
In-employment guidelines | Under the Articles of Association, Executive Directors are required to hold at least 2,500 shares and have one year from their date of appointment to the Board to acquire these. The share ownership guideline for the Chief Executive Officer during their employment is 400 per cent of salary. Executive Directors normally have five years from the later of the date of their appointment or promotion, or the date of an increase in these guidelines, to build this level of ownership. Shares earned and deferred under the AIP are included in calculating the Executive Director’s shareholding for these purposes, as are shares held by members of an Executive Director’s household. Unvested share awards under long-term incentive plans are not included but vested share awards under long-term incentive plans which are subject to a post- vesting holding period are included. Should an Executive Director not meet the share ownership guidelines, the Committee retains the discretion to determine how this should be addressed, taking account of all the prevailing circumstances. |
Post-Directorship guidelines | When an Executive Director leaves the Board, they will be required to hold the lower of their actual shareholding on the date of them stepping down from the Board and their in-employment share ownership guideline for a period of two years. The Committee has the discretion to disapply or reduce this requirement in extenuating circumstances, for example if the Executive Director takes up a role with a regulator or for compassionate reasons. This obligation will be implemented by requiring Executive Directors leaving the Board to obtain clearance to deal in the Company’s shares during the two years during which this post-Directorship share ownership guideline applies, in the same way as they must during the time on the Board. |
Circumstances where the Committee may exercise its discretion to apply malus or clawback to an award | |
Malus Allows deferred cash awards and unvested shares awarded under deferred bonus and LTIP plans to be forfeited or reduced in certain circumstances. | Malus may be applied where there are exceptional circumstances, such as: –a material misstatement in the published results of any member of the Group, for any period during or after the performance period (or if no performance periods are applicable, the vesting period); –an error in the assessment of any applicable performance conditions, the determination of the relevant bonus or the number of shares subject to an award (or where such assessment was based on inaccurate or misleading information); –gross misconduct; –a breach by the Executive Director of any restrictive covenants or other similar undertakings; –where the Executive Director has caused a material financial loss for the Group as a result of (i) reckless, negligent or wilful actions or omissions; or (ii) inappropriate values or behaviour; –where a member of the Group is censured by a regulatory body or suffers significant reputational damage; and –insolvency or corporate failure. |
Clawback Allows cash and share awards, including shares subject to the holding period, to be recovered before or after release in certain circumstances. | Clawback may be applied where there are exceptional circumstances, such as the circumstances listed above: –For the PLTIP, at any time before the fifth anniversary of the award date; and –For the AIP, at any time before the fifth anniversary of the end of the bonus performance period. |


$15.65m | ||||||
$12.60m | 58% | |||||
$8.14m | 48% | |||||
45% | ||||||
32% | 26% | |||||
$2.46m | 25% | |||||
100% | 30% | 20% | 16% |
n | Fixed Pay | n | Short-term incentives | n | Long-term incentives |
Minimum | In line with expectations | Maximum | Share price growth | |
Fixed pay | –Base salary at 1 January 2026. –Pension allowance for the year has been calculated at 13% of salary in line with this Policy. –Estimated value of other benefits based on amounts paid in 2025. | |||
Annual bonus | No bonus paid | 50% of maximum AIP | 100% of maximum AIP | |
Long-term incentives (excludes dividends) | No PLTIP vesting | Vesting of 60% of PLTIP award (midway between threshold and maximum) | Vesting of 100% of PLTIP award | Vesting of 100% of PLTIP award; plus, share price growth of 50 per cent over three years. |
Element | Principles | Potential variations |
Base pay | The salary for a new Executive Director will be set using the approach set out in the Fixed pay Policy table. | |
Benefits and pension | The benefits for a new Executive Director will be consistent with those outlined in the Fixed pay Policy table. | |
Variable remuneration opportunity | The variable remuneration opportunities for a new Executive Director would be consistent with the limits and structures outlined in the Annual bonus and Long- term incentive plan award Policy tables. | |
Awards and contractual rights forfeited when leaving previous employer | On joining the Board from within the Group, the Committee may allow an Executive Director to retain any outstanding deferred bonus and/or long-term incentive awards and/or other contractual arrangements that they held on their appointment. These awards (which may have been made under plans not listed in this Policy) would usually remain subject to the original rules, performance conditions and vesting schedule applied to them when they were awarded. If an externally appointed Executive Director forfeits one or more bonuses (including outstanding deferred bonuses) on leaving a previous employer, these payments or awards may be replaced in either cash, or awards of Prudential shares of an equivalent value. Replacement awards will normally be released on the same schedule as the foregone bonuses. If an externally appointed Executive Director forfeits one or more long-term incentive awards on leaving a previous employer, these may be replaced with Prudential awards with an equivalent value. Replacement awards will generally be made under the terms of a long-term incentive plan approved by shareholders, and vest on the same schedule as the foregone awards. Where forgone awards were subject to performance conditions, performance conditions will normally be applied to awards replacing foregone long- term incentive awards; these will usually be the same as those applied to the long-term incentive awards made to Prudential Executive Directors in the year in which the forfeited award was made, the original conditions applied by the previous employer or other performance conditions which the Committee believes are appropriate in the circumstances. Where foregone awards were not subject to performance conditions, performance conditions will not normally be applied to awards replacing them. Replacement awards will normally be subject to malus and clawback. If an externally appointed Executive Director incurs costs or other losses in connection with joining Prudential (such as buying out their notice period with a previous employer at the Company’s request), the Executive Director may be reimbursed, including any tax payable in respect of the costs or losses. | The Committee may consider compensating a newly-appointed Executive Director for other relevant contractual rights forfeited when leaving their previous employer and/or for remuneration foregone as a result of leaving their previous employer. The use of Listing Rule 9.3.2 may be used to facilitate the recruitment of an Executive Director. The Committee does not anticipate using this rule on a routine basis but reserves the right to do so in an exceptional circumstance. For example, this rule may be required if, for any reason, like-for-like replacement awards on recruitment could not be made under existing plans. This provision would only be used to compensate for remuneration forfeited or foregone on leaving a previous employer. |
Element | Principles | Potential variations |
Notice periods | The Company’s policy is that Executive Directors’ service contracts will not require the Company to give an Executive Director more than 12 months’ notice without prior shareholder approval. A shorter notice period may be offered where this is in line with market practice in an Executive Director’s location. The Company is required to give to, and to receive from, the current Executive Director 12 months’ notice of termination. An Executive Director whose contract is terminated would be entitled to salary and benefits in respect of their notice period. The payment of the salary and benefits would either be phased over the notice period or, alternatively, a payment in lieu of notice may be made. In agreeing the terms of departure for any Executive Director, other than on death or disablement, the Company will have regard to the need to mitigate the costs for the Company, which would normally be reduced or cease if the departing Executive Director secures alternative paid employment during the notice period. | If an Executive Director is dismissed for cause, their contract would be terminated with immediate effect and they would not receive any payments in relation to their notice period. Should an Executive Director die, their estate would not be entitled to receive payments and benefits in respect of their notice period – provisions are made under the Company’s life assurance scheme to provide for this circumstance. Should an Executive Director step down from the Board but remain employed by the Group, they would not receive any payment in lieu of notice in respect of their service as a Director. |
Outstanding deferred bonus awards | The treatment of outstanding deferred bonuses will be decided by the Committee, taking into account the circumstances of the departure including the performance of the Executive Director. Deferred bonus awards are normally retained by participants leaving the Company. Awards will usually vest on the original timetable and will not normally be released early on termination. Prior to release, awards remain subject to the malus terms originally applied to them. The clawback provisions will continue to apply. | Any Executive Director dismissed for cause would forfeit all outstanding deferred bonus awards. Should an Executive Director die, outstanding deferred bonus awards will be released as soon as possible after the date of death. In the case of ill health and in other exceptional circumstances, the Committee has the discretion to accelerate the vesting of any outstanding deferred bonus awards. Should an Executive Director step down from the Board but remain employed by the Group, they would retain any outstanding deferred bonus awards. These awards would remain subject to the original rules and vesting schedule applied to them when they were awarded. |
Unvested long-term incentive awards | The treatment of unvested long-term incentive awards will be decided by the Committee, taking into account the circumstances of the departure including the performance of the Executive Director. Where an Executive Director is determined to be a good leaver, unvested long-term incentive awards will normally subsist. These awards will ordinarily be pro- rated, unless the Committee determines otherwise, to reflect the proportion of the performance period that has elapsed, and will vest on the original timescale. Awards will remain subject to the original performance conditions assessed over the entire performance period, unless the Committee decides to assess the performance conditions over a shorter period. Good leavers are defined as those who leave as a result of injury or disability, retirement with the approval of the employing company, their employing company or business ceasing to be part of the Group, or in any other circumstances at the discretion of the Committee. Individuals who die in service will also be treated as good leavers. Where an Executive Director is not determined to be a good leaver, unvested long-term incentive awards will lapse on cessation of employment. Awards remain subject to the malus and clawback terms and holding periods originally applied to them. | Any Executive Director dismissed for cause would forfeit all unvested long-term incentive awards. If the Committee has judged that the departing Executive Director should retain their unvested long- term incentive awards with the expectation that: –the Executive Director is retiring from their professional executive career; and/or –the Executive Director will not be seeking to secure alternative employment with another organisation of comparable size as the Company or that is within the financial services sector, the Committee retains the power to lapse all unvested long-term incentive awards should the Committee deem that the Executive Director has subsequently secured similar paid executive employment elsewhere. On death, disablement and in other exceptional circumstances, the Committee has discretion to release unvested long-term incentive awards earlier than the end of the vesting period. The malus and clawback provisions would continue to apply. Should an Executive Director step down from the Board but remain employed by the Group, they would retain any outstanding long-term incentive awards which they held on their change of role. These awards would remain subject to the original rules, performance conditions and vesting schedule. |
Element | Principles | Potential variations |
Vested long- term incentive awards, subject to the holding period | The treatment of vested long-term incentive awards within their holding period will be decided by the Committee, taking into account the circumstances of the departure. Executive Directors will normally retain their vested long-term incentive awards that remain subject to the holding period. Normally these awards will remain subject to the holding period and be released in accordance with the original timescale. Awards remain subject to the malus and clawback terms originally applied to them. | Any Executive Director dismissed for cause would normally forfeit vested long-term incentive awards. On death, disablement and in other exceptional circumstances, the Committee has discretion to release vested long-term incentive awards earlier than the end of the holding period. The malus and clawback provisions would continue to apply. Should an Executive Director step down from the Board but remain employed by the Group, they would retain any vested long-term incentive awards that remain subject to the holding period. These awards would remain subject to the original rules and release schedule applied to them when they were awarded (ie the holding period will continue to apply). |
Bonus for final year of service | The payment of any bonus for the final year of service will be decided by the Committee, giving full consideration to the circumstances of the departure including the performance of the Executive Director. The Committee may award a departing Executive Director a bonus which will usually be pro-rated to reflect the portion of the final financial year in which they served which had elapsed on the last day that they worked. Any such bonus would normally be calculated with reference to financial, functional and/or personal performance measures in the usual way. If appropriate, the Committee may, at its discretion waive any requirement for a portion of the final bonus to be deferred. | Any Executive Director dismissed for cause would not be eligible for any bonus that has not been paid. Should an Executive Director die, or in any other exceptional circumstances (such as an Executive Director’s terminal illness), whilst serving as an employee, a time pro-rated bonus may be awarded. In such circumstances, deferral will not be applied and the payment will be made wholly in cash. The Committee may decide to award an Executive Director stepping down from the Board but remaining with the Group a bonus pro-rated to reflect the portion of the financial year which had elapsed on the date of their change of role. This would be calculated with reference to financial, functional and/or personal performance measures in the usual way. The Committee may determine that a portion of such a bonus must be deferred. |
Other payments | Consistent with other employees, Executive Directors may receive payments to compensate them for the loss of employment rights on termination. Payments may include: –A nominal amount for agreeing to non-solicitation and confidentiality clauses; –Directors and Officers insurance cover for a specified period following the Executive Director’s termination date; –Payment for outplacement services; –Statutory redundancy payments or gratuities (where applicable); –Reimbursement of legal fees; –Support with preparation of tax returns; and –Repatriation assistance. The Committee reserves the right to make additional exit payments where such payments are made in good faith: –In discharge of an existing legal obligation (or by way of damages for breach of such an obligation); or –By way of settlement or compromise of any claim arising in connection with the termination of a Director’s office or employment. | |
Post- Directorship guidelines | –When an Executive Director leaves the Board, they will be subject to post-cessation share ownership guidelines. –Further details are included in the section on ‘Share ownership guidelines for Executive Directors’. |
Treatment | |
Deferred AIP Awards | In the event of a corporate transaction (eg takeover, material merger, or demerger, winding up etc.), the Committee will determine whether awards will: |
–Vest; and/or –Continue in accordance with the rules of the plan; and/or –Lapse and, in exchange, the participant will be granted an award under any other share or cash incentive plan which the Committee considers to be broadly equivalent to the award. | |
Long-term incentive awards | In the case of a corporate transaction (e.g. takeover, material merger, or demerger, winding up etc.), the Committee will determine whether awards will: |
–Be exchanged for replacement awards (either in cash or shares) of equal value unless the Committee and successor company agree that the original award will continue; or –Vest (to the extent determined by the Committee). | |
Where awards vest, the Committee will have regard to (i) the performance of the Company, (ii) unless the Committee determines otherwise, the proportion of the performance period that has elapsed and (iii) any other matter that the Committee considers relevant or appropriate. Vested awards will normally be released from any relevant holding period. |
Fees | Benefits | Share Ownership Guidelines | |
Non-executive Directors | All Non-executive Directors receive a basic fee for their duties as a Board member. Additional fees are paid for added responsibilities such as Chairship and membership of committees, acting as the Senior Independent Director or carrying out any other role determined by the Board from time to time. Fees may be denominated and paid in any currency the Board Committee determines and are paid to Non-executive Directors subject to any appropriate deductions. A portion of the fees may be delivered in shares without performance conditions, based on the market value of the shares, if the Board deems that this is appropriate. The basic and additional fees are usually reviewed annually by the Board with any changes normally effective from 1 July. In determining the level of fees, the Board considers factors including: | Non-executive Directors do not currently receive benefits or a pension allowance or participate in the Group’s employee pension schemes. Non-executive Directors receive reimbursed business expenses (including any relevant tax liability, banking fees and any other reasonable fees for professional services such as legal, tax, property and financial advice) incurred when travelling overseas in performance of duties or due to the Company’s corporate structure. If as a consequence of the Company’s corporate structure, Non-executive Directors are required to prepare personal tax returns in Hong Kong and/or the UK, in addition to preparing their personal tax return for the jurisdiction which is their place of residence, the Company will reimburse the costs of personal tax return preparation for whichever locations are not their place of residence (including payment of any tax cost associated with the provision of the benefit). | Under the Articles of Association, Non- executive Directors are required to hold at least 2,500 shares and have one year, from their date of appointment to the Board, to acquire these. It is further expected that Non-executive Directors will hold shares with a value equivalent to one times the annual basic fee (excluding additional fees for Chairship and membership of any committees). Non-executive Directors will normally be expected to attain this level of share ownership within three years of their date of appointment. |
–The time commitment and other requirements of the role; –Group financial performance; –Salary increases for all employees; and –Market data. | |||
If, in a particular year, the number of meetings and/or time commitment is materially greater than usual, the Company may determine that the provision of additional fees in respect of that year is fair and reasonable. Should a new committee or working group be formed, or the remit of an existing committee (for which duties were previously paid or unpaid) be materially expanded, or a new Non-executive Director role established, the new or additional fees paid for acting as the chair or a member of the committee will be commensurate with the new or additional responsibilities and time commitment involved. The fees paid to Non-executive Directors in aggregate will not exceed the limit specified by the Articles of Association. Non-executive Directors are not eligible to participate in annual bonus plans or long- term incentive plans. |
Fees | Benefits | Share Ownership Guidelines | |
Chair | The Chair receives an annual fee for the performance of their role. This fee is agreed by the Committee. The fee may be denominated and paid in any currency the Committee determines and is paid to the Chair subject to any appropriate deductions. A portion of the fee may be delivered to the Chair in shares without performance conditions, based on the market value of the shares, if the Committee deems this to be appropriate. On appointment, the fee may be fixed for a specified period of time. Following the fixed period (if applicable) this fee will normally be reviewed annually. Any changes in the fee are usually effective from 1 July. In determining the level of the fee for the Chair, the Committee considers factors including: | The Chair may be offered benefits including: | Under the Articles of Association, the Chair is required to hold at least 2,500 shares and has one year, from their date of appointment to the Board, to acquire these. The Chair has a share ownership guideline. This is currently one times the annual fee and it is normally expected that this level of share ownership would be attained within five years of the date of appointment. |
–Health and wellness benefits; –Protection and security benefits; –Transport benefits; –Reimbursement of business expenses (including any relevant tax liability, banking fees and any other reasonable fees for professional services such as legal, tax, property and financial advice) incurred when travelling overseas in performance of duties or due to the Company’s corporate structure; and –Relocation and location-specific benefits (where appropriate). | |||
If as a consequence of the Company’s corporate structure, the Chair is required to prepare personal tax returns in Hong Kong and/or the UK, in addition to preparing their personal tax return for the jurisdiction which is their place of residence, the Company may reimburse the costs of personal tax return preparation for whichever locations are not their place of residence (including payment of any tax cost associated with the provision of the benefit). The maximum paid will be the cost to the Company of providing these benefits. The Chair is not eligible to receive a pension allowance or to participate in the Group’s employee pension schemes. | |||
–The time commitment and other requirements of the role; –The performance and experience of the Chair; –Internal relativities; –Company financial performance; and –Market data. | |||
The Chair is not eligible to participate in annual bonus plans or long-term incentive plans. |
Plan name | Year of award | Conditional share awards outstanding at 1 Jan 2025 (Number of shares) | Conditional awards in 2025 (Number of shares) | Market price at date of award (HK dollars) | Dividend equivalents on vested shares (Number of shares released) | Rights exercised in 2025 | Rights lapsed in 2025 | Conditional share awards outstanding at 31 December 2025 (Number of shares) | Date of end of performance period | |
Anil Wadhwani | ||||||||||
PLTIP | 2023 | 438,098 | – | 107.4 | – | – | – | 438,098 | 31 Dec 25 | |
PLTIP | 2024 | 697,317 | 75.1 | – | – | – | 697,317 | 31 Dec 26 | ||
PLTIP | 2025 | – | 635,353 | 82.75 | – | – | – | 635,353 | 31 Dec 27 | |
1,135,415 | 635,353 | – | – | – | 1,770,768 |
Year of grant | Conditional share awards outstanding at 1 Jan 2025 (Number of shares) | Conditionally awarded in 2025 (Number of shares) | Dividends accumulated in 20251 (Number of shares) | Shares released in 2025 (Number of shares) | Conditional share awards outstanding at 31 December 2025 (Number of shares) | Date of end of restricted period | Date of release | Market price at date of award (HK dollars) | Market price at date of vesting or release (HK dollars) | |
Anil Wadhwani | ||||||||||
Deferred 2023 annual incentive award | 2023 | 34,232 | – | 675 | – | 34,907 | 31 Dec 25 | 114.3 | ||
Deferred 2024 annual incentive award | 2024 | 132,790 | – | 2,623 | – | 135,413 | 31 Dec 26 | 75.1 | ||
Deferred 2025 annual incentive award | 2025 | – | 106,435 | 2,102 | 108,537 | 31 Dec 27 | 82.8 | |||
167,022 | 106,435 | 5,400 | – | 278,857 | ||||||
Year of Expiration | Options Outstanding Under Savings Related Share Option Schemes (in millions) | Shares Outstanding Under Other Awards (in millions) | Total (in millions) |
2026 | 0.010 | 7.361 | 7.371 |
2027 | 0.006 | 6.564 | 6.570 |
2028 | 0.020 | 3.471 | 3.491 |
2029 | 0.019 | 0.004 | 0.023 |
2030 | 0.024 | – | 0.024 |
2031 | – | – | – |
Total | 0.079 | 17.400 | 17.479 |
2025 | 2024 | 2023 | |
Asia and Africa operations note | 14,770 | 14,851 | 14,479 |
Head office function | 568 | 561 | 551 |
Total Group | 15,338 | 15,412 | 15,030 |
Main activity | Country of incorporation | |
Prudential Assurance Company Singapore (Pte) Limited | Insurance | Singapore |
PT Prudential Life Assurance | Insurance | Indonesia |
Prudential Hong Kong Limited | Insurance | Hong Kong, China |
Prudential Assurance Malaysia Berhad | Insurance | Malaysia |
Year | Name of Company | Date Prudential was notified | Number of Prudential shares held | Total number of voting rights held | % of total voting rights attaching to issued share capital | Change in interest |
2023 | Norges Bank1 | January | 81,606,950 | 82,856,666 | 3.01 | Decrease in interest |
2023 | Norges Bank2 | March | 84,451,785 | 85,503,331 | 3.10 | Increase in interest |
2024 | UBS Group AG - Investment Bank & Global Wealth Management3 | September | 142,921,434 | 147,711,614 | 5.41 | Increase in interest |
2024 | UBS Group AG - Investment Bank & Global Wealth Management4 | September | – | Below 5% | – | Decrease in interest |
2024 | Norges Bank5 | September | 113,736,635 | 113,899,085 | 4.21 | Increase in interest |
2025 | Norges Bank | January | 133,901,071 | 133,901,071 | 5.05 | Increase in interest |
2025 | BlackRock, Inc.6 | March | 86,062,389 | 169,811,259 | 6.45 | Increase in interest |
2025 | BlackRock, Inc.7 | April | 160,579,923 | 166,829,075 | 6.35 | Decrease in interest |
2025 | Norges Bank | July | 129,001,525 | 129,001,525 | 4.99 | Decrease in interest |
2025 | BlackRock, Inc.8 | September | 121,431,446 | 176,302,530 | 6.84 | Increase in interest |
2025 | BlackRock, Inc.9 | September | 169,673,441 | 176,689,294 | 6.86 | Increase in interest |
2025 | Norges Bank | November | 101,764,021 | 101,764,021 | 3.97 | Decrease in interest |
2026 | Norges Bank | March | 101,906,209 | 101,906,209 | 4.02 | Increase in interest |
2026 | Norges Bank10 | March | 100,596,209 | 101,812,778 | 4.02 | Decrease in interest |
2026 | Norges Bank11 | March | 101,510,455 | 102,214,467 | 4.04 | Increase in interest |
Shareholder | Date advised | Percentage of voting rights | Voting rights |
BlackRock, Inc.9 | September 2025 | 6.86 | 176,689,294 |
Norges Bank11 | March 2026 | 4.04 | 102,214,467 |
Category | ADR Depositary actions | Associated fee or charge |
ADS issuance or cancellation | Each person for whom ADRs are issued or are being cancelled | Up to US$5.00 for each 100 ADSs (or fraction thereof) |
Cash dividends or distributions, stock dividends or distributions, other distributions or rights exercises | Each person to whom the distribution is made | Up to US$5.00 for each 100 ADSs (or fraction thereof) held |
Depositary services | Each person holding ADSs on the applicable record date(s) established by the ADR Depositary | Up to US$5.00 for each 100 ADSs (or fraction thereof) held on the applicable record date(s) established by the ADR Depositary |
Registration of ADS transfers or ADS conversions | Each person for whom ADSs are transferred or converted or to whom ADSs are transferred or converted ADS are delivered | Up to US$5.00 for each 100 ADSs (or fraction thereof) transferred or converted |
Currency charges | Charges incurred by the ADR Depositary in the conversion of foreign currency into US Dollars | Amount paid by the ADR Depositary, and such charges are deductible from the foreign currency |
Period | Total number of shares purchased* | Average price paid per share ($) | Total number of shares purchased as part of publicly announced plans or programs† | Approximate value of shares that may yet be purchased under plans or programs ($) |
January 2025 | 14,156,426 | 7.80 | 14,027,963 | 1,101,426,182 |
February 2025 | 11,133,729 | 8.67 | 11,016,784 | 1,005,881,290 |
March 2025 | 8,753,830 | 9.86 | 8,650,128 | 920,609,219 |
April 2025 | 18,664,827 | 9.85 | 17,449,798 | 749,633,415 |
May 2025 | 9,478,725 | 11.29 | 8,621,017 | 652,120,868 |
June 2025 | 13,049,859 | 12.02 | 12,643,798 | 500,018,075 |
July 2025 | 12,205,953 | 12.47 | 7,382,557 | 408,008,855 |
August 2025 | 6,350,490 | 13.11 | 6,105,457 | 328,014,961 |
September 2025 | 6,418,491 | 13.69 | 6,282,320 | 241,947,532 |
October 2025 | 6,769,725 | 13.74 | 4,457,259 | 183,697,410 |
November 2025 | 5,792,891 | 14.06 | 5,645,846 | 104,361,333 |
December 2025 | 7,164,305 | 14.84 | 7,030,344 | – |
Note | 2025 $m | 2024 $m | |
Audit fees: | |||
Audit of the Company’s annual accounts | 5.3 | 5.3 | |
Audit of subsidiaries pursuant to legislation | 6.0 | 6.0 | |
1 | 11.3 | 11.3 | |
Audit-related assurance services | 2 | 4.2 | 5.2 |
Other fees paid to the auditors for other assurance services | 0.8 | 1.2 | |
Total fees payable to the auditor | 16.3 | 17.7 |
Section | Page | |||
Report of Independent Registered Public Accounting Firm | 166 | |||
Consolidated income statement | 169 | |||
Consolidated statement of comprehensive income | 170 | |||
Consolidated statement of changes in equity | 171 | |||
Consolidated statement of financial position | 173 | |||
Consolidated statement of cash flows | 174 | |||
Section | Page | Section | Page | |
Notes to the financial statements | ||||
C3 Insurance and reinsurance contracts | 210 | |||
A Basis of preparation and accounting policies | 175 | C3.1 Group overview | 210 | |
A1 Basis of preparation and exchange rates | 175 | C3.2 Analysis of movements in insurance and | 211 | |
A2 New accounting pronouncements not yet effective | 176 | reinsurance contract balances (excluding | ||
A3 Critical accounting policies, estimates | 176 | JVs and associates) | ||
and judgements | C3.3 Analysis of movements in insurance and | 217 | ||
reinsurance contract balances | ||||
B Earnings performance | 184 | (including JVs and associates) | ||
B1 Analysis of performance by segment | 184 | C3.4 Products and determining contract | 224 | |
B1.1 Segment results | 184 | liabilities | ||
B1.2 Determining operating segments and | 185 | C4 Intangible assets | 228 | |
performance measure of operating segments | C4.1 Goodwill | 228 | ||
B1.3 Revenue | 186 | C4.2 Other intangible assets | 229 | |
B1.4 Net insurance and reinsurance finance | 189 | C5 Borrowings | 230 | |
income (expense) | C5.1 Core structural borrowings of | 230 | ||
B1.5 Additional segmental analysis of | 190 | shareholder-financed businesses | ||
profit after tax | C5.2 Operational borrowings | 230 | ||
B2 Insurance service expenses and other | 190 | C6 Risk and sensitivity analysis | 231 | |
expenditure | C6.1 Sensitivity to key market risks | 231 | ||
B2.1 Staff and employment costs | 191 | C6.2 Sensitivity to insurance risks | 234 | |
B2.2 Share-based payments | 192 | C7 Tax assets and liabilities | 234 | |
B2.3 Key management remuneration | 194 | C7.1 Current tax | 234 | |
B2.4 Fees payable to the auditor | 194 | C7.2 Deferred tax | 235 | |
B3 Tax charge | 195 | C8 Share capital, share premium and own shares | 235 | |
B3.1 Total tax charge by segment | 195 | C9 Capital | 237 | |
B3.2 Reconciliation of effective | 196 | C9.1 Group objectives, policies and processes | 237 | |
tax rate | for managing capital | |||
B4 Earnings per share | 197 | C9.2 Local capital regulations | 237 | |
B5 Dividends | 198 | C9.3 Transferability of capital resources | 238 | |
C10 Property, plant and equipment | 239 | |||
C Financial Position | 199 | |||
C1 Group assets and liabilities | 199 | D Other information | 240 | |
C1.1 Group investments by business type | 199 | D1 Contingencies and related obligations | 240 | |
C1.2 Other assets and liabilities | 202 | D2 Ownership interest in Prudential Assurance | 240 | |
C1.3 Cash and cash equivalents | 202 | Malaysia Berhad | ||
C1.4 Provisions | 202 | D3 Post balance sheet events | 240 | |
C2 Measurement of financial assets and liabilities | 203 | D4 Related party transactions | 240 | |
C2.1 Determination of fair value | 203 | D5 Commitments | 241 | |
C2.2 Fair value measurement hierarchy | 204 | D6 Investments in subsidiary undertakings, | 241 | |
C2.3 Additional information on financial | 206 | joint ventures and associates | ||
instruments | D6.1 Basis of consolidation | 241 | ||
D6.2 Dividend restrictions and minimum capital | 242 | |||
requirements | ||||
D6.3 Investment in joint ventures | 242 | |||
and associates | ||||
D6.4 Related undertakings | 245 | |||
Valuation of best estimate insurance contract liabilities | |
Description of the Matter | The Group recorded insurance contract liabilities (net of insurance contract assets) of $172.7 billion as at 31 December 2025 on its Consolidated Statement of Financial Position, of which $146.7 billion, as disclosed in Note C3.1(a) to the consolidated financial statements, relates to best estimate liabilities (BEL) for future cash flows, adjusted to reflect the time value of money and financial risks. As disclosed in note A3(a) to the consolidated financial statements, key assumptions include discount rates (including the illiquidity premium adjustment) and investment return assumptions (together the “economic assumptions”) and operating assumptions in respect of mortality, morbidity (including medical claims costs), persistency and expenses (including IFRS 17 Insurance Contracts attribution). Auditing the valuation of BEL was complex and required significant auditor judgment due to the complexity of the fulfilment cashflow models, the selection and use of economic and operating assumptions and the sensitivity of the fulfilment cash flow models to the assumptions set by management. |
How We Addressed the Matter in Our Audit | We obtained an understanding, evaluated the design, and tested the operating effectiveness of management’s controls over the valuation of BEL. The controls we tested related to, among other areas, setting economic and operating assumptions and model changes. To test the valuation of BEL, our procedures included, among others, involving our actuarial professionals, to assess the fulfilment cashflow models and assumptions with respect to compliance with the Group’s IFRS 17 valuation policies. We tested the implementation of the economic and operating assumptions in the models. For economic assumptions, we tested discount rates and investment return assumptions for a sample of currencies, including by reference to yield curves and the Group’s economic scenario generators. For discount rates, we also compared the information used to determine the illiquidity premium, to the characteristics of the liabilities, asset allocations, and yields-to-maturity and allowance for credit risk on the reference portfolio of assets. For operating assumptions, we compared the key assumptions used in the valuation of BEL, including mortality, morbidity and persistency, with the results of management’s experience investigations, market trends and regulatory developments around product features and pricing, as relevant. We also evaluated the Group’s expense assumptions, by comparing them to the Group’s historical, current and projected expense levels and policy relating to the attribution of expenses to insurance contracts. For a sample of new models and changes to existing models, we compared management’s model validation results with the terms and conditions of the related insurance contracts and the Group’s IFRS 17 valuation policies. In addition, we performed an independent recalculation of the modelled BEL for a sample of insurance contract groups (ICGs) and compared the results to the output of the fulfilment cashflow models used by management. |
Revenue recognition in respect of release of contractual service margin | |
Description of the Matter | The Group recorded insurance revenue of $11.1 billion for the year ended 31 December 2025 in its Consolidated Income Statement, of which $2.4 billion relates to release of contractual service margin (CSM) as disclosed in Note B1.3 to the consolidated financial statements. There is significant judgment and complexity involved in determining the initial CSM and subsequent movements, including release of CSM, which directly impacts insurance revenue. The release of CSM for the period is measured based on coverage units provided, as described in Note A3(a) to the consolidated financial statements. As disclosed in Note C3.4(a) to the consolidated financial statements, the release of CSM for the period is based on the opening CSM adjusted for movements in the period, including the CSM for new contracts issued in the year, interest accretion for contracts measured using the General Measurement Model (“GMM”) and the impact of changes in the operating and economic assumptions (including the change in the fair value of underlying items for contracts measured using the Variable Fee Approach (VFA)). Auditing the release of CSM was complex and required significant auditor judgment, due to the complexity of the calculation of the CSM and its interaction with the valuation of best estimate liabilities described above, and the judgment involved in the determination of the coverage units. |
How We Addressed the Matter in Our Audit | We obtained an understanding, evaluated the design, and tested the operating effectiveness of management’s controls over the calculation and release of CSM. The controls we tested related to, among other areas, the determination of coverage units, the change management and governance process over the CSM calculation model, and management review controls over CSM movements during the period, including release of CSM. To test the calculation and release of CSM, with the support of our actuarial professionals, our audit procedures included, testing the determination of coverage units and the release of CSM, through reperformance of the calculation for a sample of ICGs and comparing the release pattern to our expectations, based on the prior year release pattern and changes in the business and economic environment during the period. For a sample of new contracts issued during the year, we recalculated the initial CSM, including, where relevant, the identification of onerous contracts. For movements relating to interest accretion and the impact of assumption changes, we compared the impact of operating and economic assumption changes (including changes in the fair value of underlying items for contracts measuring using VFA) in the CSM movement to related changes in the BEL calculation, including considering whether they related to past or future service, and reperformed the calculation of interest accretion for contracts measured using GMM. |
Note | 2025 $m | 2024 $m | 2023 $m | |
Insurance revenue | B1.3 | |||
Insurance service expense: | ||||
Claims incurred | ( | ( | ( | |
Directly attributable expenses incurred | ( | ( | ( | |
Amortisation of insurance acquisition cash flows | ( | ( | ( | |
Other insurance service expenses | ( | ( | ( | |
( | ( | ( | ||
Net expense from reinsurance contracts held | ( | ( | ( | |
Insurance service result | ||||
Investment return: | ||||
Interest revenue calculated using the effective interest method | ||||
Other investment return on financial investments | ||||
B1.3 | ||||
Fair value movements on investment contract liabilities | ( | ( | ( | |
Net insurance and reinsurance finance income (expense): | ||||
Net finance expense from insurance contracts | B1.4 | ( | ( | ( |
Net finance (expense) income from reinsurance contracts held | B1.4 | ( | ( | |
( | ( | ( | ||
Net investment result | ||||
Other revenue | B1.3 | |||
Non-insurance expenditure | B2 | ( | ( | ( |
Finance costs: interest on core structural borrowings of shareholder-financed businesses | ( | ( | ( | |
Gain (loss) attaching to corporate transactions | B1.1 | ( | ( | |
Share of profit (loss) from joint ventures and associates, net of related tax | D6.3 | ( | ||
Profit before tax (being tax attributable to shareholders’ and policyholders’ returns) note | ||||
Tax charge attributable to policyholders' returns | ( | ( | ( | |
Profit before tax attributable to shareholders' returns | ||||
Total tax charge attributable to shareholders' and policyholders' returns | B3.1 | ( | ( | ( |
Remove tax charge attributable to policyholders' returns | B3.2 | |||
Tax charge attributable to shareholders' returns | B3.2 | ( | ( | ( |
Profit for the year | B1.5 | |||
Attributable to: | ||||
Equity holders of the Company | ||||
Non-controlling interests | ||||
Profit for the year |
Earnings per share (in cents) | Note | 2025 | 2024 | 2023 |
Based on profit attributable to equity holders of the Company: | B4 | |||
Basic | ||||
Diluted |
2025 $m | 2024 $m | 2023 $m | |
Profit for the year | |||
Other comprehensive income (loss) | |||
Items that may be reclassified subsequently to profit or loss: | |||
Exchange translation movements and net investment hedges | ( | ( | |
Cumulative exchange loss of disposed businesses recycled through profit or loss | |||
( | ( | ||
Items that will not be reclassified subsequently to profit or loss: | |||
Valuation movements on retained interest in Jackson classified as FVOCI under IFRS 9 note | |||
Total comprehensive income for the year | |||
Attributable to: | |||
Equity holders of the Company | |||
Non-controlling interests | |||
Total comprehensive income for the year |
Year ended 31 Dec 2025 $m | |||||||||
Note | Share capital | Share premium | Capital redemption reserve | Retained earnings | Translation reserve | Share- holders' equity | Non- controlling interests | Total equity | |
Reserves | |||||||||
Profit for the year | – | – | – | – | |||||
Other comprehensive income | – | – | – | – | |||||
Total comprehensive income for the year | – | – | – | ||||||
Transactions with owners of the Company | |||||||||
Dividends | B5 | – | – | – | ( | – | ( | ( | ( |
Effect of scrip dividends | C8 | – | – | – | – | – | |||
Reserve movements in respect of share-based payments | – | – | – | – | – | ||||
Effect of transactions relating to non- controlling interests | – | – | – | – | ( | ( | |||
New share capital subscribed | C8 | – | – | – | – | – | |||
Share repurchases/buybacks | C8 | ( | – | ( | – | ( | – | ( | |
Movement in own shares in respect of share-based payment plans | – | – | – | ( | – | ( | – | ( | |
Net (decrease) increase in equity | ( | ||||||||
Balance at beginning of year | |||||||||
Balance at end of year | |||||||||
Year ended 31 Dec 2024 $m | |||||||||
Note | Share capital | Share premium | Capital redemption reserve | Retained earnings | Translation reserve | Share- holders' equity | Non- controlling interests | Total equity | |
Reserves | |||||||||
Profit for the year | – | – | – | – | |||||
Other comprehensive (loss) income | – | – | – | – | ( | ( | ( | ||
Total comprehensive income (loss) for the year | – | – | – | ( | |||||
Transactions with owners of the Company | |||||||||
Dividends | B5 | – | – | – | ( | – | ( | ( | ( |
Effect of scrip dividends | C8 | – | – | – | – | – | |||
Reserve movements in respect of share-based payments | – | – | – | – | – | ||||
Adjustment to non-controlling interest for Malaysia conventional life business on 1 January 2024 | D2 | – | – | – | ( | – | ( | ||
Effect of transactions relating to other non-controlling interests | – | – | – | ( | – | ( | ( | ( | |
Share repurchases/buybacks | C8 | ( | – | ( | – | ( | – | ( | |
Movement in own shares in respect of share-based payment plans | – | – | – | ( | – | ( | – | ( | |
Net (decrease) increase in equity | ( | – | ( | ( | ( | ||||
Balance at beginning of year | – | ||||||||
Balance at end of year | |||||||||
Year ended 31 Dec 2023 $m | |||||||||
Note | Share capital | Share premium | Retained earnings | Translation reserve | Fair value reserve | Share- holders' equity | Non- controlling interests | Total equity | |
Reserves | |||||||||
Profit for the year | – | – | – | – | |||||
Other comprehensive (loss) income | – | – | – | ( | ( | ( | ( | ||
Total comprehensive income (loss) for the year | – | – | ( | ||||||
Transactions with owners of the Company | |||||||||
Dividends | B5 | – | – | ( | – | – | ( | ( | ( |
Transfer of fair value reserve following disposal of investment in Jackson | – | – | – | ( | – | – | |||
Reserve movements in respect of share- based payments | – | – | ( | – | – | ( | – | ( | |
Effect of transactions relating to non- controlling interests | – | – | – | – | – | ||||
New share capital subscribed | C8 | – | – | – | – | ||||
Movement in own shares in respect of share-based payment plans | – | – | – | – | – | ||||
Net increase (decrease) in equity | ( | ( | ( | ||||||
Balance at beginning of year | |||||||||
Balance at end of year | |||||||||
Note | 31 Dec 2025 $m | 31 Dec 2024 $m | |
Assets | |||
Goodwill | C4.1 | ||
Other intangible assets | C4.2 | ||
Property, plant and equipment | C10 | ||
Insurance contract assets | C3.1 | ||
Reinsurance contract assets | C3.1 | ||
Deferred tax assets | C7.2 | ||
Current tax recoverable | C7.1 | ||
Investments in joint ventures and associates accounted for using the equity method | D6.3 | ||
Investment properties | C1.1 | ||
Loans | C1.1 | ||
Equity securities and holdings in collective investment schemes note | C1.1 | ||
Debt securities note | C1.1 | ||
Derivative assets | C2.2 | ||
Deposits | C1.1 | ||
Accrued investment income | C1.2 | ||
Other debtors | C1.2 | ||
Assets held for sale | |||
Cash and cash equivalents | C1.3 | ||
Total assets | |||
Equity | |||
Shareholders' equity | |||
Non-controlling interests | |||
Total equity | |||
Liabilities | |||
Insurance contract liabilities | C3.1 | ||
Reinsurance contract liabilities | C3.1 | ||
Investment contract liabilities without discretionary participation features | C2.2 | ||
Core structural borrowings of shareholder-financed businesses | C5.1 | ||
Operational borrowings | C5.2 | ||
Obligations under funding, securities lending and sale and repurchase agreements | C2.3 | ||
Net asset value attributable to unit holders of consolidated investment funds | C2.3 | ||
Deferred tax liabilities | C7.2 | ||
Current tax liabilities | C7.1 | ||
Accruals, deferred income and other creditors | C1.2 | ||
Provisions | C1.4 | ||
Derivative liabilities | C2.2 | ||
Liabilities held for sale | |||
Total liabilities | |||
Total equity and liabilities |
Note | 2025 $m | 2024 $m | 2023 $m | |
Cash flows from operating activities | ||||
Profit before tax (being tax attributable to shareholders' and policyholders' returns) | ||||
Movements in operating assets and liabilities: | ||||
Investments | ( | ( | ( | |
Other non-investment and non-cash assets | ||||
Insurance and reinsurance contract assets and liabilities | ||||
Other non-insurance liabilities | ( | ( | ||
Other adjustments to profit before tax for non-cash movements: | ||||
Interest and dividend income and interest payments included in profit before tax | ( | ( | ( | |
Other non-cash items included in profit before tax | ( | |||
Operating cash items: | ||||
Interest receipts | ||||
Interest payments | ( | ( | ( | |
Dividend receipts | ||||
Tax paid | ( | ( | ( | |
Net cash flows from operating activities note (i) | ||||
Cash flows from investing activities | ||||
Purchases of property, plant and equipment | C10 | ( | ( | ( |
Disposal of property, plant and equipment | ||||
Acquisition of distribution rights and other intangibles | ( | ( | ( | |
Disposal of businesses, net of associated tax note (ii) | ||||
Cash advanced to Mainland China life joint venture note (i) | ( | ( | ||
Disposal of Jackson shares | ||||
Net cash flows from investing activities | ( | ( | ||
Cash flows from financing activities | ||||
Structural borrowings of shareholder-financed businesses: note (iii) | ||||
Issuance (redemption) of debt, net of costs | C5.1 | ( | ||
Interest paid | ( | ( | ( | |
Payment of principal portion of lease liabilities | ( | ( | ( | |
Acquisition of non-controlling interests | ( | |||
Equity capital: | ||||
Issues of ordinary share capital | C8 | |||
Share repurchases/buybacks (including costs) | ( | ( | ||
External dividends: | ||||
Dividends paid to equity holders of the Company | B5 | ( | ( | ( |
Dividends paid to non-controlling interests | ( | ( | ( | |
Net cash flows from financing activities | ( | ( | ( | |
Net increase (decrease) in cash and cash equivalents | ( | |||
Cash and cash equivalents at 1 Jan | ||||
Effect of exchange rate changes on cash and cash equivalents | ( | ( | ||
Cash and cash equivalents at 31 Dec | C1.3 |
Balance at 1 Jan $m | Cash movements $m | Non-cash movements $m | Balance at 31 Dec $m | ||||
Issuance of debt | Redemption of debt | Foreign exchange movement | Other movements | ||||
2025 | |||||||
2024 | ( | ||||||
2023 | ( | ||||||
Closing rate at year end | Average rate for the year to date | |||||
USD : local currency | 31 Dec 2025 | 31 Dec 2024 | 2025 | 2024 | 2023 | |
Chinese yuan (CNY) | ||||||
Hong Kong dollar (HKD) | ||||||
Indian rupee (INR) | ||||||
Indonesian rupiah (IDR) | ||||||
Malaysian ringgit (MYR) | ||||||
Singapore dollar (SGD) | ||||||
Taiwan dollar (TWD) | ||||||
Thai baht (THB) | ||||||
UK pound sterling (GBP) | ||||||
Vietnamese dong (VND) | ||||||
Determination of fulfilment cash flows used in the measurement of insurance and reinsurance contract assets and liabilities (impacts $(144.7) billion of net best estimate insurance and reinsurance contract balances, excluding those held by joint ventures and associates) | |
Estimates of future cash flows | The Group’s process for estimating future cash flows incorporates, in an unbiased way, all reasonable and supportable information that is available without undue cost or effort at the reporting date. This information includes both internal and external historical data about claims and other experience, updated to reflect current expectations of future events. As this is a prediction of the future, significant judgement is applied in determining the assumptions that underpin the estimation of future cash flows. These assumptions include, but are not limited to, operating assumptions such as morbidity, mortality, persistency and expenses, and economic assumptions such as risk-free rates and illiquidity premium. Granular assumptions are set at a business unit level. The demographic assumptions are consistent with those used in other metrics such as TEV reporting. The Risk Review included in this Annual Report discusses the insurance and market risks the Group faces and how these risks are mitigated. When estimating future cash flows, the Group takes into account current expectations of future events (other than those from future legislation or regulatory changes that have not been substantively enacted) that might affect those cash flows. Cash flows within the boundary of a contract (the Group’s accounting policy on contract boundary is given below) relate directly to the fulfilment of the contract, including those for which the Group has discretion over the amount or timing. These include future premium receipts, payments to (or on behalf of) policyholders, insurance acquisition cash flows and other costs that are incurred in fulfilling contracts. In relation to reinsurance contracts held, the probability weighted estimates of the present value of future cash flows include the potential credit losses and losses from other disputes to reflect the non- performance risk of the reinsurers. The sensitivity of shareholder equity and CSM to insurance risks is set out in note C6.2. |
Expense assumptions used in future cash flow estimation | Insurance acquisition cash flows (as discussed below) and other costs that are incurred in fulfilling contracts comprise both direct costs and an allocation of fixed and variable overheads incurred by the insurance entities. The Group projects estimates of future expenses relating to the fulfilment of contracts within the scope of IFRS 17 using current expense levels adjusted for inflation. Costs that are incurred in fulfilling the contracts include, but are not limited to, claims handling costs, policy administration expenses, investment management expenses, income tax and other costs specifically chargeable to the policyholders under the terms of the contracts. Expenses included in estimated future cash flows comprise expenses directly attributable to the groups of contracts, including an allocation of fixed and variable overheads incurred by the insurance entities. Investment management expenses in relation to the management of the assets backing policyholder liabilities are included in the fulfilment cash flows for business using the variable fee approach (VFA) model, other participating business using the general model and general model non-participating business where the Group performs investment management activities to enhance benefits from insurance coverage for policyholders. The future expenses of internal asset management and other services excludes the projected future profits or losses generated by any non-insurance entities within the Group in providing those services (ie the IFRS results for the life insurance operations in the consolidated financial statements assume that the cost of internal asset management and other services will be that incurred by the Group as a whole, not the cost that will be borne by the insurance business). Most of the costs incurred by the insurance entities within the Group are considered to be incurred for the purpose of selling and fulfilling insurance contracts and are hence treated as attributable expenses. Cash flows that are not directly attributable to a portfolio of insurance contracts, such as some product development and training costs, are recognised in other operating expenses as incurred. |
Policyholder benefits | The assumptions used to project the cash flows also reflect the actions that management would take over the duration of the projection, the time it would take to implement these actions and any expenses incurred in taking those actions. Management actions encompass, but are not confined to, investment allocation decisions, levels of regular and final bonuses and crediting rates. For participating contracts, estimated future claim payments include bonuses paid to policyholders determined by reference to the relevant profit-sharing arrangement. For example, for the Group’s with-profits business in Hong Kong, Singapore and Malaysia, asset shares are used to determine payments to policyholders. Where cash flows from one group of contracts affect, or are affected by, cash flows in other groups of contracts (eg for with-profits business), the fulfilment cash flows for a group include payments arising from the terms of existing contracts to policyholders in other groups and exclude payments to policyholders in the group that have been included in the fulfilment cash flows of another group. |
Determination of fulfilment cash flows used in the measurement of insurance and reinsurance contract assets and liabilities (impacts $(144.7) billion of net best estimate insurance and reinsurance contract balances, excluding those held by joint ventures and associates) | |
Insurance acquisition cash flows | Insurance acquisition cash flows arise from the activities of selling, underwriting and starting a group of insurance contracts that are directly attributable to the portfolio of contracts to which the group belongs. Insurance acquisition cash flows that are directly attributable to a group of contracts (eg non-refundable commissions paid on issuance of a contract) are allocated to that group and to the groups that will include renewals of those contracts. Bancassurance payments (eg upfront payments to sell insurance contracts to distribution partners) are capitalised under IAS 38 as intangible assets and amortised on a basis to reflect the pattern in which the future economic benefits are expected to be consumed by reference to new business production levels. The amortisation of the bancassurance intangibles is considered to constitute insurance acquisition cash flows. They generally form part of fulfilment cash flows and are amortised implicitly in line with the coverage unit pattern. |
Determining the point of recognition and the boundary of an insurance contract | The point of initial recognition of a group of contracts is the earliest of the premium due date, the date coverage starts and, for an onerous contract, the date the contract is signed and accepted by both parties. There is limited judgement involved in relation to most contracts issued by the Group as the coverage period generally starts from the premium due date. The contract boundary defines which future cash flows are included in the measurement of a contract. The boundary of the fulfilment cash flows under IFRS 17 is considered to be the point at which the Group both no longer has substantive rights and obligations under the insurance contract to provide services or compel the policyholder to pay premiums. The contract boundary is assessed at inception and then reassessed only when there are changes in features or circumstances that alter the commercial substance of the contract or when there are changes in the products within a portfolio. The reassessment of the contract boundary for any changes is performed at the end of each reporting period. For most contracts issued by the Group, there is little judgement involved in determining the contract boundary as either a single premium is received for a contract that is expected to continue for a long period or a guaranteed premium is received for regular premium contracts. For certain contracts where the premiums are not guaranteed, more judgement is involved in assessing the Group’s substantive rights and obligations. When determining the boundary for these contracts various factors are taken into consideration by the Group such as the Group’s practical ability to terminate or refuse renewal of a contract, the Group’s ability to fully reprice at the individual contract level and whether the Group has the ability to reassess risks at a portfolio level and set a price that fully reflects the risks of that portfolio. The Group has some immaterial business that is general insurance in nature and which is considered to have a boundary of one year. Where riders attach to and are not separated from a base contract, the contract boundary is determined based on the component of the contract that has the longest contract boundary. Future cash flows relating to riders that are not purchased at the inception of the base contract, but are added at a later date, are not included within the contract boundary at initial recognition. As the addition of these riders is the exercise of an option under the contract, it is not considered a contract modification but is instead treated as changes in fulfilment cash flows. Similar considerations to those applying to underlying insurance contracts apply in determining the contract boundary of groups of reinsurance contracts held. Further detail on reinsurance contracts, including on recognition is set out in note C3.4. |
Determination of discount rates | |
Discount rate and risk-free rate | IFRS 17 enables discount rates to be calculated on a top-down or bottom-up basis. The Group elects to determine discount rates on a bottom-up basis, starting with a liquid risk-free yield curve and adding an illiquidity premium to reflect the characteristics of the insurance contracts. |
Risk-free rates are based on government bond yields for all currencies except HKD where risk-free rates are based on swap rates due to the higher liquidity of the HKD swap market. Government bond yields and swap rates are obtained from publicly available data sources. Yield curves are constructed by using a market-observed curve up to a last liquid point and then extrapolating to an ultimate forward rate. | |
Where cash flows vary based on the return on underlying items, the projected earned rate is set equal to the discount rate. Where stochastic modelling techniques are used, the projected average investment returns are calibrated to be equal to the deterministic discount rate (including the illiquidity premium). | |
The illiquidity premium is calculated as the yield-to-maturity on a reference portfolio of assets with similar liquidity characteristics to the insurance contracts (in particular, corporate bonds) less the risk-free curve, and an allowance for credit risk. | |
The allowance for credit risk includes a credit risk premium, which is derived through a lifetime projection of expected bond cash flows, allowing for the risk of downgrades and defaults. The allowance for credit risk ranges between between | |
A proportion of the reference portfolio’s illiquidity premium (either portfolios of insurance contracts reflecting the liquidity characteristics of the insurance contracts. The liquidity characteristics are assessed from the policyholders’ perspective. Consideration is given to the nature of premiums, the level of underwriting, and the surrender and other benefit features of the portfolios. A product’s illiquidity premium is restricted to be no greater than reasonably expected to be earned on the assets backing the insurance contract liabilities, over the duration of the insurance contracts. | |
contracts for major currencies. These discount rates include the illiquidity premium applied to the portfolios written in each currency. A range is shown to represent the fact that different products The ranges below reflect only the actual proportions applied for each currency. For the major currencies shown below, except Hong Kong dollar and Malaysian ringgit, all three proportions apply and hence the spread is indicative of the illiquidity premium applying to the term specified. | |
31 Dec 2025 % | |||||
1 year | 5 years | 10 years | 15 years | 20 years | |
Chinese yuan (CNY) | |||||
Hong Kong dollar (HKD) | |||||
Indonesian rupiah (IDR) | |||||
Malaysian ringgit (MYR) | |||||
Singapore dollar (SGD) | |||||
United States dollar (USD) | |||||
31 Dec 2024 % | |||||
1 year | 5 years | 10 years | 15 years | 20 years | |
Chinese yuan (CNY) | |||||
Hong Kong dollar (HKD) | |||||
Indonesian rupiah (IDR) | |||||
Malaysian ringgit (MYR) | |||||
Singapore dollar (SGD) | |||||
United States dollar (USD) | |||||
Determination of risk adjustment for non-financial risk | |
Risk adjustment for non-financial risk | The risk adjustment for non-financial risk reflects the compensation the Group requires for bearing the uncertainty about the amount and timing of the cash flows from non-financial risk as the Group fulfils insurance contracts. For reinsurance contracts held, the risk adjustment for non‑financial risk represents the amount of risk being transferred by the Group to the reinsurer. The risk adjustment for non-financial risk is determined by the Group using a confidence level approach. This is implemented through the use of provisions for adverse deviations (PADs) calibrated using non-financial risk distributions and correlation assumptions. The PADs are applied to best estimate assumptions and hence the risk adjustment is calculated on a contract by contract basis. The Group’s risk adjustment allows for all insurance, persistency and expense risks and operational risks specific to uncertainty in the amount and timing of insurance contract cash flows. Reinsurance counterparty default risk is excluded from the calculation. Diversification is included on a net of reinsurance basis within each insurance entity of the Group. Diversification is not allowed for between entities. By applying a confidence level technique, the Group estimates the probability distribution of the expected present value of the future cash flows from insurance contracts at each reporting date and calculates the risk adjustment for non-financial risk as the excess of the value at risk at the 75th percentile (the target confidence level) over the expected present value of the future cash flows. The confidence level is calibrated over a one-year period. |
Determination of coverage units | |
Coverage units | The proportion of CSM recognised in profit or loss at the end of each period for a group of contracts is determined as the ratio of: –the coverage units in the period; divided by –the sum of the coverage units in the period and the present value of expected coverage units in future periods. The total number of coverage units in a group reflects the quantity of service provided determined by considering the quantity of benefits for each contract and its expected coverage period. The Group defines the quantity of benefits for insurance services as the maximum amount that a policyholder receives when an insured event takes place, for example the sum assured, the annual limit for a medical plan or the present value of a stream of payments. The quantity of benefits is updated each period. Investment-related and investment-return services are assumed to be constant over time. Where there are multiple different services in a group of contracts (for example, both insurance and investment services are provided), the quantities of benefits for the different types of service are combined using weighting factors. These weighting factors are defined as the present value of expected outflows for each type of service, determined at a contract level. The expected coverage period is the expected duration up to the contract boundary. The expected coverage period of the contracts in a group and the calculation of future coverage units allows for expected decrements (eg deaths and lapses) in each future period using current best estimate assumptions consistent with the best estimate liabilities (BEL) calculation. The Group elects to allow for the time value of money by discounting future coverage units in the determination of the proportion of CSM recognised in profit or loss. Determination of coverage units for groups of reinsurance contracts held follows the same principles as for groups of underlying contracts. |
Insurance finance income and expenses | |
Disaggregation between profit or loss and other comprehensive income | IFRS 17 allows an accounting policy choice between: –Including insurance finance income or expenses for the period in profit or loss; or –Disaggregating insurance finance income or expenses for the period to include in profit or loss an amount determined by a systematic allocation of the expected total insurance finance income or expenses over the duration of the group of contracts, with the balance being included in other comprehensive income. The Group has not elected to disaggregate insurance finance income and expenses between profit or loss and other comprehensive income. |
Risk mitigation | |
Risk mitigation option | IFRS 17 allows the option in certain circumstances to not recognise a change in the CSM to reflect some or all of the changes in the effect of the time value of money and financial risk on: –the amount of the entity’s share of the underlying items if the entity mitigates the effect of financial risk on that amount using derivatives or reinsurance contracts held; and –the fulfilment cash flows if the entity mitigates the effect of financial risk on those fulfilment cash flows using derivatives, non-derivative financial instruments measured at fair value through profit or loss, or reinsurance contracts held. The Group does not utilise the risk mitigation option in its IFRS 17 VFA liability accounting except in connection with a short-term premium prepayment option available on certain participating products in Hong Kong. |
The effect of accounting estimates made in interim financial statements | |
Effect of estimates made in interim financial statements | IFRS 17 allows an accounting policy choice as to whether to change the treatment of accounting estimates made in previous interim financial statements when applying IFRS 17 in the annual reporting period. |
The Group has elected to allow updates to accounting estimates made in interim financial statements when applying IFRS 17 in the annual reporting period. | |
Presentation of results before tax attributable to shareholders | |
Profit before tax is a significant IFRS income statement item. The Group has chosen to present a measure of profit before tax attributable to shareholders that distinguishes between tax borne by shareholders and tax attributable to policyholders to support understanding of the performance of the Group. Profit before tax attributable to shareholders is $ compares to profit before tax of $ Consolidated income statement. | Total tax charge for the Group reflects tax that relates to shareholders’ profit and also tax attributable to policyholders through the interest in with-profits or unit-linked funds. Reported IFRS profit before the tax measure is therefore not representative of pre-tax profit attributable to shareholders. Accordingly, in order to provide a measure of pre-tax profit attributable to shareholders, the Group has chosen to adopt an income statement presentation of the tax charge and pre-tax results that distinguishes between policyholders’ and shareholders’ returns. |
Segmental analysis of results and earnings attributable to shareholders | |
The Group uses adjusted operating profit as the segmental measure of its results. | The basis of calculation of adjusted operating profit is provided in note B1.2. The vast majority of the Group’s investments are valued at fair value through profit and loss. Short-term fluctuations in the fair value of investments are only partially offset by the effect of economic changes on insurance contract assets and liabilities and so affect the result for the year. The Group therefore provides additional analysis of results before and after the effects of short-term interest rate and other market fluctuations, together with other items that are of a short-term, volatile or one-off nature. |
VFA eligibility assessment | ||
The Group applies judgements in assessing the VFA eligibility of contracts. Application of the VFA impacts the calculation of the CSM at the balance sheet date, which in turn impacts the future year’s amortisation recognised in the income statement. Unlike the general measurement model (GMM) approach, the VFA absorbs economic impacts within the CSM, rather than in the profit and loss account. The total insurance and reinsurance CSM at the balance sheet date is $ and associates, and the CSM amortisation (net of reinsurance) recognised in the income statement is $( Approximately (including joint ventures and associates and net of reinsurance) at 31 December 2025 was calculated under the VFA. | IFRS 17 requires the use of the VFA for insurance contracts with direct participation features, ie substantially investment-related service contracts for which, at inception: –the contractual terms specify that the policyholder participates in a share of a clearly identified pool of underlying items; –the entity expects to pay to the policyholder an amount equal to a substantial share of the fair value returns on the underlying items; and –the entity expects a substantial proportion of any change in the amounts to be paid to the policyholder to vary with the change in fair value of the underlying items. The following key judgements have been made in assessing VFA eligibility: | |
Definition of substantial | The term substantial is interpreted to mean greater than per cent. | |
Contractual terms | In some circumstances contractual terms are implied by customary business practices. | |
Granularity of assessment | The assessment has been carried out at a contract level. However, to the extent insurance contracts in a group affect the cash flows to policyholders of contracts in other groups (referred to as 'mutualisation'), eligibility for the VFA has been assessed at the level at which such mutualisation occurs (eg fund level). | |
Calculation basis | VFA eligibility assessments have been performed on a basis consistent with how the Group measures its realistic expectations, for example when pricing, monitoring or setting returns to policyholders. | |
Contracts not qualifying for the VFA are accounted for under the GMM or premium allocation approach (PAA). The PAA is not used significantly within the Group. The measurement model (VFA or GMM) used for key products is set out in note C3.4. | ||
Carrying value of distribution rights intangible assets | |
The Group applies judgement to assess whether factors such as the financial performance of the distribution arrangements, or changes in relevant legislation and regulatory requirements indicate an impairment of intangible assets representing distribution rights. To determine the recoverable amount, the Group estimates the discounted future expected cash flows arising from the cash generating units (CGUs) containing the distribution rights. Impacts $ shown in note C4.2. | Distribution rights relate to bancassurance partnership arrangements for the distribution of products for the term of the contractual agreement with the bank partner, for which an asset is recognised based on fees paid and fees payable not subject to performance conditions. Distribution rights impairment testing is conducted when there is an indication of an impairment. |
To assess indicators of an impairment, the Group monitors a number of internal and external factors, including indications that the financial performance of the arrangement is likely to be worse than expected and changes in relevant legislation and regulatory requirements that could impact the Group’s ability to continue to sell new business through the bancassurance channel, and then applies judgement to assess whether these factors indicate that an impairment has occurred. If an impairment has occurred, a charge is recognised in the income statement for the difference between the carrying value and recoverable amount of the asset. The recoverable amount is the greater of fair value less costs to sell and value in use. Value in use is calculated as the present value of future expected cash flows from the asset or the CGUs to which it is allocated. | |
Financial investments – Valuation | |
Financial investments held at fair value, net of derivative liabilities, excluding those held by joint ventures and associates is $ C2.2. Financial investments held at amortised cost, comprising loans and deposits, represent $ of the Group’s total assets. The Group estimates the fair value of financial investments that are not actively traded using quotations from independent third parties or internally developed pricing models. | The Group holds the majority of its financial investments at fair value through profit or loss. Financial investments held at amortised cost, excluding cash and cash equivalents, primarily comprise loans and deposits. |
Determination of fair value | |
The fair values of the financial instruments for which fair valuation is required under IFRS Standards are determined by the use of quoted market prices for exchange-quoted investments or by using quotations from independent third parties such as brokers and pricing services or by using appropriate valuation techniques. Further details are included in note C2.1. The estimated fair value of derivative financial instruments reflects the estimated amount the Group would receive or pay in an arm’s-length transaction. This amount is determined using quoted prices if exchange listed, quotations from independent third parties or valued internally using standard market practices. Quoted market prices are used to value investments having quoted prices. Actively traded investments without quoted prices are valued using prices provided by third parties such as brokers or pricing services. Financial investments measured at fair value are classified into a three-level hierarchy as described in note C2.1. If the market for a financial investment of the Group is not active, the Group establishes fair value by using quotations from independent third parties, such as brokers or pricing services, or by using internally developed pricing models. Priority is given to publicly available prices from independent sources when available, but overall the source of pricing and/or the valuation technique is chosen with the objective of arriving at a fair value measurement, which reflects the price at which an orderly transaction would take place between market participants on the measurement date. Changes in assumptions relating to these variables could positively or negatively impact the reported fair value of these financial investments. Details of the financial investments classified as ‘level 3’ to which valuation techniques are applied and the sensitivity of profit before tax to a change in the valuation of these items, are presented in note C2.2. | |
2025 $m | 2024 $m | 2023 $m | ||
Note | note (i) | note (i) | note (i) | |
Hong Kong | ||||
Indonesia | ||||
Mainland China note (ii) | ||||
Malaysia | ||||
Singapore | ||||
Growth markets and other note (iii) | ||||
Eastspring | ||||
Other income and expenditure unallocated to a segment: | ||||
Net investment return and other items note (iv) | ( | ( | ||
Interest payable on core structural borrowings | ( | ( | ( | |
Corporate expenditure | ( | ( | ( | |
Total other expenditure | ( | ( | ( | |
Restructuring and IFRS 17 implementation costs note (v) | ( | ( | ( | |
Adjusted operating profit | B1.2 | |||
Tax charge on adjusted operating profit | B3.2 | ( | ( | ( |
Adjusted operating profit after tax | ||||
Short-term interest rate and other market fluctuations | ( | ( | ||
Gain (loss) attaching to corporate transactions note (vi) | ( | ( | ||
Tax (charge) credit on non-operating result | B3.2 | ( | ||
Profit for the year | B1.5 | |||
Attributable to: | ||||
Equity holders of the Company | ||||
Non-controlling interests | ||||
Profit for the year |
Basic earnings per share (in cents) | 2025 | 2024 | 2023 | |
Note | note (i) | note (i) | note (i) | |
Based on adjusted operating profit, net of tax and non-controlling interest | B4 | |||
Based on profit for the year, net of non-controlling interest | B4 |
2025 $m | ||||||||||
Insurance operations note (i) | ||||||||||
Hong Kong | Indonesia | Malaysia | Singapore | Growth markets and other | Eastspring | Inter- segment elimination | Total segment | Unallocated to a segment (central operations) | Total | |
Insurance revenue | ||||||||||
Amounts relating to changes in the liability for remaining coverage: | ||||||||||
Expected claims and other directly attributable expenses | – | – | – | |||||||
Change in risk adjustment for non-financial risk | – | – | – | |||||||
Release of CSM for services provided | – | – | – | |||||||
Other adjustments note (ii) | – | – | – | |||||||
Recovery of insurance acquisition cash flows | – | – | – | |||||||
– | – | – | ||||||||
Other revenue note (iii) | – | – | ||||||||
Total revenue from external customers note (iv) | – | – | ||||||||
Intra-group revenue | – | – | – | – | – | ( | – | – | – | |
Investment return | ||||||||||
Interest income | – | |||||||||
Dividend and other investment income | – | – | ||||||||
Investment appreciation (depreciation) | – | ( | ||||||||
– | ( | |||||||||
Total revenue | ( | ( | ||||||||
2024 $m | ||||||||||
Insurance operations note (i) | ||||||||||
Hong Kong | Indonesia | Malaysia | Singapore | Growth markets and other | Eastspring | Inter- segment elimination | Total segment | Unallocated to a segment (central operations) | Total | |
Insurance revenue | ||||||||||
Amounts relating to changes in the liability for remaining coverage: | ||||||||||
Expected claims and other directly attributable expenses | – | – | – | |||||||
Change in risk adjustment for non- financial risk | – | – | – | |||||||
Release of CSM for services provided | – | – | – | |||||||
Other adjustments note (ii) | – | – | – | |||||||
Recovery of insurance acquisition cash flows | – | – | – | |||||||
– | – | – | ||||||||
Other revenue note (iii) | – | – | – | |||||||
Total revenue from external customers note (iv) | – | – | ||||||||
Intra-group revenue | – | – | – | – | – | ( | – | – | – | |
Investment return | ||||||||||
Interest income | – | |||||||||
Dividend and other investment income | – | – | ||||||||
Investment appreciation (depreciation) | ( | ( | – | |||||||
( | – | |||||||||
Total revenue | ( | |||||||||
2023 $m | ||||||||||
Insurance operations note (i) | ||||||||||
Hong Kong | Indonesia | Malaysia | Singapore | Growth markets and other | Eastspring | Inter- segment elimination | Total segment | Unallocated to a segment (central operations) | Total | |
Insurance revenue | ||||||||||
Amounts relating to changes in the liability for remaining coverage: | ||||||||||
Expected claims and other directly attributable expenses | – | – | – | |||||||
Change in risk adjustment for non- financial risk | – | – | – | |||||||
Release of CSM for services provided | – | – | – | |||||||
Other adjustments note (ii) | – | – | – | |||||||
Recovery of insurance acquisition cash flows | – | – | – | |||||||
– | – | – | ||||||||
Other revenue note (iii) | – | – | ||||||||
Total revenue from external customers note (iv) | – | |||||||||
Intra-group revenue | – | – | – | – | – | ( | – | – | – | |
Investment return | ||||||||||
Interest income | – | |||||||||
Dividend and other investment income | – | |||||||||
Investment appreciation (depreciation) | – | ( | ||||||||
– | ||||||||||
Total revenue | ( | |||||||||
2025 $m | 2024 $m | 2023 $m | |
Interest income calculated using the effective interest method | |||
Net gains on financial instruments at FVTPL note | |||
Dividend income from Jackson shares designated at FVOCI recognised in the income statement | |||
Other investment returns (including foreign exchange gains and losses) | |||
Movement in amounts attributable to external unit holders of consolidated investment funds | ( | ( | ( |
Investment return recognised in the income statement | |||
Valuation movements in Jackson shares recognised in other comprehensive income | |||
Total investment return recognised in the income statement and other comprehensive income |
2025 $m | 2024 $m | 2023 $m | |
Net finance (expense) income from insurance contracts notes (i)(ii) | |||
Accretion of interest on GMM contracts | ( | ( | ( |
Changes in fair value of underlying assets and other adjustments relating to VFA contracts | ( | ( | ( |
Effect of changes in interest rates and other financial assumptions | ( | ( | ( |
Effect of measuring changes in estimates at current rates and adjusting the CSM at locked-in rates | |||
Net foreign exchange gain | |||
Other finance (expense) from insurance contracts note (iii) | ( | ( | ( |
( | ( | ( | |
Net finance income (expense) from reinsurance contracts held notes (i)(ii) | |||
Accretion of interest on GMM contracts | |||
Effect of changes in interest rates and other financial assumptions | ( | ( | |
Effect of measuring changes in estimates at current rates and adjusting the CSM at locked-in rates | ( | ( | |
Net foreign exchange (loss) gain | ( | ( | |
Other finance income from reinsurance contracts note (iv) | ( | ||
( | ( |
2025 $m | 2024 $m | 2023 $m | |
Profit after tax | Profit after tax | Profit after tax | |
Hong Kong | |||
Indonesia | |||
Mainland China note | ( | ( | |
Malaysia note | |||
Singapore | |||
Growth markets and other note | |||
Asset management | |||
Total segment profit | |||
Unallocated to a segment (central operations) | ( | ( | ( |
Total profit after tax |
2025 $m | 2024 $m | 2023 $m | |
Expenses attributed to insurance acquisition cash flows note (i) | |||
Other directly attributable expenses note (ii) | |||
Other expenditure note (iii) | |||
Total expenses |
2025 $m | 2024 $m | 2023 $m | |
Hong Kong | |||
Indonesia | |||
Malaysia | |||
Singapore | |||
Growth markets and other | |||
Eastspring | |||
Total segment | |||
Unallocated to a segment (central operations) | |||
Total depreciation and amortisation |
2025 $m | 2024 $m | 2023 $m | |
Wages and salaries | |||
Social security costs | |||
Defined contribution pension schemes | |||
Total Group |
2025 | 2024 | 2023 | |
Asia and Africa operations note | |||
Head office function | |||
Total Group |
Share scheme | Description |
Prudential Global Long Term Incentive Plan (PG LTIP) | The PG LTIP provides eligible employees with conditional awards. Awards are discretionary and vest after one, two or three years subject to the employee being in employment. Vesting of awards may also be subject to performance conditions. All awards are made in Prudential shares. In countries where share awards are not feasible for reasons including securities and/or tax considerations, awards will be replaced by the cash value of the shares that would otherwise have vested. |
Prudential Agency Long-Term Incentive Plan (LTIP) | Certain agents are eligible to be granted awards in Prudential shares under the Prudential Agency LTIP. These awards are structured in a similar way to the PG LTIP described above, with most awards granted with a three-year vesting period. |
Restricted Share Plan (RSP) | The Company operates the RSP for certain employees. Awards under this plan are discretionary, and the vesting of awards may be subject to performance conditions. |
Deferred bonus plans | The Company operates a number of deferred bonus plans including the Group Deferred Bonus Plan (GDBP) and the Prudential Deferred Bonus Plan. There are no performance conditions attached to deferred share awards made under these arrangements. |
Savings-related share option schemes | Eligible agents in certain business units are able to participate in the International Savings- Related Share Option Scheme for Non-Employees (ISSOSNE). The plan is similar to the HMRC-approved Save As You Earn (Sharesave) share option scheme in the UK which is open to eligible employees. |
Share purchase plans | Eligible employees in the UK are invited to participate in the Company’s HMRC-approved UK Share Incentive Plan (SIP). The plan allows the purchase of Prudential plc shares each month. Staff based in Asia and Africa are eligible to participate in the Prudential All Employee Share Purchase Plan (PRUshareplus) which is run in a similar way. |
Options outstanding under Sharesave and ISSOSNE schemes | Awards outstanding under incentive plans | |||||||||
2025 | 2024 | 2023 | 2025 | 2024 | 2023 | |||||
Number of options | Weighted average exercise price | Number of options | Weighted average exercise price | Number of options | Weighted average exercise price | Number of awards | ||||
millions | £ | millions | £ | millions | £ | millions | ||||
Balance at beginning of year | ||||||||||
Granted | ||||||||||
Exercised | ( | ( | ( | ( | ( | ( | ||||
Forfeited | – | – | – | ( | ( | ( | ||||
Cancelled | ( | ( | ( | – | ( | |||||
Lapsed/expired | – | – | – | ( | ( | ( | ||||
Balance at end of year | ||||||||||
Options immediately exercisable at end of year | ||||||||||
Outstanding | Exercisable | |||||||||||||||
Number outstanding millions | Weighted average remaining contractual life years | Weighted average exercise prices £ | Number exercisable millions | Weighted average exercise prices £ | ||||||||||||
2025 | 2024 | 2023 | 2025 | 2024 | 2023 | 2025 | 2024 | 2023 | 2025 | 2024 | 2023 | 2025 | 2024 | 2023 | ||
Between £ and £ | – | – | – | – | – | – | – | |||||||||
Between £ and £ | – | – | – | – | ||||||||||||
Between £ and £ | – | – | ||||||||||||||
Between £ and £ | – | – | – | |||||||||||||
Between £ and £ | – | – | – | – | – | – | – | – | – | – | – | |||||
Between £ and £ | – | – | – | – | – | – | – | – | ||||||||
Total | ||||||||||||||||
2025 | 2024 | 2023 | |||||||||
Sharesave and ISSOSNE options | Prudential LTIP (TSR) | Other awards | Sharesave and ISSOSNE options | Prudential LTIP (TSR) | Other awards | Sharesave and ISSOSNE options | Prudential LTIP (TSR) | Other awards | |||
Dividend yield (%) | – | – | – | – | – | – | |||||
Expected volatility (%) | – | – | – | ||||||||
Risk-free interest rate (%) | – | – | – | ||||||||
Expected option life (years) | – | – | – | – | – | – | |||||
Weighted average exercise price (£) | £ | – | – | £ | – | – | £ | – | – | ||
Weighted average share price at grant date (£/HKD) | £ | HKD | – | £ | HKD | – | £ | HKD | – | ||
Weighted average fair value at grant date (£/HKD) | £ | HKD | HKD | £ | HKD | HKD | £ | HKD | HKD | ||
2025 $m | 2024 $m | 2023 $m | |
Total Salaries and short term benefits | |||
Share based payments and other long term awards | |||
Payments made on appointment | |||
Post-employment benefits | |||
Total key management remuneration |
2025 $m | 2024 $m | 2023 $m | |
Audit of the Company’s annual accounts | |||
Audit of subsidiaries pursuant to legislation | |||
Audit fees payable to the auditor | |||
Audit-related assurance services note (i) | |||
Other assurance services | |||
Non-audit fees payable to the auditor | |||
Total fees payable to the auditor |
2025 $m | 2024 $m | 2023 $m | |
Hong Kong | ( | ( | ( |
Indonesia | ( | ( | ( |
Malaysia | ( | ( | ( |
Singapore | ( | ( | ( |
Growth markets and other | ( | ( | ( |
Eastspring note (i) | ( | ( | ( |
Total segment note (ii) | ( | ( | ( |
Unallocated to a segment (central operations) | ( | ( | |
Total tax charge note (iii) | ( | ( | ( |
2025 $m | 2024 $m | 2023 $m | |
Current tax arising from: | |||
Corporation tax | ( | ( | ( |
Adjustments in respect of prior years note | ( | ||
Pillar Two income taxes (see below) | ( | ||
Total current tax charge | ( | ( | ( |
Deferred tax arising from: | |||
Origination and reversal of temporary differences | ( | ( | ( |
Adjustment in respect of a tax loss, tax credit or temporary difference from a prior year | ( | ||
Total deferred tax charge | ( | ( | ( |
Total tax charge | ( | ( | ( |
2025 | 2024 | 2023 | ||||||
$m | ETR % | $m | ETR % | $m | ETR % | |||
Profit before tax (being tax attributable to shareholders’ and policyholders’ returns) | ||||||||
Tax charge attributable to policyholders’ returns note (i) | ( | ( | ( | |||||
Profit before tax attributable to shareholders' returns | ||||||||
Tax charge at the expected rate | ( | ( | ( | |||||
Effects of recurring tax reconciliation items: | ||||||||
Income not taxable or taxable at concessionary rates note (ii) | ( | ( | ( | |||||
Deductions and losses not allowable for tax purposes note (iii) | ( | ( | ( | |||||
Items related to taxation of life insurance businesses note (iv) | ( | ( | ( | |||||
Deferred tax adjustments including unrecognised tax losses | ( | ( | ||||||
Effect of results of joint ventures and associates note (v) | ( | ( | ( | |||||
Irrecoverable withholding taxes note (vi) | ( | ( | ( | |||||
Pillar Two income taxes | ( | |||||||
Other | ( | ( | ||||||
Total credit (charge) on recurring items | ( | ( | ( | |||||
Effects of non-recurring tax reconciliation items: | ||||||||
Adjustments to tax charge in relation to prior years | ( | |||||||
Movements in provisions for open tax matters note (vii) | ( | ( | ||||||
Adjustments in relation to business disposals and corporate transactions | ( | ( | ( | |||||
Total credit (charge) on non-recurring items | ( | ( | ( | |||||
Tax charge attributable to shareholders' returns | ( | ( | ( | |||||
Tax charge attributable to policyholders’ returns note (i) | ( | ( | ( | |||||
Tax charge attributable to shareholders' and policyholders' returns | ( | ( | ( | |||||
Profit before tax attributable to shareholders’ returns analysed into: | ||||||||
Adjusted operating profit | ||||||||
Non-operating result note (viii) | ( | ( | ||||||
Profit before tax attributable to shareholders' returns | ||||||||
Tax charge attributable to shareholders' returns analysed into: | ||||||||
Tax charge on adjusted operating profit | ( | ( | ( | |||||
Tax (charge) credit on non-operating result note (viii) | ( | |||||||
Tax charge attributable to shareholders' returns | ( | ( | ( | |||||
Actual tax rate on: | ||||||||
Adjusted operating profit: | ||||||||
Including non-recurring tax reconciling items note (ix) | ||||||||
Excluding non-recurring tax reconciling items | ||||||||
Profit before tax attributable to shareholders' returns note (ix) | ||||||||
2025 $m | |
Balance at 1 Jan | ( |
Movements in the current year included in tax charge attributable to shareholders | |
Provisions utilised in the year | |
Other movements (including interest arising on open tax matters and amounts included in the Group’s share of profits from joint ventures and associates, net of related tax) | ( |
Balance at 31 Dec | ( |
2025 % | ||||||||
Hong Kong | Indonesia | Malaysia | Singapore | Growth markets and other | Eastspring | Other (central) operations | Total attributable to shareholders | |
Tax rate on adjusted operating profit | ( | |||||||
Tax rate on profit before tax | ( | |||||||
2024 % | ||||||||
Hong Kong | Indonesia | Malaysia | Singapore | Growth markets and other | Eastspring | Other (central) operations | Total attributable to shareholders | |
Tax rate on adjusted operating profit | ( | |||||||
Tax rate on profit before tax | ( | |||||||
2023 % | ||||||||
Hong Kong | Indonesia | Malaysia | Singapore | Growth markets and other | Eastspring | Other central operations | Total attributable to shareholders | |
Tax rate on adjusted operating profit | ||||||||
Tax rate on profit before tax | ||||||||
2025 | ||||||
Before tax | Tax | Non- controlling interests | Net of tax and non- controlling interests | Basic earnings per share | Diluted earnings per share | |
$m | $m | $m | $m | cents | cents | |
Based on profit for the year | ( | ( | ||||
Short-term interest rate and other market fluctuations | ( | ( | ( | ( | ( | |
Gain attaching to corporate transactions | ( | ( | ( | ( | ||
Based on adjusted operating profit | ( | ( | ( | ( | ||
2024 | ||||||
Before tax | Tax | Non- controlling interests | Net of tax and non- controlling interests | Basic earnings per share | Diluted earnings per share | |
$m | $m | $m | $m | cents | cents | |
Based on profit for the year | ( | ( | ||||
Short-term interest rate and other market fluctuations | ( | |||||
Loss attaching to corporate transactions | ( | |||||
Based on adjusted operating profit | ( | ( | ||||
2023 | ||||||
Before tax | Tax | Non- controlling interests | Net of tax and non- controlling interests | Basic earnings per share | Diluted earnings per share | |
$m | $m | $m | $m | cents | cents | |
Based on profit for the year | ( | ( | ||||
Short-term interest rate and other market fluctuations | ( | |||||
Loss attaching to corporate transactions | ||||||
Based on adjusted operating profit | ( | ( | ||||
2025 | 2024 | 2023 | |||||||
Cents per share | $m | Cents per share | $m | Cents per share | $m | ||||
Dividends relating to reporting year:* | |||||||||
First interim dividend | |||||||||
Second interim dividend | |||||||||
Total relating to reporting year | |||||||||
Dividends paid in reporting year: | |||||||||
Current year first interim dividend | |||||||||
Second interim dividend for prior year | |||||||||
Total paid in reporting year | |||||||||
31 Dec 2025 $m | |||||||
Asia and Africa | Unallocated to a segment | Group total | |||||
Insurance | |||||||
Funds with policyholder participation | Unit-linked funds | Other | Eastspring | Total | |||
note (i) | |||||||
Debt securities | |||||||
Sovereign debt | |||||||
Indonesia | – | – | |||||
Singapore | – | – | |||||
Thailand | – | – | |||||
United States | – | – | |||||
Vietnam | – | – | |||||
Other (predominantly Asia) | – | – | |||||
Subtotal | – | – | |||||
Other government bonds | |||||||
AAA | – | – | |||||
AA+ to AA- | – | – | |||||
A+ to A- | – | – | |||||
BBB+ to BBB- | – | – | |||||
Below BBB- and unrated | – | – | |||||
Subtotal | – | ||||||
Corporate bonds | |||||||
AAA | – | – | |||||
AA+ to AA- | – | – | |||||
A+ to A- | – | ||||||
BBB+ to BBB- | – | ||||||
Below BBB- and unrated | – | – | |||||
Subtotal | |||||||
Asset-backed securities | |||||||
AAA | – | – | |||||
AA+ to AA- | – | – | – | ||||
A+ to A- | – | – | – | ||||
BBB+ to BBB- | – | – | – | ||||
Below BBB- and unrated | – | – | |||||
Subtotal | – | – | |||||
Total debt securities notes (ii)(iii) | |||||||
Loans | |||||||
Mortgage loans | – | – | – | ||||
Other loans | – | – | – | – | |||
Total loans | – | – | – | ||||
Equity securities and holdings in collective investment schemes | |||||||
Direct equities note (ii) | |||||||
Collective investment schemes | – | ||||||
Total equity securities and holdings in collective investment schemes | |||||||
Derivative assets | |||||||
Deposits | |||||||
Total financial investments | |||||||
Investment properties | – | – | – | – | |||
Cash and cash equivalents | |||||||
Total investments | |||||||
31 Dec 2024 $m | |||||||
Asia and Africa | Unallocated to a segment | ||||||
Insurance | |||||||
Funds with policyholder participation | Unit-linked funds | Other | Eastspring | Total | Group total | ||
note (i) | |||||||
Debt securities | |||||||
Sovereign debt | |||||||
Indonesia | – | – | |||||
Singapore | – | – | |||||
Thailand | – | – | |||||
United States | – | – | |||||
Vietnam | – | – | |||||
Other (predominantly Asia) | – | ||||||
Subtotal | – | ||||||
Other government bonds | |||||||
AAA | – | – | |||||
AA+ to AA- | – | – | |||||
A+ to A- | – | – | |||||
BBB+ to BBB- | – | – | |||||
Below BBB- and unrated | – | – | |||||
Subtotal | – | – | |||||
Corporate bonds | |||||||
AAA | – | – | |||||
AA+ to AA- | – | – | |||||
A+ to A- | – | ||||||
BBB+ to BBB- | – | ||||||
Below BBB- and unrated | – | – | |||||
Subtotal | – | ||||||
Asset-backed securities | |||||||
AAA | – | – | |||||
AA+ to AA- | – | – | – | ||||
A+ to A- | – | – | – | ||||
BBB+ to BBB- | – | – | – | ||||
Below BBB- and unrated | – | – | |||||
Subtotal | – | – | |||||
Total debt securities notes (ii)(iii) | |||||||
Loans | |||||||
Mortgage loans | – | – | – | ||||
Other loans | – | – | – | – | |||
Total loans | – | – | – | ||||
Equity securities and holdings in collective investment schemes | |||||||
Direct equities note (ii) | – | ||||||
Collective investment schemes | – | ||||||
Total equity securities and holdings in collective investment schemes | – | ||||||
Derivative assets | |||||||
Deposits | |||||||
Total financial investments | |||||||
Investment properties | – | – | – | – | |||
Cash and cash equivalents | |||||||
Total investments | |||||||
31 Dec 2025 $m | 31 Dec 2024 $m | |
Debt securities held by consolidated investment funds | ||
Direct equities held by consolidated investment funds* |
31 Dec 2025 $m | 31 Dec 2024 $m | |
Total accrued investment income, primarily interest receivable | ||
Other debtors | ||
Total accrued investment income and other debtors | ||
Analysed as: | ||
Expected to be settled within one year | ||
Expected to be settled beyond one year | ||
Total accrued investment income and other debtors |
31 Dec 2025 $m | 31 Dec 2024 $m | |
Accruals and deferred income | ||
Interest payable | ||
Other creditors | ||
Total accruals, deferred income and other creditors |
31 Dec 2025 $m | 31 Dec 2024 $m | |
Cash | ||
Cash equivalents | ||
Total cash and cash equivalents | ||
Analysed as: | ||
Held by the Group’s holding and non-regulated entities and available for general use | ||
Other funds not available for general use by the Group, including funds held for the benefit of policyholders | ||
Total cash and cash equivalents |
2025 $m | 2024 $m | |
Balance at 1 Jan | ||
Charge (credit) to income statement: | ||
Additional provisions | ||
Unused amounts released | ( | ( |
Utilisation during the year | ( | ( |
Exchange differences | ( | |
Balance at 31 Dec |
31 Dec 2025 $m | ||||
Level 1 | Level 2 | Level 3 | ||
Quoted prices (unadjusted) in active markets | Valuation based on significant observable market inputs | Valuation based on significant unobservable market inputs | Total | |
note (iii) | ||||
Loans note (iv) | ||||
Equity securities and holdings in collective investment schemes | ||||
Debt securities note (i) | ||||
Derivative assets | ||||
Derivative liabilities | ( | ( | ( | |
Total financial investments, net of derivative liabilities | ||||
Investment contract liabilities without DPF note (ii) | ( | ( | ||
Net asset value attributable to unit holders of consolidated investment funds | ( | ( | ||
Total financial instruments at fair value | ||||
Percentage of total (%) | ||||
31 Dec 2024 $m | ||||
Level 1 | Level 2 | Level 3 | ||
Quoted prices (unadjusted) in active markets | Valuation based on significant observable market inputs | Valuation based on significant unobservable market inputs | Total | |
note (iii) | ||||
Loans note (iv) | ||||
Equity securities and holdings in collective investment schemes | ||||
Debt securities note (i) | ||||
Derivative assets | ||||
Derivative liabilities | ( | ( | ( | |
Total financial investments, net of derivative liabilities | ||||
Investment contract liabilities without DPF note (ii) | ( | ( | ||
Net asset value attributable to unit holders of consolidated investment funds | ( | ( | ||
Total financial instruments at fair value | ||||
Percentage of total (%) | ||||
31 Dec 2025 $m | |||
Equity securities and holdings in collective investment schemes | Debt securities | Group total | |
Balance at 1 Jan | |||
Total gain in income statement note | |||
Exchange differences recorded in other comprehensive income | |||
Purchases and other additions | |||
Sales, maturities and capital distribution | ( | ( | ( |
Transfers out of Level 3 | ( | ( | |
Balance at 31 Dec | |||
31 Dec 2024 $m | |||
Equity securities and holdings in collective investment schemes | Debt securities | Group total | |
Balance at 1 Jan | |||
Total gain in income statement note | |||
Exchange differences recorded in other comprehensive income | ( | ( | ( |
Purchases and other additions | |||
Sales, maturities and capital distribution | ( | ( | ( |
Balance at 31 Dec | |||
2025 $m | 2024 $m | |
Equity securities and holdings in collective investment schemes | ( | |
Debt securities | ||
Net unrealised gains (losses) on financial instruments still held at the end of the year | ( |
31 Dec 2025 $m | 31 Dec 2024 $m | ||||
Carrying value | Fair value | Carrying value | Fair value | ||
Financial assets | |||||
Loans note (i) | |||||
Financial liabilities | |||||
Core structural borrowings of shareholder-financed businesses note (ii) | ( | ( | ( | ( | |
Operational borrowings (excluding lease liabilities) note (i) | ( | ( | ( | ( | |
Obligations under funding, securities lending and sale and repurchase agreements note (i) | ( | ( | ( | ( | |
Net financial liabilities at amortised cost note (iii) | ( | ( | ( | ( | |
Financial instruments | Classification under IFRS 9 |
Financial assets | |
Loans | Amortised cost (31 Dec 2025: $ $ |
Mandatorily at FVTPL (31 Dec 2025: $ $ | |
Equity securities and portfolio holdings in collective investment schemes | Mandatorily at FVTPL |
Debt securities | Mandatorily at FVTPL |
Derivative assets | Mandatorily at FVTPL |
Accrued investment income | Amortised cost |
Deposits | Amortised cost |
Cash and cash equivalents | Amortised cost |
Other debtors | Amortised cost |
Financial liabilities | |
Investment contract liabilities without DPF | Mandatorily at FVTPL |
Derivative liabilities | Mandatorily at FVTPL |
Core structural borrowings of shareholder-financed businesses | Amortised cost |
Operational borrowings | Amortised cost |
Obligations under funding, securities lending and sale and repurchase agreements | Amortised cost |
Net asset value attributable to unit holders of consolidated investment funds note | Designated at FVTPL |
Other liabilities | Amortised cost |
31 Dec 2025 $m | ||||||||||||
Total carrying value | Contractual maturity profile for financial liabilities | |||||||||||
1 year or less | 1-2 years | 2-5 years | 5-10 years | 10-15 years | 15-20 years | Over 20 years | No stated maturity | Total undiscounted cash flows | ||||
Investment contracts without DPF note | ||||||||||||
Core structural borrowings of shareholder-financed businesses | ||||||||||||
Lease liabilities under IFRS 16 | ||||||||||||
Other operational borrowings | ||||||||||||
Obligations under funding, securities lending and sale and repurchase agreements | ||||||||||||
Accruals, deferred income and other liabilities | ||||||||||||
Net asset value attributable to unit holders of consolidated investment funds | ||||||||||||
Total non-derivative financial liabilities | ||||||||||||
31 Dec 2024 $m | ||||||||||||
Total carrying value | Contractual maturity profile for financial liabilities | |||||||||||
1 year or less | 1-2 years | 2-5 years | 5-10 years | 10-15 years | 15-20 years | Over 20 years | No stated maturity | Total undiscounted cash flows | ||||
Investment contracts without DPF note | ||||||||||||
Core structural borrowings of shareholder-financed businesses | ||||||||||||
Lease liabilities under IFRS 16 | ||||||||||||
Other operational borrowings | ||||||||||||
Obligations under funding, securities lending and sale and repurchase agreements | ||||||||||||
Accruals, deferred income and other liabilities | ||||||||||||
Net asset value attributable to unit holders of consolidated investment funds | ||||||||||||
Total non-derivative financial liabilities | ||||||||||||
Carrying value of net derivatives $m | |||
Derivative assets | Derivative liabilities | Net derivative position | |
31 Dec 2025 | ( | ( | |
31 Dec 2024 | ( | ( | |
31 Dec 2025 $m | |||||
Gross amount included in the balance sheet | Related amounts not offset in the balance sheet | Net amount included in the balance sheet | |||
Financial instruments | Cash collateral | Securities collateral | |||
note (i) | note (ii) | note (iii) | note (iv) | ||
Derivative assets | ( | ( | – | ||
Reverse repurchase agreements | – | – | ( | – | |
Total financial assets | ( | ( | ( | ||
Derivative liabilities | ( | ( | |||
Securities lending and repurchase agreements | ( | – | ( | ||
Total financial liabilities | ( | ( | |||
31 Dec 2024 $m | |||||
Gross amount included in the balance sheet | Related amounts not offset in the balance sheet | Net amount included in the balance sheet | |||
Financial instruments | Cash collateral | Securities collateral | |||
note (i) | note (ii) | note (iii) | note (iv) | ||
Derivative assets | ( | ( | – | ||
Reverse repurchase agreements | – | – | ( | – | |
Total financial assets | ( | ( | ( | ||
Derivative liabilities | ( | ( | |||
Securities lending and repurchase agreements | ( | – | ( | ||
Total financial liabilities | ( | ( | |||
Excluding JVs and associates $m | Including JVs and associates $m note (i) | ||||||||||||
(Assets) | Liabilities | Net liabilities (assets) | (Assets) | Liabilities | Net liabilities (assets) | ||||||||
Insurance | RI | Insurance | RI | Insurance | RI | Insurance | RI | Insurance | RI | Insurance | RI | ||
note (ii) | note (ii) | ||||||||||||
As at 31 Dec 2025 | |||||||||||||
Best estimate liabilities (BEL) | ( | ( | ( | ( | ( | ( | |||||||
Risk adjustment for non- financial risk (RA) | ( | ( | ( | ( | ( | ( | |||||||
Contractual service margin (CSM) | ( | ( | ( | ( | |||||||||
Insurance contract balances notes C3.2 C3.3 | ( | ( | ( | ( | ( | ( | |||||||
Assets for insurance acquisition cash flows | ( | ( | ( | ( | |||||||||
Insurance and reinsurance contract liabilities (assets) | ( | ( | ( | ( | ( | ( | |||||||
As at 31 Dec 2024 | |||||||||||||
Best estimate liabilities (BEL) | ( | ( | ( | ( | ( | ( | |||||||
Risk adjustment for non- financial risk (RA) | ( | ( | ( | ( | ( | ( | |||||||
Contractual service margin (CSM) | ( | ( | ( | ( | |||||||||
Insurance contract balances notes C3.2 C3.3 | ( | ( | ( | ( | ( | ( | |||||||
Assets for insurance acquisition cash flows | ( | ( | ( | ( | |||||||||
Insurance and reinsurance contract liabilities (assets) | ( | ( | ( | ( | ( | ( | |||||||
Excluding JVs and associates | |||||||||
2025 $m | |||||||||
Insurance | Reinsurance | ||||||||
BEL | RA | CSM | Total | BEL | RA | CSM | Total | ||
note (b) | note (b) | ||||||||
Opening assets | ( | ( | ( | ( | ( | ( | |||
Opening liabilities | ( | ||||||||
Net liabilities (assets) at 1 Jan | ( | ( | ( | ( | |||||
Changes that relate to future service | |||||||||
Changes in estimates that adjust the CSM | ( | ( | ( | ||||||
Changes in estimates that result in losses or reversal of losses on onerous contracts | – | ( | – | – | ( | ||||
New contracts in the year | ( | ( | ( | ( | |||||
( | ( | ( | ( | ||||||
Changes that relate to current service | |||||||||
Release of CSM to profit or loss | – | – | ( | ( | – | – | |||
Release of risk adjustment to profit or loss | – | ( | – | ( | – | – | |||
Experience adjustments | ( | – | – | ( | – | – | |||
( | ( | ( | ( | ||||||
Changes that relate to past service | |||||||||
Adjustments to assets and liabilities for incurred claims | ( | – | – | ( | ( | ( | – | ( | |
Insurance service result | ( | ( | ( | ( | |||||
Net finance (income) expense | |||||||||
Accretion of interest on GMM contracts note (i) | ( | ( | ( | ( | ( | ||||
Other net finance (income) expense | ( | ( | ( | ||||||
( | ( | ||||||||
Total amount recognised in income statement | ( | ( | |||||||
Effect of movements in exchange rates | ( | ( | ( | ||||||
Total amount recognised in comprehensive income | ( | ( | |||||||
Cash flows | |||||||||
Premiums received net of ceding commissions paid | – | – | ( | – | – | ( | |||
Insurance acquisition cash flows | ( | – | – | ( | – | – | – | – | |
Claims and other insurance service expenses net of recoveries from reinsurance received note (ii) | ( | – | – | ( | – | – | |||
Total cash flows | – | – | ( | – | – | ( | |||
Other changes note (iii) | ( | – | ( | – | – | ||||
Closing assets | ( | ( | ( | ( | ( | ( | |||
Closing liabilities | ( | ||||||||
Net liabilities (assets) at 31 Dec | ( | ( | ( | ( | |||||
Excluding JVs and associates | |||||||||
2024 $m | |||||||||
Insurance | Reinsurance | ||||||||
BEL | RA | CSM | Total | BEL | RA | CSM | Total | ||
note (b) | note (b) | ||||||||
Opening assets | ( | ( | ( | ( | ( | ||||
Opening liabilities | ( | ( | |||||||
Net liabilities (assets) at 1 Jan | ( | ( | |||||||
Changes that relate to future service | |||||||||
Changes in estimates that adjust the CSM | ( | – | ( | ( | – | ||||
Changes in estimates that result in losses or reversal of losses on onerous contracts | – | – | – | ||||||
New contracts in the year | ( | ( | ( | ( | |||||
( | ( | ( | |||||||
Changes that relate to current service | |||||||||
Release of CSM to profit or loss | – | – | ( | ( | – | – | |||
Release of risk adjustment to profit or loss | – | ( | – | ( | – | – | |||
Experience adjustments | ( | – | – | ( | – | – | |||
( | ( | ( | ( | ||||||
Changes that relate to past service | |||||||||
Adjustments to assets and liabilities for incurred claims | ( | – | ( | ( | – | – | ( | ||
Insurance service result | ( | ( | ( | ( | |||||
Net finance (income) expense | |||||||||
Accretion of interest on GMM contracts note (i) | ( | ( | ( | ( | ( | ||||
Other net finance (income) expense | |||||||||
( | ( | ||||||||
Total amount recognised in income statement | ( | ||||||||
Effect of movements in exchange rates | ( | ( | ( | ( | – | ( | |||
Total amount recognised in comprehensive income | ( | ( | ( | ||||||
Cash flows | |||||||||
Premiums received net of ceding commissions paid | – | – | ( | – | – | ( | |||
Insurance acquisition cash flows | ( | – | – | ( | – | – | – | – | |
Claims and other insurance service expenses net of recoveries from reinsurance received note (ii) | ( | – | – | ( | – | – | |||
Total cash flows | – | – | ( | – | – | ( | |||
Other changes note (iii) | ( | ( | – | ( | ( | – | – | ( | |
Closing assets | ( | ( | ( | ( | ( | ( | |||
Closing liabilities | ( | ||||||||
Net liabilities (assets) at 31 Dec | ( | ( | ( | ( | |||||
Insurance contracts (excluding JVs and associates) | |||||||||
2025 $m | 2024 $m | ||||||||
Contracts under MRA | Contracts under FVA | Other contracts* | Total CSM | Contracts under MRA | Contracts under FVA | Other contracts* | Total CSM | ||
Balance at 1 Jan | |||||||||
Changes that relate to future service | |||||||||
Changes in estimates that adjust the CSM | ( | ||||||||
New contracts in the year | – | – | – | – | |||||
( | |||||||||
Changes that relate to current service | |||||||||
Release of CSM to profit or loss | ( | ( | ( | ( | ( | ( | ( | ( | |
( | ( | ( | ( | ||||||
Net finance (income) expenses from insurance contracts | ( | ||||||||
Effect of movements in exchange rates | ( | ( | ( | ||||||
Balance at 31 Dec | |||||||||
Reinsurance contracts (excluding JVs and associates) | |||||||||
2025 $m | 2024 $m | ||||||||
Contracts under MRA | Contracts under FVA | Other contracts* | Total CSM | Contracts under MRA | Contracts under FVA | Other contracts* | Total CSM | ||
Balance at 1 Jan | ( | ( | ( | ( | ( | ( | |||
Changes that relate to future service | |||||||||
Changes in estimates that adjust the CSM | ( | ( | |||||||
New contracts in the year | – | – | ( | ( | – | – | |||
( | ( | ||||||||
Changes that relate to current service | |||||||||
Release of CSM to profit or loss | |||||||||
( | ( | ||||||||
Net finance (income) expenses from reinsurance contracts | ( | ( | ( | ( | ( | ( | |||
Effect of movements in exchange rates | ( | ( | |||||||
Balance at 31 Dec | ( | ( | ( | ( | ( | ( | |||
Excluding JVs and associates | |||||||||
2025 $m | |||||||||
Insurance | Reinsurance | ||||||||
Liabilities for remaining coverage | Liabilities for incurred claims | Liabilities for remaining coverage | Liabilities for incurred claims | ||||||
Excluding loss component | Loss component | Total | Excluding loss- recovery component | Loss- recovery component | Total | ||||
note (i) | note (i) | ||||||||
Opening assets | ( | ( | ( | ( | ( | ( | |||
Opening liabilities | ( | ||||||||
Net liabilities (assets) at 1 Jan | ( | ( | ( | ( | |||||
Insurance revenue | |||||||||
Contracts measured under the modified retrospective approach | ( | – | – | ( | |||||
Contracts measured under the fair value approach | ( | – | – | ( | |||||
Other contracts note (ii) | ( | – | – | ( | |||||
( | – | – | ( | ||||||
Insurance service expense | |||||||||
Incurred claims and other directly attributable expenses | – | ( | |||||||
Amortisation of insurance acquisition cash flows | – | – | |||||||
Losses or reversal of losses on onerous contracts | – | – | |||||||
Adjustments to liability for incurred claims | – | – | ( | ( | |||||
( | |||||||||
Net (income) expense from reinsurance contracts held | ( | ( | |||||||
Insurance service result | ( | ( | ( | ( | ( | ||||
Investment components and premium refunds | ( | – | – | ( | – | – | |||
Net finance (income) expenses from insurance and reinsurance contracts | 1 | ||||||||
Total amount recognised in income statement | ( | ( | ( | ( | |||||
Effect of movement in exchange rates | ( | ( | ( | ||||||
Total amount recognised in comprehensive income | ( | ( | ( | ||||||
Cash flows | |||||||||
Premiums received net of ceding commissions paid | – | – | ( | – | – | ( | |||
Insurance acquisition cash flows | ( | – | – | ( | – | – | – | ||
Claims and other insurance service expenses net of recoveries from reinsurance received note (iii) | – | – | ( | ( | – | – | |||
Total cash flows | – | ( | ( | – | ( | ||||
Other changes note (iv) | ( | ( | ( | – | |||||
Closing assets | ( | ( | ( | ( | ( | ( | |||
Closing liabilities | ( | ||||||||
Net liabilities (assets) at 31 Dec | ( | ( | ( | ( | |||||
Excluding JVs and associates | |||||||||
2024 $m | |||||||||
Insurance | Reinsurance | ||||||||
Liabilities for remaining coverage | Liabilities for incurred claims | Liabilities for remaining coverage | Liabilities for incurred claims | ||||||
Excluding loss component | Loss component | Total | Excluding loss- recovery component | Loss- recovery component | Total | ||||
note (i) | note (i) | ||||||||
Opening assets | ( | ( | ( | ( | ( | ( | |||
Opening liabilities | ( | ( | |||||||
Net liabilities (assets) at 1 Jan | ( | ( | ( | ( | |||||
Insurance revenue | |||||||||
Contracts measured under the modified retrospective approach | ( | – | – | ( | |||||
Contracts measured under the fair value approach | ( | – | – | ( | |||||
Other contracts note (ii) | ( | – | – | ( | |||||
( | – | – | ( | ||||||
Insurance service expense | |||||||||
Incurred claims and other directly attributable expenses | – | ( | |||||||
Amortisation of insurance acquisition cash flows | – | – | |||||||
Losses or reversal of losses on onerous contracts | – | – | |||||||
Adjustments to liability for incurred claims | – | – | ( | ( | |||||
Net (income) expense from reinsurance contracts held | – | – | – | – | ( | ||||
Insurance service result | ( | ( | ( | ||||||
Investment components and premium refunds | ( | – | – | – | ( | – | |||
Net finance (income) expenses from insurance and reinsurance contracts | – | – | |||||||
Total amount recognised in income statement | ( | ( | |||||||
Effect of movement in exchange rates | ( | ( | ( | ( | ( | ||||
Total amount recognised in comprehensive income | ( | ( | ( | ||||||
Cash flows | |||||||||
Premiums received net of ceding commissions paid | – | – | ( | – | – | ( | |||
Insurance acquisition cash flows | ( | – | – | ( | – | – | – | – | |
Claims and other insurance service expenses net of recoveries from reinsurance received note (iii) | – | – | ( | ( | – | – | |||
Total cash flows | – | ( | ( | – | ( | ||||
Other changes note (iv) | ( | ( | ( | ( | ( | – | ( | ||
Closing assets | ( | ( | ( | ( | ( | ( | |||
Closing liabilities | ( | ||||||||
Net liabilities (assets) at 31 Dec | ( | ( | ( | ( | |||||
Excluding JVs and associates | |||||||
2025 $m | 2024 $m | ||||||
Profitable contracts issued | Onerous contracts issued | Total | Profitable contracts issued | Onerous contracts issued | Total | ||
Estimate of present value of expected future cash outflows: | |||||||
Insurance acquisition cash flows | |||||||
Claims and other directly attributable expenses | |||||||
Estimate of present value of expected future cash inflows | ( | ( | ( | ( | ( | ( | |
Risk adjustment for non-financial risk | |||||||
CSM | – | – | |||||
Loss recognised on initial recognition | |||||||
Excluding JVs and associates | |||||||
2025 $m | 2024 $m | ||||||
Contracts initiated without loss-recovery component | Contracts initiated with loss-recovery component | Total | Contracts initiated without loss-recovery component | Contracts initiated with loss-recovery component | Total | ||
Estimate of present value of expected future cash outflows | – | – | |||||
Estimate of present value of expected future cash inflows | ( | ( | ( | ( | ( | ( | |
Risk adjustment for non-financial risk | ( | – | ( | ( | – | ( | |
CSM | ( | – | ( | – | |||
Profit recognised on initial recognition | – | ( | ( | – | ( | ( | |
Including JVs and associates | |||||||||
2025 $m | |||||||||
Insurance | Reinsurance | ||||||||
BEL | RA | CSM | Total | BEL | RA | CSM | Total | ||
note (b) | note (b) | ||||||||
Opening assets | ( | ( | ( | ( | ( | ( | |||
Opening liabilities | ( | ||||||||
Net liabilities (assets) at 1 Jan | ( | ( | ( | ( | |||||
Changes that relate to future service | |||||||||
Changes in estimates that adjust the CSM | ( | ( | ( | ||||||
Changes in estimates that result in losses or reversal of losses on onerous contracts | – | ( | – | ( | |||||
New contracts in the year | ( | ( | ( | ( | |||||
( | ( | ( | |||||||
Changes that relate to current service | |||||||||
Release of CSM to profit or loss | – | – | ( | ( | – | – | |||
Release of risk adjustment to profit or loss | – | ( | – | ( | – | – | |||
Experience adjustments | ( | – | – | ( | – | – | |||
( | ( | ( | ( | ||||||
Changes that relate to past service | |||||||||
Adjustments to assets and liabilities for incurred claims | ( | ( | – | ( | ( | ( | – | ( | |
Insurance service result | ( | ( | ( | ||||||
Net finance (income) expense | |||||||||
Accretion of interest on GMM contracts note (i) | ( | ( | ( | ( | |||||
Other net finance (income) expense | ( | ( | ( | ||||||
( | ( | ||||||||
Total amount recognised in income statement | ( | ||||||||
Effect of movements in exchange rates | ( | ( | |||||||
Total amount recognised in comprehensive income | ( | ||||||||
Cash flows | |||||||||
Premiums received net of ceding commissions paid | – | – | ( | – | – | ( | |||
Insurance acquisition cash flows | ( | – | – | ( | – | – | |||
Claims and other insurance service expenses net of recoveries from reinsurance received note (ii) | ( | – | – | ( | – | – | |||
Total cash flows | – | – | ( | – | – | ( | |||
Other changes note (iii) | ( | – | – | ( | – | – | |||
Closing assets | ( | ( | ( | ( | ( | ( | |||
Closing liabilities | ( | ||||||||
Net liabilities (assets) at 31 Dec | ( | ( | ( | ( | |||||
Including JVs and associates | |||||||||
2024 $m | |||||||||
Insurance | Reinsurance | ||||||||
BEL | RA | CSM | Total | BEL | RA | CSM | Total | ||
note (b) | note (b) | ||||||||
Opening assets | ( | ( | ( | ( | ( | ||||
Opening liabilities | ( | ( | |||||||
Net liabilities (assets) at 1 Jan | ( | ( | ( | ||||||
Changes that relate to future service | |||||||||
Changes in estimates that adjust the CSM | ( | – | ( | ( | – | ||||
Changes in estimates that result in losses or reversal of losses on onerous contracts | – | – | |||||||
New contracts in the year | ( | ( | ( | ( | |||||
( | ( | ( | |||||||
Changes that relate to current service | |||||||||
Release of CSM to profit or loss | – | – | ( | ( | – | – | |||
Release of risk adjustment to profit or loss | – | ( | – | ( | – | – | |||
Experience adjustments | ( | – | – | ( | – | – | |||
( | ( | ( | ( | ||||||
Changes that relate to past service | |||||||||
Adjustments to assets and liabilities for incurred claims | ( | – | ( | ( | – | ( | |||
Insurance service result | ( | ( | ( | ( | |||||
Net finance (income) expense | |||||||||
Accretion of interest on GMM contracts note (i) | ( | ( | ( | ( | |||||
Other net finance (income) expense | |||||||||
( | ( | ||||||||
Total amount recognised in income statement | ( | ||||||||
Effect of movements in exchange rates | ( | ( | ( | ( | ( | ||||
Total amount recognised in comprehensive income | ( | ||||||||
Cash flows | |||||||||
Premiums received net of ceding commissions paid | – | – | ( | – | – | ( | |||
Insurance acquisition cash flows | ( | – | – | ( | – | – | |||
Claims and other insurance service expenses net of recoveries from reinsurance received note (ii) | ( | – | – | ( | – | – | |||
Total cash flows | – | – | ( | – | – | ( | |||
Other changes note (iii) | ( | ( | – | ( | ( | – | ( | ||
Closing assets | ( | ( | ( | ( | ( | ( | |||
Closing liabilities | ( | ||||||||
Net liabilities (assets) at 31 Dec | ( | ( | ( | ( | |||||
Insurance contracts (including JVs and associates) | |||||||||
2025 $m | 2024 $m | ||||||||
Contracts under MRA | Contracts under FVA | Other contracts* | Total CSM | Contracts under MRA | Contracts under FVA | Other contracts* | Total CSM | ||
Balance at 1 Jan | |||||||||
Changes that relate to future service | |||||||||
Changes in estimates that adjust the CSM | ( | ( | ( | ||||||
New contracts in the year | – | – | – | – | |||||
( | ( | ||||||||
Changes that relate to current service | |||||||||
Release of CSM to profit or loss | ( | ( | ( | ( | ( | ( | ( | ( | |
( | ( | ( | ( | ||||||
Net finance (income) expenses from insurance contracts | ( | ||||||||
Effect of movements in exchange rates | ( | ( | ( | ( | |||||
Balance at 31 Dec | |||||||||
FRA | MRA | FVA | |
Cohort | Cohort | Cohort | |
Mainland China | n/a | 2016 – 2021 | Pre-2016 |
Hong Kong | 2010 – 2021 | n/a | Pre-2010 |
Singapore | 2009 – 2021 | n/a | Pre-2009 |
Malaysia | 2010 – 2021 (Unit-linked) 2010 – 2021 (Non- participating) | 2000 – 2009 (Unit-linked) | Pre-1999 (Unit-linked) Pre-2009 (Non- participating) Pre-2021 (Other) |
Indonesia note (i) | 2010 – 2021 | 2007 – 2009 | Pre-2007 |
Growth markets and other | See note (ii) | See note (ii) | See note (ii) |
Reinsurance contracts (including JVs and associates) | |||||||||
2025 $m | 2024 $m | ||||||||
Contracts under MRA | Contracts under FVA | Other contracts* | Total CSM | Contracts under MRA | Contracts under FVA | Other contracts* | Total CSM | ||
Balance at 1 Jan | – | ( | ( | ( | – | ( | ( | ( | |
Changes that relate to future service | |||||||||
Changes in estimates that adjust the CSM | – | ( | ( | ( | – | ||||
New contracts in the year | – | – | – | – | |||||
– | ( | – | |||||||
Changes that relate to current service | |||||||||
Release of CSM to profit or loss | – | – | |||||||
– | – | ||||||||
Net finance (income) expenses from reinsurance contracts | – | ( | ( | ( | – | ( | ( | ( | |
Effect of movements in exchange rates | – | ( | – | ( | ( | ||||
Balance at 31 Dec | – | ( | ( | ( | – | ( | ( | ( | |
Insurance $m | Reinsurance $m | ||||||||
Liabilities (assets) | |||||||||
BEL | RA | CSM | Total | BEL | RA | CSM | Total | ||
As at 31 Dec 2025 | |||||||||
Mainland China | ( | ( | ( | ||||||
Hong Kong | ( | ( | ( | ( | |||||
Indonesia | ( | ( | |||||||
Malaysia | ( | ||||||||
Singapore | ( | ( | ( | ||||||
Growth markets and other | ( | ( | ( | ||||||
Total insurance segments | ( | ( | ( | ( | |||||
As at 31 Dec 2024 | |||||||||
Mainland China | ( | ( | ( | ||||||
Hong Kong | ( | ( | ( | ( | |||||
Indonesia | ( | ||||||||
Malaysia | ( | ||||||||
Singapore | ( | ( | ( | ||||||
Growth markets and other | ( | ( | ( | ||||||
Total insurance segments | ( | ( | ( | ( | |||||
Insurance $m | |||||||
Mainland China | Hong Kong | Indonesia | Malaysia | Singapore | Growth markets and other | Total insurance segments | |
Net liabilities (assets) at 1 Jan 2024 | |||||||
Insurance service result | ( | ( | ( | ( | ( | ( | ( |
Net finance (income) expenses from insurance contracts | |||||||
Accretion of interest on GMM contracts | |||||||
Other net finance expense | ( | ||||||
( | |||||||
Total amount recognised in income statement | ( | ( | |||||
Effect of movements in exchange rates | ( | ( | ( | ( | ( | ||
Total amount recognised in comprehensive income | ( | ( | |||||
Total cash flows | ( | ||||||
Other changes | – | ( | ( | ( | ( | ( | ( |
Net liabilities (assets) at 31 Dec 2024/1 Jan 2025 | |||||||
Insurance service result | ( | ( | ( | ( | ( | ( | ( |
Net finance (income) expenses from insurance contracts | |||||||
Accretion of interest on GMM contracts | ( | ||||||
Other net finance (income) expense | |||||||
Total amount recognised in income statement | |||||||
Effect of movements in exchange rates | ( | ( | |||||
Total amount recognised in comprehensive income | |||||||
Total cash flows | ( | ||||||
Other changes | – | ( | ( | ( | ( | ||
Net liabilities (assets) at 31 Dec 2025 | |||||||
Reinsurance $m | |||||||
Mainland China | Hong Kong | Indonesia | Malaysia | Singapore | Growth markets and other | Total insurance segments | |
Net liabilities (assets) at 1 Jan 2024 | ( | ( | ( | ( | |||
Insurance service result | ( | ||||||
Net finance (income) expenses from reinsurance contracts | |||||||
Accretion of interest on GMM contracts | ( | ( | ( | ( | ( | ||
Other net finance (income) expense | ( | ( | ( | ||||
( | ( | ( | |||||
Total amount recognised in income statement | ( | ||||||
Effect of movements in exchange rates | ( | ( | |||||
Total amount recognised in comprehensive income | ( | ||||||
Total cash flows | ( | ( | ( | ( | ( | ( | |
Other changes | – | ( | ( | ||||
Net liabilities (assets) at 31 Dec 2024/1 Jan 2025 | ( | ( | ( | ( | ( | ||
Insurance service result | ( | ||||||
Net finance (income) expenses from reinsurance contracts | |||||||
Accretion of interest on GMM contracts | ( | ( | ( | ( | ( | ||
Other net finance (income) expense | ( | ||||||
( | ( | ||||||
Total amount recognised in income statement | ( | ||||||
Effect of movements in exchange rates | ( | ( | ( | ||||
Total amount recognised in comprehensive income | ( | ||||||
Total cash flows | ( | ( | ( | ( | ( | ||
Other changes | – | ( | |||||
Net liabilities (assets) at 31 Dec 2025 | ( | ( | ( | ( | ( | ( | |
31 Dec 2025 $m | |||
Total as reported on the consolidated statement of financial position | Group’s share relating to JVs and associates | Total including Group’s share relating to JVs and associates | |
1 year or less | |||
After 1 year to 2 years | |||
After 2 years to 3 years | |||
After 3 years to 4 years | |||
After 4 years to 5 years | |||
After 5 years to 10 years | |||
After 10 years to 15 years | |||
After 15 years to 20 years | |||
After 20 years | |||
Total insurance CSM | |||
31 Dec 2024 $m | |||
Total as reported on the consolidated statement of financial position | Group’s share relating to JVs and associates | Total including Group’s share relating to JVs and associates | |
1 year or less | |||
After 1 year to 2 years | |||
After 2 years to 3 years | |||
After 3 years to 4 years | |||
After 4 years to 5 years | |||
After 5 years to 10 years | |||
After 10 years to 15 years | |||
After 15 years to 20 years | |||
After 20 years | |||
Total insurance CSM | |||
31 Dec 2025 $m | |||
Total as reported on the consolidated statement of financial position | Group’s share relating to JVs and associates | Total including Group’s share relating to JVs and associates | |
1 year or less | ( | ( | |
After 1 year to 2 years | ( | ( | |
After 2 years to 3 years | ( | ( | |
After 3 years to 4 years | ( | ( | |
After 4 years to 5 years | ( | ( | |
After 5 years to 10 years | ( | ( | |
After 10 years to 15 years | ( | ( | |
After 15 years to 20 years | ( | ( | |
After 20 years | ( | ( | |
Total reinsurance CSM | ( | ( | |
31 Dec 2024 $m | |||
Total as reported on the consolidated statement of financial position | Group’s share relating to JVs and associates | Total including Group’s share relating to JVs and associates | |
1 year or less | ( | ( | ( |
After 1 year to 2 years | ( | ( | |
After 2 years to 3 years | ( | ( | |
After 3 years to 4 years | ( | ( | |
After 4 years to 5 years | ( | ( | |
After 5 years to 10 years | ( | ( | |
After 10 years to 15 years | ( | ( | |
After 15 years to 20 years | ( | ( | |
After 20 years | ( | ( | ( |
Total reinsurance CSM | ( | ( | |
31 Dec 2025 $m | |||
Total as reported on the consolidated statement of financial position | Group’s share relating to JVs and associates | Total including Group’s share relating to JVs and associates | |
1 year or less | ( | ( | ( |
After 1 year to 2 years | ( | ( | |
After 2 years to 3 years | |||
After 3 years to 4 years | |||
After 4 years to 5 years | |||
After 5 years to 10 years | |||
After 10 years to 15 years | |||
After 15 years to 20 years | |||
After 20 years* | |||
Total expected future cash flows from insurance contract liabilities | |||
31 Dec 2024 $m | |||
Total as reported on the consolidated statement of financial position | Group’s share relating to JVs and associates | Total including Group’s share relating to JVs and associates | |
1 year or less | ( | ( | ( |
After 1 year to 2 years | ( | ( | |
After 2 years to 3 years | |||
After 3 years to 4 years | |||
After 4 years to 5 years | |||
After 5 years to 10 years | |||
After 10 years to 15 years | |||
After 15 years to 20 years | |||
After 20 years* | |||
Total expected future cash flows from insurance contract liabilities | |||
31 Dec 2025 $m | |||
Total as reported on the consolidated statement of financial position | Group’s share relating to JVs and associates | Total including Group’s share relating to JVs and associates | |
1 year or less | |||
After 1 year to 2 years | ( | ||
After 2 years to 3 years | ( | ||
After 3 years to 4 years | |||
After 4 years to 5 years | |||
After 5 years to 10 years | ( | ||
After 10 years to 15 years | |||
After 15 years to 20 years | ( | ( | |
After 20 years | |||
Total expected future cash flows from reinsurance contract liabilities | |||
31 Dec 2024 $m | |||
Total as reported on the consolidated statement of financial position | Group’s share relating to JVs and associates | Total including Group’s share relating to JVs and associates | |
1 year or less | |||
After 1 year to 2 years | ( | ||
After 2 years to 3 years | ( | ||
After 3 years to 4 years | ( | ||
After 4 years to 5 years | ( | ||
After 5 years to 10 years | ( | ||
After 10 years to 15 years | |||
After 15 years to 20 years | ( | ( | |
After 20 years | |||
Total expected future cash flows from reinsurance contract liabilities | |||
Contract type | Description and material features | Measurement model |
With-profits contracts (written in Hong Kong, Singapore and Malaysia) | Provides savings and/or protection where the basic sum assured can be enhanced by a profit share (or bonus) from the underlying fund as determined at the discretion of the local business unit. With-profits products often offer a guaranteed maturity or surrender value. Declared regular bonuses are guaranteed once vested. Future bonus rates and cash dividends are not guaranteed. Market value adjustments and surrender charges are used for certain products where the law permits such adjustments. Guarantees are predominantly supported by the segregated funds and their estates. Additional health and protection benefits can be provided through riders (which are not separated from the base with-profits contracts). | All with-profits contracts of the Group written in Hong Kong, Singapore and Malaysia are measured using the VFA model. The shareholders’ share of the excess of the assets of the with-profits funds over policyholder liabilities is recognised within shareholders’ equity. |
Other participating contracts | Similar to the with-profits contracts, other participating contracts include savings and/or protection elements, with policyholders and shareholders sharing in the returns of the underlying funds. | Other participating contracts of the Group are measured under the VFA model except for the contracts without distinct segregated funds written by the Group’s life joint venture in Mainland China, where the GMM approach is applied. |
Unit-linked contracts | Combines savings with health and protection riders (which, under IFRS 17, are not separated from the base contract). The cash value of the policy primarily depends on the value of the underlying unitised funds. | Unit-linked contracts are measured either under the VFA or the GMM depending on the relative size of the savings and protection benefits of the contract. The larger the protection component the more likely the contract is required to be measured under the GMM. |
Health and protection – Shareholder- backed participating critical illness contracts | Shareholder-backed participating critical illness contracts are written by the Group’s Hong Kong business. These products combine critical illness and death benefits with a savings element. These are whole life products and have regular premium payments with a limited payment term. | Shareholder-backed participating critical illness contracts are measured under the VFA. |
Health and protection – Other | In addition to supplementary heath and protection contract products attached to with-profits and unit- linked contracts described above, the Group also offers stand-alone health and protection products. These are non-participating contracts that provide mortality and/or morbidity benefits including health, disability, critical illness and accident coverage. | Stand-alone non-par health and protection (excluding shareholder-backed participating critical illness) contracts are measured under the GMM. |
Non- participating term, whole life and endowment assurance contracts | Non-participating savings and/or protection where the benefits are guaranteed, determined by a set of defined market-related parameters, or determined at the discretion of the local business unit. These products often offer a guaranteed maturity and/or surrender value. It is common in Asia for regulations or market-driven demand and competition to provide some form of capital value protection and minimum crediting interest rate guarantees. This is reflected within the guaranteed maturity and surrender values. Guarantees are supported by shareholders. | These contracts are measured under the GMM. |
2025 $m | 2024 $m | |
Carrying value at 1 Jan | ||
Exchange differences | ( | |
Reclassification as held for sale | ( | |
Carrying value at 31 Dec |
2025 $m | 2024 $m | ||||||
Distribution rights | Other intangibles | Total | Distribution rights | Other intangibles | Total | ||
note (i) | note (ii) | note (i) | note (ii) | ||||
Balance at 1 Jan | |||||||
Cost | |||||||
Accumulated amortisation and other charges | ( | ( | ( | ( | ( | ( | |
Additions | |||||||
Amortisation and other charges | ( | ( | ( | ( | ( | ( | |
Disposals and transfers | ( | ( | ( | ( | ( | ||
Exchange differences and other movements | ( | ( | ( | ||||
Balance at 31 Dec | |||||||
Comprising: | |||||||
Cost | |||||||
Accumulated amortisation and other charges | ( | ( | ( | ( | ( | ( | |
Balance at 31 Dec | |||||||
31 Dec 2025 $m | 31 Dec 2024 $m | |
Subordinated debt | ||
US$ | ||
£ | ||
US$ | ||
SGD | ||
Senior debt note (ii) | ||
£ | ||
US$ | ||
US$ | ||
Total core structural borrowings of shareholder-financed businesses |
31 Dec 2025 $m | 31 Dec 2024 $m | |
Borrowings in respect of short-term fixed income securities programmes (commercial paper) | ||
Lease liabilities under IFRS 16 | ||
Other borrowings | ||
Total operational borrowings |
31 Dec 2025 $m | 31 Dec 2024 $m | ||||
Change in local currency to $ exchange rates | Decrease of | Increase of | Decrease of | Increase of | |
Profit after tax for the year | ( | ( | |||
Shareholders’ equity | ( | ( | |||
Base values | 2025 $m | 2024 $m |
Profit after tax for the year for the Group | ||
Group shareholders’ equity as at 31 Dec | ||
CSM as at 31 Dec including JVs and associates |
31 Dec 2025 $m | 31 Dec 2024 $m | ||||
Interest rates and consequential effects | - | + | - | + | |
Increase (decrease) to shareholders’ equity: | |||||
Financial assets note | ( | ( | |||
Net insurance contract liabilities (including CSM) note | ( | ( | |||
Net effect on shareholders' equity | ( | ( | |||
Increase (decrease) to profit after tax: | |||||
Net effect on profit after tax | ( | ( | |||
Increase (decrease) to CSM liability: | |||||
CSM note | ( | ( | |||
31 Dec 2025 $m | 31 Dec 2024 $m | ||||
Equity/property market values | - | + | - | + | |
Increase (decrease) to shareholders’ equity: | |||||
Financial assets note | ( | ( | |||
Net insurance contract liabilities (including CSM) note | ( | ( | |||
Net effect on shareholders' equity | ( | ( | |||
Increase (decrease) to profit after tax: | |||||
Net effect on profit after tax | ( | ( | |||
Increase (decrease) to CSM liability: | |||||
CSM note | ( | ( | |||
2025 $m | |||||
Net effect on shareholders’ equity and profit after tax attributable to equity holders | Net effect on CSM | ||||
Sensitivity to insurance risk: | Gross of reinsurance | Net of reinsurance | Gross of reinsurance | Net of reinsurance | |
Maintenance expenses – | ( | ( | ( | ( | |
Lapse rates – | ( | ( | ( | ( | |
Mortality and morbidity – | ( | ( | ( | ( | |
2024 $m | |||||
Net effect on shareholders’ equity and profit after tax attributable to equity holders | Net effect on CSM | ||||
Sensitivity to insurance risk: | Gross of reinsurance | Net of reinsurance | Gross of reinsurance | Net of reinsurance | |
Maintenance expenses – | ( | ( | ( | ( | |
Lapse rates – | ( | ( | ( | ( | |
Mortality and morbidity – | ( | ( | ( | ( | |
2025 $m | ||||
Net deferred tax liabilities (assets) at 1 Jan | Movement in income statement | Other movements including foreign exchange movements | Net deferred tax liabilities (assets) at 31 Dec | |
Unrealised losses or gains on investments | ||||
Balances relating to insurance and reinsurance contracts | ||||
Short-term temporary differences | ( | ( | ||
Unused tax losses | ( | ( | ( | ( |
Net deferred tax liabilities | ||||
2024 $m | ||||
Net deferred tax liabilities (assets) at 1 Jan | Movement in income statement | Other movements including foreign exchange movements | Net deferred tax liabilities (assets) at 31 Dec | |
Unrealised losses or gains on investments | ( | |||
Balances relating to insurance and reinsurance contracts | ( | |||
Short-term temporary differences | ( | ( | ||
Unused tax losses | ( | ( | ( | |
Net deferred tax liabilities | ( | |||
2025 | 2024 | ||||||
Issued shares of 5p each fully paid | Number of ordinary shares | Share capital | Share premium | Number of ordinary shares | Share capital | Share premium | |
$m | $m | $m | $m | ||||
Balance at 1 Jan | |||||||
Shares issued under share-based schemes | |||||||
Shares issued under scrip dividends | |||||||
Shares cancelled on repurchases/ buybacks | ( | ( | ( | ( | |||
Balance at 31 Dec | |||||||
Share price range | ||||
Number of shares to subscribe for | from (in pence) | to (in pence) | Exercisable by year | |
31 Dec 2025 | 2031 | |||
31 Dec 2024 | 2030 | |||
2025 $m | 2024 $m | |
Share repurchases to neutralise share scheme issuances | ||
Share repurchases to neutralise impact of scrip dividend | ||
Share buyback programme to return capital to shareholders (excluding costs) | ||
Total cash paid on repurchases and buybacks (excluding costs) | ||
Costs associated with buyback | ||
Redemption liability/release associated with buyback | ( | |
Total cost recognised in retained earnings on share repurchases and buybacks |
Share price | ||||
Number of shares | Low £ | High £ | Cost $ | |
January | ||||
February | ||||
March | ||||
April | ||||
May | ||||
June | ||||
July | ||||
August | ||||
September | ||||
October | ||||
November | ||||
December | ||||
Total | ||||
2025 $m | 2024 $m | |
Balance at 1 Jan | ||
Gains (losses) during the year | ||
Movement in capital requirement | ( | |
Net distributions made to the parent company | ( | ( |
Exchange and other movements | ( | ( |
Balance at 31 Dec |
31 Dec 2025 $m | 31 Dec 2024 $m | |
Property, plant and equipment held at cost note (a) | ||
Owner occupied properties held at fair value note (b) | ||
Total property, plant and equipment |
2025 $m | 2024 $m | ||||||||
Group occupied property | Tangible assets | Right-of- use assets | Total | Group occupied property | Tangible assets | Right-of- use assets | Total | ||
Balance at 1 Jan | |||||||||
Cost | |||||||||
Accumulated depreciation | ( | ( | ( | ( | ( | ( | ( | ( | |
Opening net book amount | |||||||||
Additions | |||||||||
Depreciation charge | ( | ( | ( | ( | ( | ( | ( | ||
Disposals, impairment and lease modifications | ( | ( | ( | ||||||
Effect of movements in exchange rates | ( | ( | ( | ||||||
Balance at 31 Dec | |||||||||
Representing: | |||||||||
Cost | |||||||||
Accumulated depreciation | ( | ( | ( | ( | ( | ( | ( | ( | |
Closing net book amount | |||||||||
2025 $m | 2024 $m | |
Hong Kong | ||
Indonesia | ||
Malaysia | ||
Singapore | ||
Growth markets and other | ||
Eastspring | ||
Total segment | ||
Unallocated to a segment (central operations) | ||
Total capital expenditure on property, plant and equipment |
31 Dec 2025 $m | 31 Dec 2024 $m | ||||
Consolidated statement of financial position line items | Investment funds | Other structured entities | Investment funds | Other structured entities | |
Equity securities and holdings in collective investment schemes | – | – | |||
Debt securities | – | – | |||
Total investments in unconsolidated structured entities | |||||
2025 $m | 2024 $m | 2023 $m | |
Mainland China | ( | ( | |
Malaysia | |||
Growth markets and other note | |||
Insurance operations | ( | ||
Eastspring | |||
Total segment and Group total | ( |
Statement of financial position | 31 Dec 2025 $m | 31 Dec 2024 $m |
Total assets | ||
Total liabilities (including non-controlling interest) note | ||
Shareholders’ equity | ||
The above amounts of assets and liabilities include the following: | ||
Cash and cash equivalents | ||
Financial liabilities (excluding trade and other payables and provisions) |
Income statement | 2025 $m | 2024 $m | 2023 $m |
Revenue | |||
Profit (loss) for the year after tax | ( | ||
The above profit (loss) for the year includes the following: | |||
Depreciation and amortisation | ( | ( | ( |
Interest income | |||
Interest expense | ( | ( | ( |
Income tax credit (charge) | ( |
31 Dec 2025 $m | 31 Dec 2024 $m | |
Net assets of the Mainland China joint venture as shown above ( | ||
Proportion owned by the joint venture partner ( | ||
Carrying amount of the Group’s interest in the joint venture ( |
Prudential plc | |||||||||||||||||||||||||
Prudential Corporation Asia Limited | Prudential Group Holdings Limited and subsidiaries | ||||||||||||||||||||||||
CITIC- Prudential Life Insurance Company Limited (Mainland China life joint venture) | Prudential Hong Kong Limited Prudential General Insurance Hong Kong Limited | PT Prudential Life Assurance PT Prudential Sharia Life Assurance (Indonesia) | Prudential Assurance Malaysia Berhad Prudential BSN Takaful Berhad | Prudential Assurance Company Singapore (Pte) Limited | Eastspring Investment s Group Pte. Ltd and subsidiaries | Growth markets and other entities (including Africa, Cambodia, India, Laos, Myanmar, the Philippines, Taiwan, Thailand, Vietnam) | Prudential Internation al Treasury Limited | Prudential Funding (Asia) plc | |||||||||||||||||
Abbreviation | Class of share held |
LBG | Limited by Guarantee |
MI | Membership Interest |
MI – WFOE | Membership Interest of a Wholly Foreign Owned Enterprise in Mainland China |
MI – JV | Membership Interest of a Sino-Foreign Equity Joint Venture in Mainland China |
OS | Ordinary Shares |
PI | Partnership Interest |
PS | Preference Shares |
U | Units |
Name of entity | Classes of shares held | Proportion held | Registered office address |
Prudential Corporation Asia Limited | OS | 13th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong | |
Prudential Group Holdings Limited | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom |
Name of entity | Classes of shares held | Proportion held | Registered office address |
Aberdeen Cash Creation Fund | U | 28th Floor Bangkok City Tower, 179 South Sathorn Road, Thungmahamek, Sathorn, Bangkok 10120, Thailand | |
Aberdeen Standard Global Opportunities Fund | U | 7 Straits View, #23-04, Marina One East Tower, Singapore 018936 | |
Aberdeen Standard Singapore Equity Fund | U | ||
ABRDN India Opportunities Fund | U | ||
Alternatives North America, Ltd. | U | PO Box 1093, Queensgate House, Grand Cayman, KY1-1102, Cayman Islands | |
ARDIAN Prudential Infrastructure Sub- Fund | U | 1 Temasek Avenue, #36-01 Millenia Tower, Singapore 039192 | |
ARDIAN Prudential PE Sub-Fund | U | ||
ARDIAN Prudential RE Sub-Fund | U | ||
ATRAM - PRUINVEST PHP Liquid Fund | U | 8th Floor 8 Rockwell Building, Metro Manila Manila, Philippines | |
ATRAM Global Technology Feeder Fund | U | ||
ATRAM Philippine Equity Index Tracker Fund - Class V | U | ||
Barings International Umbrella Fund- Barings Global Balanced Fund | U | 21st Floor, No. 333, Sec. 1, Keelong Rd, Taipei | |
Blackrock Global Funds Systematic Global Equity High Income Fund | U | Twenty Anson, #18-01, 20 Anson Road, Singapore 079912 | |
BOCHK Aggressive Growth Fund | U | 27th Floor, Bank of China Tower, 1 Garden Road, Hong Kong | |
BOCHK Balanced Growth Fund | U | ||
BOCHK China Equity Fund | U | ||
BOCHK Conservative Growth Fund | U | ||
BOCHK US Dollar Money Market Fund | U | ||
BOCI-Prudential Asset Management Limited | OS | ||
BOCI-Prudential Trustee Limited | OS | Suites 1501-1507 & 1513-1516, 15th Floor, 1111 King's Road, Taikoo Shing, Hong Kong | |
BSP Debt Fund V Unlevered (Non US) LP | U | c/o Benefit Street Partners LLC, New York, New York 10019 | |
Capital East Millennium Equity Fund | U | 105, Taipei City, Songshan District, Dongxing Rd, No.8 8F | |
Cathay High Yield EX China Cash Pay 1-5 Year 2% Issuer Capped ETF | U | 6th Floor, No.39, Sec.2, Dunhua South. Rd., Taipei, Taiwan | |
CITIC-Prudential Fund Management Company Limited | MI - JV | 19th Floor, No. 16, Yincheng Road, China (Shanghai) Pudong New Area, Shanghai, China | |
CITIC-Prudential Life Insurance Company Limited | MI - JV | Room 1101-A, 1201, 1301, 1401, 1501, 1601, 1701, 1801, Unit 01, Building 1, No. B2, North Road of East Third Ring Road, Chaoyang District, Beijing, PRC,100027, China | |
Eastspring Al-Wara' Investments Berhad | OS | Level 25, Menara Hong Leong, No. 6 Jalan Damanlela, Bukit Damansara, 50490 Kuala Lumpur, Wilayah Persekutuan, Malaysia | |
Eastspring Asia Pacific High Yield Equity Fund | U | 4th Floor, No.1, Songzhi Rd., Xinyi Dist., Taipei, Taiwan | |
Eastspring Asset Management (Thailand) Co., Ltd. | OS | 944 Mitrtown Office Tower, 9th Floor, Rama 4 Road, Wangmai, Pathumwan, Bangkok 10330, Thailand | |
Eastspring Global Private Credit Fund | U | 7 Straits View, #09-01 Marina One East Tower, Singapore 018936 | |
Eastspring Global Real Assets & Private Equity Fund | U | ||
Eastspring Global Real Estate Fund | U | ||
Eastspring Global Technology Fund | U | 944 Mitrtown Office Tower, 9th floor, Rama 4 road, Wangmai Pathumwan, Bangkok 10330, Thailand | |
Eastspring Investment Management (Shanghai) Company Limited | MI - WFOE | Unit 2901, 29th Floor Azia Center, 1233 Lujiazui Ring Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, 200120, China |
Eastspring Investments - Asia Select Bond Fund | U | 26, Boulevard Royal, L-2449, Luxembourg | |
Eastspring Investments - Asia Opportunities Equity Fund | U | ||
Eastspring Investments - Asia Pacific Equity Fund | U | ||
Eastspring Investments - Asian Bond Fund | U | ||
Eastspring Investments - Asian Dynamic Fund | U | ||
Eastspring Investments - Asian Equity Fund | U | ||
Eastspring Investments - Asian Equity Income Fund | U | ||
Eastspring Investments - Asian High Yield Bond Fund | U | ||
Eastspring Investments - Asian Local Bond Fund | U | ||
Eastspring Investments - Asian Low Volatility Equity Fund | U | ||
Eastspring Investments - Asian Multi Factor Equity Fund | U | ||
Eastspring Investments - China A Shares Growth Fund | U | ||
Eastspring Investments - China Bond Fund | U | ||
Eastspring Investments - China Equity Fund | U | ||
Eastspring Investments - Dragon Peacock Fund | U | ||
Eastspring Investments - European Investment Grade Bond Fund | U | ||
Eastspring Investments - Global Emerging Markets Bond Fund | U | ||
Eastspring Investments - Global Emerging Markets Dynamic Fund | U | ||
Eastspring Investments - Global Emerging Markets ex-China Dynamic Fund | U | ||
Eastspring Investments - Global Equity Navigator Fund | U | ||
Eastspring Investments - Global Growth Equity Fund | U | ||
Eastspring Investments - Global Low Volatility Equity Fund | U | ||
Eastspring Investments - Global Market Navigator Fund | U | ||
Eastspring Investments - Global Multi Asset Balanced Fund | U | ||
Eastspring Investments - Global Multi Asset Conservative Fund | U | ||
Eastspring Investments - Global Multi Asset Dynamic Fund | U | ||
Eastspring Investments - Global Multi Asset Income Plus Growth Fund | U | ||
Eastspring Investments - Global Technology Fund | U | ||
Eastspring Investments - Greater China Equity Fund | U | ||
Eastspring Investments - India Equity Fund | U | ||
Eastspring Investments - Pan European Fund | U | ||
Eastspring Investments - US Corporate Bond Fund | U | ||
Eastspring Investments - US High Investment Grade Bond Fund | U | ||
Eastspring Investments - US High Yield Bond Fund | U | ||
Eastspring Investments - US Investment Grade Bond Fund | U |
Eastspring Investments - World Value Equity Fund | U | ||
Eastspring Investments (Hong Kong) Limited | OS | 13th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong | |
Eastspring Investments (Luxembourg) S.A. | OS | 26, Boulevard Royal, L-2449 Luxembourg | |
Eastspring Investments (Singapore) Limited | OS | 7 Straits View, #09-01 Marina One East Tower, Singapore 018936 | |
Eastspring Investments Asia Pacific ex- Japan Target Return Fund | U | Level 22, Menara Prudential, Persiaran TRX Barat, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia | |
Eastspring Investments Asian High Yield Bond MY Fund | U | ||
Eastspring Investments Berhad | OS | Level 25, Menara Hong Leong, No. 6 Jalan Damanlela, Bukit Damansara, 50490 Kuala Lumpur, Wilayah Persekutuan, Malaysia | |
Eastspring Investments Dana Dinamik | U | Level 22, Menara Prudential, Persiaran TRX Barat, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia | |
Eastspring Investments Dinasti Equity Fund | U | ||
Eastspring Investments Fund Management Limited Liability Company | MI | 23rd Floor Saigon Trade Center, 37 Ton Duc Thang Street, Sai Gon Ward, Ho Chi Minh City, Vietnam | |
Eastspring Investments Global Equity Fund | U | Level 22, Menara Prudential, Persiaran TRX Barat, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia | |
Eastspring Investments Group Pte. Ltd. | OS | 7 Straits View, #09-01 Marina One East Tower, Singapore 018936 | |
Eastspring Investments Growth Fund | U | Level 22, Menara Prudential, Persiaran TRX Barat, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia | |
Eastspring Investments Incorporated | OS | 874 Walker Road, Suite C, Dover, Kent, Delaware 19904, United States of America | |
Eastspring Investments India Consumer Equity Open Limited | OS | 3rd Floor, 355 NEX, Rue du Savoir, Cybercity Ebene 72201, Mauritius | |
Eastspring Investments India Equity Open Limited | OS | ||
Eastspring Investments India Government Bond Fund (Semi-Annual Distribution) | U | Eastspring Investments Limited, Marunouchi Park Bldg., 2-6-1 Marunochi, Chiyoda-ku, Tokyo, Japan 100-6905 | |
Eastspring Investments India Infrastructure Equity Open Limited | OS | 3rd Floor, 355 NEX, Rue du Savoir, Cybercity Ebene 72201, Mauritius | |
Eastspring Investments India Innovation High Growth Equity Fund QII | U | Eastspring Investments Limited, Marunouchi Park Bldg., 2-6-1 Marunochi, Chiyoda-ku, Tokyo, Japan 100-6905 | |
Eastspring Investments Islamic Equity Income Fund | U | Level 22, Menara Prudential, Persiaran TRX Barat, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia | |
Eastspring Investments Limited | OS | Marunouchi Park Building, 6-1 Marunouchi 2-chome, Chiyoda- Ku, Tokyo, Japan | |
Eastspring Investments Services Pte. Ltd. | OS | 7 Straits View, #09-01 Marina One East Tower, Singapore 018936 | |
Eastspring Investments SICAV-FIS - Alternative Investment Fund | U | 26, Boulevard Royal, L-2449, Luxembourg | |
Eastspring Investments Unit Trusts - Asian Balanced Fund | U | 7 Straits View, #09-01 Marina One East Tower, Singapore 018936 | |
Eastspring Investments Unit Trusts - Dragon Peacock Fund ID | U | ||
Eastspring Investments Unit Trusts - Global Technology Fund | U | ||
Eastspring Investments Unit Trusts - Pan European Fund | U | ||
Eastspring Investments Unit Trusts - Singapore ASEAN Equity Fund | U | ||
Eastspring Investments Unit Trusts - Singapore Select Bond Fund | U | ||
Eastspring Investments Vietnam ESG Equity Fund | U | 26, Boulevard Royal, L-2449, Luxembourg | |
Eastspring Investments Vietnam Navigator Fund | U | 23rd Floor, Saigon Trade Center Building, 37 Ton Duc Thang Street, Ben Nghe Ward, District 1, Ho Chi Minh City, Vietnam | |
Eastspring Overseas Investment Fund Management (Shanghai) Company Limited | MI - WFOE | Unit 2901, 29th Floor Azia Center, 1233 Lujiazui Ring Road, China (Shanghai) Pilot Free Trade Zone, Shanghai, 200120, China | |
Eastspring Private Equity Fund 2 | U | 7 Straits View, #09-01 Marina One East Tower, Singapore 018936 | |
Eastspring Securities Investment Trust Co., Ltd. | OS | 4th Floor, No.1 Songzhi Road, Taipei 110, Taiwan |
Eastspring SGD Cash Fund | U | 7 Straits View, #09-01 Marina One East Tower, Singapore 018936 | |
First Sentier Global Property Securities Fund | U | 38 Beach Road, #06-11 South Beach Tower, Singapore 189767 | |
FSITC Global Trends Fund | U | 1st Floor, No.6, Sec. 3, Minquan West Rd, Taipei, Taiwan | |
FSSA China Focus Fund | U | 70 Sir John Rogerson’s Quay, Dublin 2, D02 R296, Ireland | |
Fubon 1-5 Years US High Yield Bond Ex China ETF | U | 8th Floor, No.108, Sec.1, Dunhua South. Rd., Taipei, Taiwan | |
Fuh Hwa 1-5 Yr High Yield ETF | U | 8th & 9th Floor, No.308, Sec. 2, Bade Rd., Da-an District | |
Furnival Insurance Company PCC Limited | OS | PO Box 155, Mill Court, La Charroterie, St Peter Port, GY1 4ET, Guernsey | |
GS Twenty Two Limited | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom | |
HSBC Senior Global Infrastructure Debt Fund | U | 8 Canada Square, London, E14 5HQ, United Kingdom | |
ICICI Prudential Asset Management Company Limited | OS | 12th Floor, Narain Manzil, 23, Barakhamba Road, New Delhi 110001, India | |
ICICI Prudential Life Insurance Company Limited | OS | ICICI PruLife Towers, 1089 Appasaheb Marathe Marg, Prabhadevi, Mumbai 400025, India | |
ICICI Prudential Pension Funds Management Company Limited | OS | Unit No. A, 2nd Floor, Cnergy Building, Appasaheb Marathe Marg, Prabhadevi, Mumbai, Maharashtra - 400025, India | |
ICICI Prudential Trust Limited | OS | 12th Floor, Narain Manzil, 23, Barakhamba Road, New Delhi 110001, India | |
iShares Core MSCI Asia | U | 16th Floor, Champion Tower, 3 Garden Road, Central, Hong Kong | |
iShares MSCI Asia ex Japan Climate Action ETF | U | 20 Anson Road, #18-01 Twenty Anson, Singapore 079912 | |
iShares MSCI Europe ESG Enhanced UCITS ETF | U | 12 Throgmorton Avenue, London, EC2N 2DL, United Kingdom | |
iShares MSCI USA ESG Enhanced UCITS ETF | U | 78 Sir John Rogerson's Quay, Dublin, D02 HD32, Ireland | |
KKP Active Equity Fund | U | 209 KKP Tower A, 17 Fl., Sukhumvit 21 (Asoke), Khlong Toey Nua, Wattana, Bangkok 10110, Thailand | |
Krungsri Greater China Equity Hedged Dividend Fund | U | 12th, 18th Zone B Floor, Ploenchit Tower 898 Ploenchit Road, Lumpini Pathumwan, Bangkok 10330, Thailand | |
Lasalle Property Securities SICAV-FIS | U | 11-13 Bouldevard de la Foire, L-1528 Luxembourg | |
M&G Asia Property TS Trust | U | 8 Marina Boulevard, #05-02 Marina Bay, Financial Centre, Singapore, 018981 | |
M&G Real Estate Asia Holding Company Pte. Ltd. | OS | 138 Market Street, #35-01 CapitaGreen, Singapore 048946 | |
Manulife Asia Pacific Bond Fund | U | 9th Floor, No 89 Son Ren Road, Taipei, Taiwan | |
Manulife China Offshore Bond Fund | U | ||
Manulife Global Equity Fund | U | ||
Manulife Superior Selection China Fund | U | ||
Manulife Taiwan Dynamic Fund | U | ||
MEAG FlexConcept | U | R.C.S. Luxembourg NR. 28878, 1c, rue Gabriel Lippmann, L-5365 Munsbach | |
Nomura Global Shariah Sustainable Equity Fund | U | Suite No 12.2, Level 12, Menara IMC,No.8 Jalan Sultan Ismail,Kuala Lumpur,50250,WP Kuala Lumpur, Malaysia | |
North Sathorn Holdings Company Limited | OS | No. 63, Athenee Tower, 34th Floor, Wireless Road, Lumpini Subdistrict Pathumwan District, Bangkok Metropolis, Thailand | |
PS | |||
PCA IP Services Limited | OS | 13th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong | |
PCA Life Assurance Co., Ltd. | OS | 8th Floor, No.1 Songzhi Road, Taipei City, 11047, Taiwan | |
PCA Reinsurance Co. Ltd. | OS | Unit Level 13(A), Main Office Tower, Financial Park Labuan, Jalan Merdeka, 87000 Federal Territory of Labuan, Malaysia | |
Pinebridge ESG Emerging Market Corporate Strategy Bond Fund | U | 10th Floor, No. 144, Sec. 2, Minquan East Rd, Taipei, Taiwan | |
Pinebridge US Dual Core Income Fund | U | ||
Principal Core Fixed Income Fund | U | 44, 16th Floor, CIMB Thai Bank, Lungsuan Road, Lumpini, Bangkok 10330, Thailand | |
Principal Global Silver Age Fund | U | ||
Principal Islamic Malaysia Government Sukuk Fund | U | Level 32, Exchange 106, Lingkaran TRX, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia | |
Principal Malaysia Titans Fund | U | Level 31, Exchange 106, Lingkaran TRX, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia |
Pru Life Insurance Corporation of U.K. | OS | 9th Floor, Uptown Place Tower 1, 1 East 11th Drive, Uptown Bonifacio, 1634 Taguig City, Metro Manila, Philippines | |
Prudence Foundation | LBG | 13th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong | |
Prudential (Cambodia) Life Assurance Plc | OS | Chip Mong Tower Building, Units L19, L20, and L21, 19th, 20th, 21st Floor, Russian Federation Blvd (110), Phum 10, Sangkat Phsar Depou 3, Khan Tuol Kork, Phnom Penh, Cambodia | |
Prudential (US Holdco 1) Limited | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom | |
Prudential Africa Holdings Limited | OS | ||
Prudential Africa Services Limited | OS | 3rd Floor, One Africa Place, LR No. 1870/X/45, P.O. Box 1393-00606, Westlands, Nairobi, Kenya | |
Prudential Assurance Company Singapore (Pte) Limited | OS | 30 Cecil Street, #30-01 Prudential Tower, Singapore 049712 | |
Prudential Assurance Malaysia Berhad | OS | Level 26, Menara Prudential, Persiaran TRX Barat, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia | |
Prudential Assurance Uganda Limited | OS | 9th Floor Zebra Plaza, Plot 23 Kampala Road, P.O. Box 2660, Kampala, Uganda | |
Prudential Bermuda ISAC Ltd. | OS | Clarendon House, 2 Church Street, Hamilton HM11, Bermuda | |
Prudential Bermuda Re ISA, Ltd. | OS | ||
Prudential BSN Takaful Berhad | OS | Level 13, Menara Prudential, Persiaran TRX Barat, 55188 Tun Razak Exchange, Kuala Lumpur, Malaysia | |
Prudential Corporation Asia Limited | OS | 13th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong | |
Prudential Corporation Holdings Limited | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom | |
Prudential Enterprise Management (Beijing) Co., Ltd. | MI-WFOE | Unit 1817, Level 18, Building 1, No.1 Jianguomenwai Avenue, Chaoyang District, Beijing, China | |
Prudential Financial Advisers Singapore Pte. Ltd. | OS | 30 Cecil Street, #30-01 Prudential Tower, Singapore 049712 | |
Prudential Financial Partners HK Limited | OS | 13th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong | |
Prudential Funding (Asia) PLC | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom | |
Prudential General Insurance Hong Kong Limited | OS | 59th Floor, One Island East, 18 Westlands Road, Quarry Bay, Hong Kong | |
Prudential Group Holdings Limited | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom | |
Prudential Group Secretarial Services HK Limited | OS | 13th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong | |
Prudential Group Secretarial Services Limited | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom | |
Prudential HCL Health Insurance Limited | OS | Suite 6, 48th Floor, Commerz III, International Business Park, Oberoi Garden City, Off Western Express Highway, Goregaon (East), Mumbai, 400063, India | |
Prudential Holdings Limited | OS | 4th Floor, Saltire Court, 20 Castle Terrace, Edinburgh, EH1 2EN, United Kingdom | |
Prudential Hong Kong Limited | OS | 59th Floor, One Island East, 18 Westlands Road, Quarry Bay, Hong Kong | |
Prudential International Treasury Limited | OS | 13th Floor, One International Finance Centre, 1 Harbour View Street, Central, Hong Kong | |
Prudential Investment Fund - Post Retirement Care Investment Fund | U | F377/9/H/3, Kabulonga Road, Kabulonga, Lusaka, Zambia | |
Prudential Investment Fund - Pru Offshore Fund | U | ||
Prudential Investment Management Private Limited | OS | 1 Pasir Panjang Road, #12-02, Singapore 118479 | |
Prudential IP Services Limited | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom | |
Prudential Life Assurance (Lao) Company Limited | OS | 5th Floor, Lao International Business and Tourist Center Project (Vientiane Center), Khouvieng Road, Nongchan Village, Sisattanak District, Vientiane Capital, Lao PDR | |
Prudential Life Assurance (Thailand) Public Company Limited | OS | 944 Mitrtown Office Tower, 10th, 29th-31st Floor, Rama 4 Road, Wangmai, Pathumwan, Bangkok, 10330, Thailand | |
Prudential Life Assurance Kenya Limited | OS | Vienna Court, Ground Floor, State House Crescent, Off State House Avenue, P.O. Box 25093-00603, Nairobi, Kenya | |
Prudential Life Assurance Zambia Limited | OS | Prudential House, Plot No. 32256, Thabo Mbeki Road, P.O. Box 31357, Lusaka, Zambia | |
Prudential Life Insurance Ghana Limited | OS | 12th Floor, 335 Place, N1, North Dzorwulu, Accra, Accra Metropolitan, Greater Accra, P.O. Box AN 10476, Ghana | |
Prudential Life Vault Limited | OS | 48 Awolowo Road, South-West Ikoyi, Lagos, Nigeria | |
PS |
Prudential Mauritius Holdings Limited | OS | 3rd Floor, 355 NEX, Rue du Savoir, Cybercity Ebene 72201, Mauritius | |
Prudential Myanmar Life Insurance Limited | OS | #15-01, 15th Floor, Sule Square, 221 Sule Pagoda Road, Kyauktada Township, Yangon, Myanmar | |
Prudential Pensions Management Zambia Limited | OS | Prudential Pensions Management Zambia Limited Support Office, Plot F/377/9/H/3, Kabulonga Road, Kabulonga, Lusaka, Zambia | |
Prudential Services Asia Sdn. Bhd. | OS | Suite 1005, 10th Floor, Wisma Hamzah-Kwong Hing, No. 1 Leboh Ampang, 50100 Kuala Lumpur, Malaysia | |
PS | |||
Prudential Services Limited | OS | 5th Floor, 10 Old Bailey, London, EC4M 7NG, United Kingdom | |
Prudential Services Philippines Corporation | OS | 19th Floor Uptown Place Tower I East, 11th Drive Uptown Bonifacio Fort Bonifacio Bonifacio Global City, Taguig City, Fourth District, National Capital Region (NCR), 1630, Philippines | |
Prudential Services Singapore Pte. Ltd. | OS | 1 Pasir Panjang Road, #12-02, Singapore 118479 | |
Prudential Singapore Holdings Pte. Limited | OS | 30 Cecil Street, #30-01 Prudential Tower, Singapore 049712 | |
PS | |||
Prudential Technology and Services India Private Limited | OS | Unit 401, 4th Floor, CIGNUS, Tower-1, Whitefield Bangalore, Hoodi Village, K.R. Puram Hobli, Whitefield, Bangalore, Bangalore South, Karnataka, India, 560066 | |
Prudential Vietnam Assurance Private Limited | OS | 25th Floor Saigon Trade Center, 37 Ton Duc Thang Street, Sai Gon Ward, Ho Chi Minh City, Vietnam | |
Prudential Zenith Life Insurance Limited | OS | 6th Floor, Civic Towers, Plots Ga & G1 Ozumba Mbadiwe Avenue, Victoria Island, Lagos, Nigeria | |
PT Prudential Sharia Life Assurance | OS | Prudential Tower, 2nd Floor, Jl. Jend. Sudirman Kav. 79, Jakarta 12910, Indonesia | |
PT. Eastspring Investments Indonesia | OS | 23rd Floor, Prudential Tower, JL. Jend. Sudirman Kav.79, Jakarta 12910, Indonesia | |
PT. Prudential Life Assurance | OS | Prudential Tower, Jl. Jend. Sudirman Kav. 79, Jakarta 12910, Indonesia | |
Pulse Ecosystems Pte. Ltd. | OS | 1 Pasir Panjang Road, #12-02, Singapore 118479 | |
Reksa Dana Eastspring IDR Fixed Income Fund (NDEIFF) | U | Prudential Tower, 23rd Floor, Jl. Jend. Sudirman Kav.79, Jakarta 12910, Indonesia | |
Reksa Dana Syariah Eastspring Syariah Fixed Income Amanah | U | ||
Reksa Dana Syariah Eastspring Syariah Mixed Asset Fund | U | Prudential Tower Lantai 23, JL, Jend. Sudirman Kav. 79, Kakarta 12910 - Indonesia | |
Reksa Dana Syariah Eastspring Syariah Money Market Khazanah | U | Prudential Tower, 23rd Floor, Jl. Jend. Sudirman Kav.79, Jakarta 12910, Indonesia | |
Rhodium Investment Funds - Singapore Bond Fund | U | 7 Straits View, #09-01 Marina One East Tower, Singapore 018936 | |
Rhodium Passive Long Dated Bond Fund | U | ||
Robeco QI European Active Index Equities | U | 6, route de Trèves, L-2633 Senningerberg, Grand Duchy of Luxembourg | |
Schroder Asian Investment Grade Credit | U | 138 Market Street, #23-01 CapitaGreen, Singapore 048946 | |
Schroder Emerging Markets Fund | U | ||
Schroder Multi-Asset Revolution | U | ||
Schroder US Dollar Money Fund | U | 9th Floor, No. 108, Section 5, Xinyi Road, Taipei, Taiwan | |
Scotts Spazio Pte. Ltd. | OS | 316 Tanglin Road, #01-01,Singapore, 247978 | |
Shanghai CPE Asset Management Co., Ltd. | MI - JV | Room 101-2, No.128 North Zhangjiabang Road, Pudong District, Shanghai, China | |
Shenzhen Prudential Technology Limited | MI - WFOE | Unit 5, 8th Floor, China Resources Tower, No.2666 Keyuan South Road, Yuehai Street, Nanshan District, Shenzhen, 518054, China | |
Sri Han Suria Sdn. Bhd. | OS | Suite 1005, 10th Floor, Wisma Hamzah-Kwong Hing, No. 1 Leboh Ampang, 50100 Kuala Lumpur, Malaysia | |
Staple Limited | OS | No. 63, Athenee Tower, 34th Floor, Wireless Road, Lumpini Subdistrict Pathumwan District, Bangkok Metropolis, Thailand | |
StepStone Prudential Private Credit Fund | U | 103 South Church Street, Harbour Place, 5th Floor, KY1-1202 Cayman Islands | |
Tisco US Equity Fund | U | 48/16-17, Tisco Tower Building, 9 Floor. North Sathorn, Silom, Bangrak, Bangkok 10500 | |
United Global Innovation Fund | U | 23A, 25th Floor, Asia Centre Building, 173/27-30, 32-33 South Sathorn Road, Thungmahamek, Sathorn, Bangkok 10120, Thailand | |
United Global Quality Equity Fund | U | Jln Raja Laut, City Centre, 50100 Kuala Lumpur, Wilayah Persekutuan, Kuala Lumpur, Malaysia |
United Global Quality Growth Fund | U | 23A, 25th Floor, Asia Centre Building, 173/27-30, 32-33 South Sathorn Road, Thungmahamek, Sathorn, Bangkok 10120, Thailand | |
United-I Malaysia Discovery Fund | U | Level 20, UOB Plaza 1, 7, Jalan Raja Laut, 50350, Kuala Lumpur, Malaysia | |
United-I Malaysia Equity Fund | U | Level 20, UOB Plaza 1, 7, Jalan Raja Laut, 50350, Kuala Lumpur, Malaysia | |
UOB Smart Global Healthcare Fund | U | 23A, 25th Floor, Asia Centre Building, 173/27-30, 32-33 South Sathorn Road, Thungmahamek, Sathorn, Bangkok 10120, Thailand | |
UOB Smart Japan Small and Mid Cap Fund | U | ||
UOB Smart Millennium Growth Fund | U | ||
USD Investment Grade Infrastructure Debt Fund SCSp | U | 35a, Avenue John F. Kennedy, L-1855 Luxembourg, Grand Duchy of Luxembourg |
Name of entity | Issued and fully paid up share / registered capital |
Prudential Assurance Company Singapore (Pte) Limited | |
PT. Prudential Life Assurance | |
Prudential Hong Kong Limited | |
Prudential Assurance Malaysia Berhad |
Page | |
Profit and Loss Accounts for the years ended 31 December 2025, 2024 and 2023 | 254 |
Statements of Financial Position at 31 December 2025 and 2024 | 255 |
Statements of Changes in Equity for the years ended 31 December 2025, 2024 and 2023 | 256 |
Statements of Cash Flows for the years ended 31 December 2025, 2024 and 2023 | 257 |
Notes to the Condensed Financial Information | 258 |
Years ended 31 Dec | 2025 $m | 2024 $m | 2023 $m |
Investment income, including dividends received from subsidiary undertakings | |||
Investment expenses and charges | ( | ( | ( |
Gain on transfer of debt to Prudential Funding (Asia) PLC | |||
Write-down of investment in Prudential Group Holdings Limited | ( | ||
Gains on financial instruments held at fair value through profit and loss | ( | ||
Other corporate income (expenditure) | ( | ( | |
Foreign currency exchange losses | ( | ( | ( |
Profit on ordinary activities before tax | |||
Tax credit on profit on ordinary activities | |||
Profit for the year | |||
Other comprehensive income: | |||
Valuation movements on retained interest in Jackson measured at fair value through other comprehensive income | |||
Total comprehensive income for the year |
31 Dec 2025 $m | 31 Dec 2024 $m | |
Fixed assets | ||
Investments in subsidiary undertakings | ||
Current assets | ||
Amounts owed by subsidiary undertakings | ||
Cash at bank and in hand | ||
Prepayments and other debtors | ||
Liabilities: amounts falling due within one year | ||
Amounts owed to subsidiary undertakings | ( | ( |
Tax payable | ( | ( |
Other liabilities | ( | ( |
( | ( | |
Net current assets | ||
Total assets less current liabilities | ||
Liabilities: amounts falling due after more than one year | ||
Amounts owed to subsidiary undertakings | ( | ( |
Total net assets | ||
Capital and reserves | ||
Share capital | ||
Capital redemption reserve | ||
Share premium | ||
Profit and loss account | ||
Shareholders’ funds |
Share capital $m | Share premium $m | Capital redemption reserve $m | Profit and loss account $m | Shareholders’ funds $m | |
Balance at 1 Jan 2023 | – | ||||
Profit for the year | – | – | – | ||
Valuation movements on Jackson equity securities measured at fair value through other comprehensive income | – | – | – | ||
Total comprehensive income for the year | – | – | – | ||
Transactions with owners, recorded directly in equity | |||||
New share capital subscribed | – | – | |||
Share-based payment transactions | – | – | – | ||
Dividends | – | – | – | ( | ( |
Total transactions with owners | – | ( | ( | ||
Balance at 31 Dec 2023 / 1 Jan 2024 | – | ||||
Profit and total comprehensive income for the year | – | – | – | ||
Transactions with owners, recorded directly in equity | |||||
Share repurchase/buyback programmes | ( | – | ( | ( | |
Share-based payment transactions | – | ||||
Dividends | – | – | – | ( | ( |
Effect of scrip dividends | – | – | – | ||
Total transactions with owners | ( | ( | ( | ||
Balance at 31 Dec 2024 / 1 Jan 2025 | |||||
Profit and total comprehensive income for the year | – | – | – | ||
Transactions with owners, recorded directly in equity | |||||
New share capital subscribed | – | – | – | ||
Share repurchase/buyback programmes | ( | – | ( | ( | |
Share-based payment transactions | – | – | – | ( | ( |
Dividends | – | – | – | ( | ( |
Effect of scrip dividends | – | – | – | ||
Total transactions with owners | ( | ( | ( | ||
Balance at 31 Dec 2025 |
Years ended 31 Dec | 2025 $m | 2024 $m | 2023 $m |
Operating activities | |||
Net cash inflow from operating activities before interest and tax | |||
Interest paid | ( | ( | ( |
Dividends paid | ( | ( | ( |
Net cash flows from operating activities | |||
Financing activities | |||
Issuance of ordinary share capital | |||
Redemption of core structural borrowings | ( | ||
Movement in commercial paper and other borrowings to support a short-term fixed income securities program | ( | ||
Movement in net amount owed to subsidiary undertakings | |||
Movement in share-based payment receivable | ( | ||
Non-cash transfer of debt to Prudential Funding (Asia) plc | ( | ||
Movement in net amount owed by subsidiary undertakings | ( | ||
Share repurchase/buyback programmes (including costs) | ( | ( | |
Net cash flows from financing activities | ( | ( | ( |
Investing activities | |||
Disposal of Jackson shares | |||
Investment in subsidiaries | ( | ||
Capitalisation of intercompany loans | |||
Net cash flows from investing activities | ( | ||
Net cash (outflow) inflow for the year | ( | ( | |
Reconciliation of profit on ordinary activities before tax to net cash inflow from operating activities before interest and tax | |||
Profit on ordinary activities before tax | |||
Add back: interest charged to profit or loss | |||
Adjustments for non-cash items: | |||
Gain on transfer of subordinated liabilities and debenture loans | ( | ||
Impairment of investment in Prudential Group Holdings Limited | |||
Foreign currency exchange and other movements | ( | ( | |
Decrease (increase) in debtors | ( | ||
Increase (decrease) in creditors | ( | ||
Net cash inflow from operating activities before interest and tax |
Profit after tax | 2025 $m | 2024 $m | 2023 $m |
Profit for the year of the Company in accordance with FRS 101 | |||
Accounting policy difference note (i) | ( | ( | |
Share in the IFRS result of the Group, net of distributions to the Company note (ii) | |||
Profit after tax of the Group attributable to equity holders in accordance with IFRS |
Shareholders’ equity | 31 Dec 2025 $m | 31 Dec 2024 $m |
Shareholders’ funds of the Company in accordance with FRS 101 | ||
Accounting policy difference note (i) | ( | |
Share in the IFRS net equity of the Group note(ii) | ||
Shareholders' equity of the Group in accordance with IFRS |
Section | Page | |
I | Additional financial information | 261 |
(i) | Group capital position | 261 |
(ii) | Eastspring adjusted operating profit and funds under management or advice | 264 |
(iii) | Group funds under management | 265 |
II | Calculation of alternative performance measures | 266 |
(i) | Adjusted operating profit | 266 |
(ii) | Return on IFRS shareholders’ equity | 266 |
(iii) | IFRS shareholders’ equity per share | 266 |
(iv) | Eastspring cost/income ratio | 266 |
(v) | Insurance premiums | 266 |
31 Dec 2025 | 31 Dec 2024 | |||||||
Shareholder | Add policyholder | Total | Shareholder | Add policyholder | Total | Change in total | ||
note (1) | note (2) | note (1) | note (2) | note (3) | ||||
Group capital resources ($bn) | 27.6 | 19.3 | 46.9 | 24.8 | 16.3 | 41.1 | 5.8 | |
of which: Tier 1 capital resources ($bn) note (4) | 19.9 | 1.5 | 21.4 | 17.6 | 1.3 | 18.9 | 2.5 | |
Group Minimum Capital Requirement ($bn) | 6.0 | 0.8 | 6.8 | 5.1 | 0.7 | 5.8 | 1.0 | |
Group Prescribed Capital Requirement ($bn) | 10.5 | 13.3 | 23.8 | 8.9 | 11.3 | 20.2 | 3.6 | |
GWS capital surplus over GPCR ($bn) | 17.1 | 6.0 | 23.1 | 15.9 | 5.0 | 20.9 | 2.2 | |
GWS coverage ratio over GPCR (%) | 262% | 197% | 280% | 203% | (6)% | |||
GWS Tier 1 surplus over GMCR ($bn) | 14.6 | 13.1 | 1.5 | |||||
GWS Tier 1 coverage ratio over GMCR (%) | 316% | 325% | (9)% | |||||
Shareholder | |||||
31 Dec 2025 | 31 Dec 2024 | ||||
Impact of market sensitivities | Surplus $bn | Coverage ratio % | Surplus $bn | Coverage ratio % | |
Base position | 17.1 | 262% | 15.9 | 280% | |
Impact of: | |||||
10% increase in equity markets | 0.4 | 0% | 0.2 | (3)% | |
20% fall in equity markets | (0.7) | 9% | (0.8) | 5% | |
50 basis points reduction in interest rates | 1.3 | 9% | 1.1 | 10% | |
100 basis points increase in interest rates | (3.3) | (27)% | (2.6) | (25)% | |
100 basis points increase in credit spreads | (0.6) | (4)% | (0.5) | (4)% | |
Total | |||||
31 Dec 2025 | 31 Dec 2024 | ||||
Impact of market sensitivities | Surplus $bn | Coverage ratio % | Surplus $bn | Coverage ratio % | |
Base position | 23.1 | 197% | 20.9 | 203% | |
Impact of: | |||||
10% increase in equity markets | 1.4 | 1% | 1.1 | 1% | |
20% fall in equity markets | (2.9) | (2)% | (2.8) | (4)% | |
50 basis points reduction in interest rates | 1.1 | 4% | 0.8 | 4% | |
100 basis points increase in interest rates | (3.2) | (13)% | (2.6) | (13)% | |
100 basis points increase in credit spreads | (1.3) | (5)% | (1.3) | (7)% | |
31 Dec 2025 $bn | |||
Group IFRS shareholders’ equity | 20.1 | ||
Remove goodwill and intangibles recognised on the IFRS consolidated statement of financial position | (4.7) | ||
Add debt treated as capital under GWS note (1) | 4.1 | ||
Asset valuation differences note (2) | (0.5) | ||
Remove IFRS 17 CSM (including joint ventures and associates) note (3) | 23.9 | ||
Liability valuation (including insurance contracts) differences excluding IFRS 17 CSM note(4) | 2.9 | ||
Differences in associated net deferred tax liabilities note (5) | 1.1 | ||
Group total GWS capital resources | 46.9 |
2025 $m | 2024 AER $m | 2023 AER $m | |
Operating income before performance-related fees note (1) | 809 | 747 | 700 |
Performance-related fees | 5 | – | (2) |
Operating income (net of commission)note (2) | 814 | 747 | 698 |
Operating expense note (2) | (418) | (385) | (372) |
Group's share of tax on joint ventures' operating profit | (67) | (58) | (46) |
Adjusted operating profit | 329 | 304 | 280 |
Average funds managed or advised by Eastspring | $271.7bn | $249.3bn | $225.9bn |
Margin based on operating income note (3) | 30bps | 30bps | 31bps |
Cost/income ratio note II(v) | 52% | 52% | 53% |
Retail | Margin | Institutional | Margin | Total | Margin | |
$m | bps | $m | bps | $m | bps | |
2025 | 470 | 59 | 339 | 18 | 809 | 30 |
2024 | 414 | 62 | 333 | 18 | 747 | 30 |
2023 | 353 | 67 | 347 | 20 | 700 | 31 |
31 Dec 2025 $bn | 31 Dec 2024 $bn | |
External funds under management note (1) | ||
Retail | 63.7 | 64.5 |
Institutional | 23.9 | 31.0 |
Money market funds (MMF) | 15.6 | 13.9 |
103.2 | 109.4 | |
Internal funds under management or advice: | ||
Internal funds under management | 127.5 | 115.4 |
Internal funds under advice | 47.0 | 33.2 |
174.5 | 148.6 | |
Total funds under management or advice note (2) | 277.7 | 258.0 |
31 Dec 2025 $m | 31 Dec 2024 $m | ||||||||||
Retail | Institu- tional | Total excl. MMF | MMF | Total | Retail | Institu- tional | Total excl. MMF | MMF | Total | ||
At beginning of year | 64,481 | 31,059 | 95,540 | 13,914 | 109,454 | 50,779 | 33,493 | 84,272 | 11,775 | 96,047 | |
Market gross inflows | 29,942 | 9,340 | 39,282 | 82,636 | 121,918 | 27,994 | 12,144 | 40,138 | 70,640 | 110,778 | |
Redemptions | (24,595) | (9,114) | (33,709) | (79,514) | (113,223) | (19,153) | (15,161) | (34,314) | (68,822) | (103,136) | |
Market and other movements* | (6,113) | (7,404) | (13,517) | (1,464) | (14,981) | 4,861 | 583 | 5,444 | 321 | 5,765 | |
At end of year | 63,715 | 23,881 | 87,596 | 15,572 | 103,168 | 64,481 | 31,059 | 95,540 | 13,914 | 109,454 | |
31 Dec 2025 | 31 Dec 2024 | ||||||||||
Funds under management | Funds under advice | Total | Total | ||||||||
$bn | % of total | $bn | % of total | $bn | % of total | $bn | % of total | ||||
Equity | 57.9 | 25% | 2.1 | 5% | 60.0 | 21 | 61.8 | 24% | |||
Fixed income | 40.9 | 18% | 3.0 | 6% | 43.9 | 16 | 45.2 | 17% | |||
Multi-asset | 113.0 | 49% | 41.9 | 89% | 154.9 | 56 | 134.0 | 52% | |||
Alternatives | 2.2 | 1% | – | 0% | 2.2 | 1 | 2.0 | 1% | |||
MMF | 16.7 | 7% | – | 0% | 16.7 | 6 | 15.0 | 6% | |||
Total funds | 230.7 | 100% | 47.0 | 100% | 277.7 | 100 | 258.0 | 100% | |||
31 Dec 2025 $bn | 31 Dec 2024 $bn | |
Internal funds | 223.9 | 191.3 |
Eastspring external funds note I(ii) | 103.2 | 109.4 |
Total Group funds under management note | 327.1 | 300.7 |
31 Dec 2025 $bn | 31 Dec 2024 $bn | |
Total investments held on the balance sheet (including Investment in joint ventures and associates accounted for using the equity method) | 199.5 | 169.4 |
External funds of Eastspring | 103.2 | 109.4 |
Internally managed funds held in joint ventures and associates, excluding assets attributable to external unit holders of the consolidated collective investment schemes and other adjustments | 24.4 | 21.9 |
Total Group funds under management | 327.1 | 300.7 |
2025 $m | 2024* $m | |
Adjusted operating profit | 3,306 | 3,129 |
Tax on adjusted operating profit | (534) | (547) |
Non-controlling interests' share of adjusted operating profit | (155) | (146) |
Adjusted operating profit, net of tax and non-controlling interests | 2,617 | 2,436 |
IFRS shareholders’ equity at beginning of year | 17,492 | 16,966 |
IFRS shareholders’ equity at end of year | 20,117 | 17,492 |
Average IFRS shareholders’ equity | 18,805 | 17,229 |
Operating return on IFRS shareholders’ equity (%) | 14% | 14% |
31 Dec 2025 | 31 Dec 2024 | |
Number of issued shares at the end of the year (million shares) | 2,548 | 2,658 |
Closing IFRS shareholders’ equity ($ million) | 20,117 | 17,492 |
Group IFRS shareholders’ equity per share (cents) | 790¢ | 658¢ |
2025 $m | 2024 $m | 2023 $m | |
IFRS revenue | 596 | 565 | 497 |
Share of revenue from joint ventures and associates | 437 | 385 | 330 |
Commissions and other | (219) | (203) | (129) |
Performance-related fees | (5) | – | 2 |
Operating income before performance-related fees note | 809 | 747 | 700 |
IFRS charges | 491 | 454 | 376 |
Share of expenses from joint ventures and associates | 146 | 134 | 125 |
Commissions and other | (219) | (203) | (129) |
Operating expense | 418 | 385 | 372 |
Cost/income ratio (operating expense/operating income before performance-related fees) | 52% | 52% | 53% |
2025 $m | 2024 $m | 2023 $m | |
Gross premiums earned | 28,317 | 24,262 | 22,248 |
Gross premiums earned from joint ventures and associates | 4,316 | 4,003 | 3,973 |
Total Group, including joint ventures and associates | 32,633 | 28,265 | 26,221 |
Exhibit Number | Description |
1 | Memorandum and Articles of Association of Prudential(5) |
2.1 | Second Amended and Restated Deposit Agreement, by and among Prudential, Citibank, N.A, as depositary, and holders and beneficial owners of ADSs issued thereunder(6). |
2.2 | The total amount of long-term debt securities of Prudential Funding (Asia) plc, a wholly-owned indirect subsidiary of Prudential plc authorised under any instrument does not exceed 10 per cent of the total assets of the Company on a consolidated basis. Prudential plc hereby agrees to furnish to the Securities and Exchange Commission, upon its request, a copy of any instrument defining the rights of holders of long-term debt of Prudential plc or of its subsidiaries for which consolidated or unconsolidated financial statements are required to be filed |
2.3 | Description of rights of each class of securities registered under Section 12 of the Securities Exchange Act of 1934 |
4.1 | Prudential Long-Term Incentive plan(5), Prudential Deferred Annual Incentive Plan(5) |
4.2 | Executive Director’s Service Contract - Anil Wadhwani(4) |
4.3 | Form of Letter of Appointment for Non-executive Directors(2), form of Letter of Appointment for the Chair, Shriti Vadera(3) and form of Letter of Appointment for the Chair-Designate, Sir Douglas Flint. Each Letter of appointment substantially follows the form exhibited. |
4.4 | Other benefits between the Prudential Group and the Directors. Each of the Directors has the benefit of a deed of indemnity granted by the Company which substantially follows the form exhibited(1) |
8.0 | Subsidiaries of Prudential (set forth in Note D6.4 to the consolidated financial statements included in this Form 20- F) |
11.1 | Prudential's Code of Conduct(5) |
11.2 | Insider Trading Policies(7)(8) |
12.1 | Certification of Prudential plc’s Chief Executive Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002 |
12.2 | Certification of Prudential plc’s Chief Financial Officer pursuant to Section 302 of the Sarbanes Oxley Act of 2002 |
13.1 | Annual certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 |
14.1 | Consent of EY LLP |
97 | Prudential Directors' compensation recovery policy(5) |
101.INS | XBRL Instance Document |
101.SCH | XBRL Taxonomy Extension Schema Linkbase Document |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase Document |
101.DEF | XBRL Taxonomy Extension Definition Linkbase Document |
101.LAB | XBRL Taxonomy Extension Label Linkbase Document |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase Document |
104 | Cover page interactive data file (formatted as inline XBRL and contained in Exhibit 101) |
Prudential plc | ||||
26 March 2026 | ||||
By: | /s/ Anil Wadhwani | |||
Name: | Anil Wadhwani | |||
Title | Chief Executive Officer | |||
FAQ
How did Prudential plc (PUK) perform financially in 2025?
What dividends did Prudential plc (PUK) pay for 2025?
How strong is Prudential plc’s (PUK) capital position?
What capital returns to shareholders is Prudential plc (PUK) planning?
How large is Prudential plc’s (PUK) asset management business Eastspring?
What are Prudential plc’s (PUK) growth objectives to 2027?







